var title_f22_43_23216="Dose rates cervical ca";
var content_f22_43_23216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brachytherapy reference points",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tandem and ovoid cervical brachytherapy illustration of point A.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23216=[""].join("\n");
var outline_f22_43_23216=null;
var title_f22_43_23217="Erythroderma";
var content_f22_43_23217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythroderma is a cutaneous reactional state characterized by erythema and scale involving greater than 50 percent of the body surface area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew Samel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23217=[""].join("\n");
var outline_f22_43_23217=null;
var title_f22_43_23218="Tooth aspiration";
var content_f22_43_23218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61759%7EPULM%2F80136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61759%7EPULM%2F80136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tooth aspiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph (left) obtained following trauma in a 28-year-old man shows a radiopaque foreign body in the right lower lobe. A fractured tooth (right) was removed bronchoscopically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dental plate fragment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Encased in the left main stem bronchus following facial trauma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23218=[""].join("\n");
var outline_f22_43_23218=null;
var title_f22_43_23219="EAS defect EUS";
var content_f22_43_23219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic ultrasound of external anal sphincter tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endorectal ultrasound image showing a moderate sized defect in the external anal sphincter (EAS).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David A Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23219=[""].join("\n");
var outline_f22_43_23219=null;
var title_f22_43_23220="Dipyridamole: Patient drug information";
var content_f22_43_23220=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dipyridamole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     see \"Dipyridamole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/43/11958?source=see_link\">",
"     see \"Dipyridamole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Persantine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Dipyridamole FC&reg;;",
"     </li>",
"     <li>",
"      Dipyridamole For Injection;",
"     </li>",
"     <li>",
"      Persantine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with a blood thinner to stop clots after a heart valve is replaced.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop strokes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691574",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect bypass grafts in the heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dipyridamole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11633 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23220=[""].join("\n");
var outline_f22_43_23220=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161435\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161436\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011359\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011358\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011363\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011364\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011366\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011361\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011362\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011367\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011368\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=related_link\">",
"      Dipyridamole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/43/11958?source=related_link\">",
"      Dipyridamole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_43_23221="Anthelminthic therapies";
var content_f22_43_23221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anthelminthic therapies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23221/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23221/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23221/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23221/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23221/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23221/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/43/23221/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helminths are multicellular parasites with complex life cycles within and outside of human hosts. The mechanisms of action for many anthelminthic agents remain incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anthelminthic drugs are used for treatment of symptomatic disease as well as for deworming in regions with high prevalence of infection and disease. In endemic areas deworming strategies have been associated with health benefits including improvements in hemoglobin levels, growth and physical fitness, cognitive performance, and nutritional status [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug therapies for helminthic diseases are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef86245 \" href=\"UTD.htm?29/18/29990\">",
"     table 1",
"    </a>",
"    ). In the United States some agents are available through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncezid/dsr/\">",
"     Centers for Disease Control and Prevention Drug Service",
"    </a>",
"    (telephone 1-404-639-3670).",
"   </p>",
"   <p>",
"    An overview of anthelminthic therapies will be presented here. Therapeutic considerations for specific helminth infections are discussed separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IVERMECTIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    is a semisynthetic derivative of avermectin, which is derived from the soil mold, Streptomyces avermitilis. Ivermectin opens glutamate-sensitive chloride channel currents in helminths, and this may be its mechanism of action [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    is the drug of choice for the treatment of onchocerciasis and for strongyloidiasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=see_link\">",
"     \"Onchocerciasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"     \"Strongyloidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    has activity against other filarial worms including Wuchereria bancrofti, Brugia malayi, Mansonella ozzardi and Loa loa. It is not the drug of choice for these infections though may be useful in certain circumstances. (See related topics).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    is effective against several intestinal nematodes including ascariasis, trichuriasis and enterobiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/5\">",
"     5",
"    </a>",
"    ]. Ivermectin is ineffective against human hookworms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=see_link\">",
"     \"Ascariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2583?source=see_link\">",
"     \"Enterobiasis and trichuriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    is also effective for treatment of ectoparasitic infections including scabies and head lice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link\">",
"     \"Scabies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=see_link\">",
"     \"Pediculosis capitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    is not recommended for pregnant or lactating patients, and its safety in children &lt;15 kg is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BENZIMIDAZOLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benzimidazole class of antiparasitic agents includes four drugs for use: thiabendazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    , and triclabendazole.",
"   </p>",
"   <p>",
"    Benzimidazoles exert their anthelminthic effect by binding to free beta-tubulin and thus inhibiting the polymerization of tubulin and microtubule-dependent glucose uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benzimidazoles should be avoided in pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Albendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    has a broad range of activity against helminthic infections, including neurocysticercosis, echinococcosis, ascariasis, hookworm, and trichuriasis. (See related topics).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    also has activity against a number of less common tissue nematode infections, including cutaneous larva migrans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/7\">",
"     7",
"    </a>",
"    ], visceral and ocular larva migrans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], gnathostomiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/10\">",
"     10",
"    </a>",
"    ], intestinal capillariasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/11\">",
"     11",
"    </a>",
"    ], clonorchiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/12\">",
"     12",
"    </a>",
"    ], lagochilascaris minor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/13\">",
"     13",
"    </a>",
"    ], and the more recently recognized human infections with the nematodes Trichinella pseudospiralis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/14\">",
"     14",
"    </a>",
"    ] and Oesophagostomum bifurcum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/15\">",
"     15",
"    </a>",
"    ]. (See related topics).",
"   </p>",
"   <p>",
"    Absorption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    is enhanced by taking it with fatty meals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/16\">",
"     16",
"    </a>",
"    ]. Side effects of albendazole include abdominal pain, nausea, vomiting, and increased hepatic transaminases; these are generally transient and usually do not require discontinuation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mebendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     Mebendazole",
"    </a>",
"    is a benzimidazole derivative that is effective against a spectrum of intestinal and tissue nematodes, including ascariasis, hookworm, enterobiasis, and trichuriasis, and as an investigational drug for Capillaria. Side effects of mebendazole include mild abdominal pain and diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Triclabendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triclabendazole is the drug of choice for treatment of liver fluke infections due to Fasciola hepatica [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Triclabendazole should be taken with food to enhance absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31735?source=see_link\">",
"     \"Liver flukes: Fascioliasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Triclabendazole is not routinely available in the United States but is available through the Centers for Disease Control under an investigational protocol (telephone 1-404-718-4745 or email parasites@cdc.gov). It may also be obtained from",
"    <a class=\"external\" href=\"file://www.pharmaworld.com/\">",
"     Victoria Pharmacy",
"    </a>",
"    in Zurich, Switzerland (www.pharmaworld.com).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21576281\">",
"    <span class=\"h2\">",
"     Thiabendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiabendazole is an older benzimidazole derivative that is active against a variety of nematode parasites but frequent and severe side effects have limited its use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/21\">",
"     21",
"    </a>",
"    ]. Adverse reactions include dizziness, nausea, vomiting, drowsiness, pruritus, headache, neuropsychiatric disturbances, hepatitis, and hypersensitivity reactions including Stevens Johnson syndrome. A topical suspension of thiabendazole has been used for cutaneous larva migrans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PRAZIQUANTEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     Praziquantel",
"    </a>",
"    has activity against schistosomiasis, intestinal tapeworms, cysticercosis, and other flukes (exclusive of Fasciola hepatica) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See related topics).",
"   </p>",
"   <p>",
"    Its mechanism of action is unknown, but in schistosomes it causes paralysis and tegumental disruption, which may then permit a synergistic host immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/24\">",
"     24",
"    </a>",
"    ]. Side effects include headache, dizziness, drowsiness, and abdominal discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other drugs are available for the treatment of specific helminthic infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diethylcarbamazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diethylcarbamazine (DEC) is a piperazine derivative that has activity against lymphatic filariasis, loiasis and visceral larva migrans. Diethylcarbamazine is microfilaricidal; the mechanism of action is uncertain.",
"   </p>",
"   <p>",
"    Side effects are generally proportional to the microfilarial burden and largely attributable to release of lipopolysaccharides and other constituents from endosymbiont Wolbachia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Symptoms include fever, headache, dizziness, and transient exacerbation of lymphangitis. DEC induces the Mazzotti reaction when administered in the setting of onchocerciasis (eg pruritus, ocular and constitutional symptoms).",
"   </p>",
"   <p>",
"    In the United States, DEC is available from the",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncezid/dsr/\">",
"     Centers for Disease Control and Prevention Drug Service",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pyrantel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyrantel is a well-tolerated pyrimidine derivative that acts against intestinal nematodes by inducing neuromuscular paralysis, allowing worms to be expelled. A single dose is usually curative for ascariasis, enterobiasis, and trichostrongyliasis, but several doses are recommended for hookworm infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=see_link\">",
"     \"Ascariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2583?source=see_link\">",
"     \"Enterobiasis and trichuriasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44168?source=see_link\">",
"     \"Miscellaneous nematodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42437?source=see_link\">",
"     \"Hookworm infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nitazoxanide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     Nitazoxanide",
"    </a>",
"    is a nitrosthiazolyl-salicylamide derivative with an uncertain mechanism of action [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/27\">",
"     27",
"    </a>",
"    ]. It has activity against cryptosporidiosis, giardiasis, ascariasis and the dwarf tapeworm, Hymenolepis nana [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/28\">",
"     28",
"    </a>",
"    ]. (see related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21576460\">",
"    <span class=\"h2\">",
"     Bithionol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bithionol has activity against paragonimiasis. Adverse cutaneous and gastrointestinal effects are common. Bithionol is available in the United States from the",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncezid/dsr/\">",
"     Centers for Disease Control and Prevention Drug Service",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36967?source=see_link\">",
"     \"Paragonimiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21576467\">",
"    <span class=\"h2\">",
"     Oxamniquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxamniquine is a tetrahydroquinolone derivative that is used as an alternative agent for the treatment of Schistosoma mansoni [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23221/abstract/22\">",
"     22",
"    </a>",
"    ]. Higher doses are required in Egypt and South Africa for partially resistant strains, but frankly resistant strains have also been encountered. Oxamniquine is well tolerated, with occasional side effects of headache, dizziness, drowsiness, and gastrointestinal disturbances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=see_link\">",
"     \"Treatment and prevention of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21576510\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Helminths are multicellular parasites with complex life cycles within and outside of human hosts. Drug therapies for helminthic diseases are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef86245 \" href=\"UTD.htm?29/18/29990\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       Ivermectin",
"      </a>",
"      is the drug of choice for the treatment of onchocerciasis and for strongyloidiasis. Ivermectin is effective against several intestinal nematodes including ascariasis, trichuriasis and enterobiasis. Ivermectin is also effective for treatment of ectoparasitic infections including scabies and head lice. see (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ivermectin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       Ivermectin",
"      </a>",
"      has activity against other filarial worms including Wuchereria bancrofti, Brugia malayi, Mansonella ozzardi and Loa loa; it is not the drug of choice for these infections though may be useful in certain circumstances. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ivermectin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       Albendazole",
"      </a>",
"      has a broad range of activity against helminthic infections, including neurocysticercosis, echinococcosis, ascariasis, hookworm, and trichuriasis. Albendazole also has activity against a number of less common tissue nematode infections. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Albendazole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Triclabendazole is the drug of choice for treatment of liver fluke infections due to Fasciola hepatica.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"       Praziquantel",
"      </a>",
"      has activity against schistosomiasis, intestinal tapeworms, cysticercosis, and other flukes (exclusive of Fasciola hepatica). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Triclabendazole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Praziquantel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diethylcarbamazine has activity against lymphatic filariasis, loiasis and visceral larva migrans. DEC induces the Mazzotti reaction when administered in the setting of onchocerciasis (eg pruritus, ocular and constitutional symptoms). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diethylcarbamazine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Drugs for Parasitic Infections, Medical Letter, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/2\">",
"      Bethony J, Brooker S, Albonico M, et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006; 367:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/3\">",
"      Gulani A, Nagpal J, Osmond C, Sachdev HP. Effect of administration of intestinal anthelmintic drugs on haemoglobin: systematic review of randomised controlled trials. BMJ 2007; 334:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/4\">",
"      Ikeda T. Pharmacological effects of ivermectin, an antiparasitic agent for intestinal strongyloidiasis: its mode of action and clinical efficacy. Nihon Yakurigaku Zasshi 2003; 122:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/5\">",
"      Naquira C, Jimenez G, Guerra JG, et al. Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg 1989; 40:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/6\">",
"      Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990; 6:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/7\">",
"      Davies HD, Sakuls P, Keystone JS. Creeping eruption. A review of clinical presentation and management of 60 cases presenting to a tropical disease unit. Arch Dermatol 1993; 129:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/8\">",
"      Bhatia V, Sarin SK. Hepatic visceral larva migrans: evolution of the lesion, diagnosis, and role of high-dose albendazole therapy. Am J Gastroenterol 1994; 89:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/9\">",
"      St&uuml;rchler D, Schubarth P, Gualzata M, et al. Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. Ann Trop Med Parasitol 1989; 83:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/10\">",
"      Kraivichian P, Kulkumthorn M, Yingyourd P, et al. Albendazole for the treatment of human gnathostomiasis. Trans R Soc Trop Med Hyg 1992; 86:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/11\">",
"      Cross JH, Basaca-Sevilla V. Albendazole in the treatment of intestinal capillariasis. Southeast Asian J Trop Med Public Health 1987; 18:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/12\">",
"      Liu YH, Wang XG, Gao P, Qian MX. Experimental and clinical trial of albendazole in the treatment of Clonorchiasis sinensis. Chin Med J (Engl) 1991; 104:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/13\">",
"      Oostburg BF. The sixth case of lagochilascariasis minor in Surinam. Trop Geogr Med 1992; 44:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/14\">",
"      Andrews JR, Ainsworth R, Abernethy D. Trichinella pseudospiralis in humans: description of a case and its treatment. Trans R Soc Trop Med Hyg 1994; 88:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/15\">",
"      Krepel HP, Haring T, Baeta S, Polderman AM. Treatment of mixed Oesophagostomum and hookworm infection: effect of albendazole, pyrantel pamoate, levamisole and thiabendazole. Trans R Soc Trop Med Hyg 1993; 87:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/16\">",
"      Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 1988; 34:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/17\">",
"      Nahmias J, Goldsmith R, Soibelman M, el-On J. Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease). Ann Trop Med Parasitol 1994; 88:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/18\">",
"      Mill&aacute;n JC, Mull R, Freise S, et al. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg 2000; 63:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/19\">",
"      Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin Infect Dis 2001; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/20\">",
"      Lecaillon JB, Godbillon J, Campestrini J, et al. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol 1998; 45:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/21\">",
"      Grove DI. Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Trans R Soc Trop Med Hyg 1982; 76:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/22\">",
"      Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med 2002; 346:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/23\">",
"      Price TA, Tuazon CU, Simon GL. Fascioliasis: case reports and review. Clin Infect Dis 1993; 17:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/24\">",
"      Brindley PJ, Sher A. Immunological involvement in the efficacy of praziquantel. Exp Parasitol 1990; 71:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/25\">",
"      Keiser PB, Reynolds SM, Awadzi K, et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J Infect Dis 2002; 185:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/26\">",
"      Cross HF, Haarbrink M, Egerton G, et al. Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. Lancet 2001; 358:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/27\">",
"      Nitazoxanide (Alinia)--a new anti-protozoal agent. Med Lett Drugs Ther 2003; 45:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23221/abstract/28\">",
"      Drugs for Parasitic Infections. Treatment guidelines from the Medical Letter Drugs. Medical Lett Drugs Ther 2007; 5 Suppl:e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 487 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-9E6818F356-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23221=[""].join("\n");
var outline_f22_43_23221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21576510\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IVERMECTIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BENZIMIDAZOLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Albendazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mebendazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Triclabendazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21576281\">",
"      Thiabendazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PRAZIQUANTEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diethylcarbamazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pyrantel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nitazoxanide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21576460\">",
"      Bithionol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21576467\">",
"      Oxamniquine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21576510\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/487\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/487|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/18/29990\" title=\"table 1\">",
"      Drugs for parasitic infections helminths",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=related_link\">",
"      Ascariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2583?source=related_link\">",
"      Enterobiasis and trichuriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42437?source=related_link\">",
"      Hookworm infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31735?source=related_link\">",
"      Liver flukes: Fascioliasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44168?source=related_link\">",
"      Miscellaneous nematodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20970?source=related_link\">",
"      Onchocerciasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36967?source=related_link\">",
"      Paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25849?source=related_link\">",
"      Pediculosis capitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=related_link\">",
"      Treatment and prevention of schistosomiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_43_23222="Sertraline: Patient drug information";
var content_f22_43_23222=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sertraline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     see \"Sertraline: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/18/7465?source=see_link\">",
"     see \"Sertraline: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zoloft&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sertraline&reg;;",
"     </li>",
"     <li>",
"      CO Sertraline;",
"     </li>",
"     <li>",
"      Dom-Sertraline;",
"     </li>",
"     <li>",
"      GD-Sertraline;",
"     </li>",
"     <li>",
"      Mylan-Sertraline;",
"     </li>",
"     <li>",
"      Nu-Sertraline;",
"     </li>",
"     <li>",
"      PHL-Sertraline;",
"     </li>",
"     <li>",
"      PMS-Sertraline;",
"     </li>",
"     <li>",
"      ratio-Sertraline;",
"     </li>",
"     <li>",
"      Riva-Sertraline;",
"     </li>",
"     <li>",
"      Sandoz-Sertraline;",
"     </li>",
"     <li>",
"      Teva-Sertraline;",
"     </li>",
"     <li>",
"      Zoloft&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat obsessive-compulsive problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat panic attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat post-traumatic stress.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat mood problems caused by monthly periods.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat social anxiety problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702917",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sertraline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705588",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Zoloft&reg; Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701365",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy. The dropper has rubber.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697339",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures or are on seizure drugs, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any natural products, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Only use the measuring device that comes with this liquid drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix liquid with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       cup of water, ginger ale, lemon-lime soda, lemonade, or orange juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink it right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11044 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23222=[""].join("\n");
var outline_f22_43_23222=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220684\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220685\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017772\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017774\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017773\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017778\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017779\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017781\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017776\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017777\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017782\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017783\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=related_link\">",
"      Sertraline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/18/7465?source=related_link\">",
"      Sertraline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_43_23223="Approach to the patient with dizziness";
var content_f22_43_23223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with dizziness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23223/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23223/contributors\">",
"     William T Branch, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23223/contributors\">",
"     Jason JS Barton, MD, PhD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23223/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23223/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23223/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23223/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/43/23223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Dizziness\" is a nonspecific term often used by patients to describe symptoms. The most common disorders lumped under this term include vertigo, nonspecific \"dizziness,\" disequilibrium, and presyncope. The first and most important step in the evaluation is to fit the patient into one of these more specific categories.",
"   </p>",
"   <p>",
"    The general approach to dizziness is reviewed here. The evaluation of vertigo and presyncope (the evaluation of which is the same as the syncope evaluation) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported proportion of patients with various etiologies of dizziness in community surveys [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/1\">",
"     1",
"    </a>",
"    ], primary care setting [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], the emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/4-8\">",
"     4-8",
"    </a>",
"    ], and the specialized dizzy clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/9-13\">",
"     9-13",
"    </a>",
"    ] are remarkably similar: approximately 40 percent of dizzy patients have peripheral vestibular dysfunction; 10 percent have a central brainstem vestibular lesion; 15 percent have a psychiatric disorder; and 25 percent have other problems, such as presyncope and disequilibrium (",
"    <a class=\"graphic graphic_table graphicRef59338 \" href=\"UTD.htm?16/21/16733\">",
"     table 1",
"    </a>",
"    ). The diagnosis remains uncertain in approximately 10 percent. The distribution of causes varies with age. The elderly have a higher incidence of central vestibular causes of vertigo (approaching 20 percent), most often due to stroke. Psychiatric conditions and presyncope account for more dizziness in younger individuals.",
"   </p>",
"   <p>",
"    The patient's description is critical for establishing the etiology of dizziness. In one series, the history was most sensitive for identifying vertigo (87 percent), presyncope (74 percent), psychiatric disorders (55 percent), and disequilibrium (33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/2\">",
"     2",
"    </a>",
"    ]. The physical examination generally confirmed but did not make the diagnosis. Positional changes in symptoms, orthostatic blood pressure and pulse changes, observation of gait, and detection of nystagmus were most helpful on physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/2\">",
"     2",
"    </a>",
"    ]. Most psychiatric disorders were not detected prior to standardized psychological testing using the diagnostic interview schedule (DIS). Not surprisingly, no patients volunteered the likelihood of a psychiatric cause of dizziness.",
"   </p>",
"   <p>",
"    Asking open-ended questions, listening to the patient's description of his or her symptoms, and checking and gathering additional information from specific questions should allow the clinician to form a hypothesis regarding the type of dizziness. As an example, a patient who says \"I nearly blacked out\" might be asked \"Do you mean you nearly fainted?\" An affirmative reply elicits another checking question, \"So you felt you were passing out?\" Checking the hypothesis by placing the symptom into context, including its time course, provoking and aggravating factors, concurrent symptoms, age, pre-existing conditions, and the findings on physical examination will narrow the differential, and allow the clinician to decide on the need for further testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evaluation.",
"   </p>",
"   <p>",
"    In addition, the physician's hypothesis must be checked against features of the other causes of dizziness. When the physician suspects the patient is suffering from vertigo, he or she may ask, \"So you say it was a spinning sensation, did you feel at all as though you were also going to pass out or faint?\" Careful listening and checking generally leads to the right hypothesis. It is important to do this initially so that the evaluation will proceed down the correct pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VERTIGO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertigo is the predominant symptom that arises from an acute asymmetry of the vestibular system. The vestibular system includes the vestibular apparatus in the inner ear, the vestibular nerve and nucleus within the medulla, as well as connections to and from the vestibular portions of the cerebellum. Vertigo is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients often experience vertigo as an illusion of motion; some interpret this as self-motion, others as motion of the environment. The most common perception is a spinning sensation; patients may also use terms such as \"whirling,\" \"tilting,\" or \"moving.\" However, not all patients describe their vertigo in such vivid terms. Vague dizziness, imbalance, or disorientation may eventually prove to be due to a vestibular problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Distinguishing vertigo from other types of dizziness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spinning quality of vertiginous sensations is notoriously unreliable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/14\">",
"     14",
"    </a>",
"    ]. Lack of spinning cannot be used to exclude vestibular disease, given the difficulty many patients have in putting their dizzy experience into words. On the other hand, some patients with presyncope from vasovagal or cardiac disease can interpret their sensation of dizziness as a spinning sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The time course, provoking factors, and aggravating factors of dizziness are more useful features in establishing the cause of dizziness. One study found that many physicians that evaluate patients with dizziness may rely too heavily on symptom quality for diagnosis and do not appreciate the clinical significance of these other features [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27785385\">",
"    <span class=\"h3\">",
"     Time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertigo is never continuous for more than a few weeks. Even when the vestibular lesion is permanent, the central nervous system adapts to the defect so that vertigo subsides over several weeks. Constant dizziness lasting months is usually psychogenic, not vestibular. However, the physician must be clear on what a patient means by \"constant.\" Some patients who say they have constant dizziness for months actually mean that they have a constant susceptibility to frequent episodic dizziness; this can be a vestibular problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27785393\">",
"    <span class=\"h3\">",
"     Provoking factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain types of vertigo occur spontaneously, while others are precipitated by maneuvers that change head position or middle ear pressure (eg, coughing, sneezing, or Valsalva maneuvers). Positional vertigo and postural presyncope are two common conditions that are frequently confused. Both are associated with dizziness upon standing, as when arising from bed. The key to the diagnosis is to determine whether dizziness can be provoked by maneuvers that change head position without lowering blood pressure or decreasing cerebral blood flow. Such maneuvers include lying down, rolling over in bed, and bending the neck back to look up. Dizziness in these settings suggests positional vertigo, not postural presyncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27785401\">",
"    <span class=\"h3\">",
"     Aggravating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;All vertigo is made worse by moving the head. This is a useful feature for distinguishing vertigo from other forms of dizziness. Many patients in the midst of a vertiginous attack are petrified to move. If head motion does not worsen the feeling, it is probably another type of dizziness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Associated signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertigo whether of central or peripheral origin is generally accompanied by nystagmus and postural instability. Other signs and symptoms may be useful in distinguishing between central and peripheral causes of vertigo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27785414\">",
"    <span class=\"h3\">",
"     Nystagmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of nystagmus suggests that dizziness is vertigo. Nystagmus is not always readily visible, although more subtle forms can be seen during funduscopy or on electronystagmography. Some types of nystagmus are only seen after a provocative maneuver (eg, Dix-Hallpike maneuver). The bilaterally symmetric appearance of a few beats of horizontal nystagmus on lateral gaze is normal (physiologic &lsquo;endpoint&rsquo; nystagmus). Pathologic nystagmus is asymmetric or more pronounced or prolonged.",
"   </p>",
"   <p>",
"    Certain features of nystagmus may suggest a central versus a peripheral cause of vertigo (",
"    <a class=\"graphic graphic_table graphicRef76359 \" href=\"UTD.htm?29/33/30235\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Positional changes such as flexing, extending, rotating, or laterally bending the cervical spine may elicit vertigo and nystagmus in susceptible patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Barany or Dix-Hallpike maneuver involves moving the patient rapidly from the sitting to the lying position with the head tilted downward off the table at 45 degrees and rotated 45 degrees to one side. This is a key diagnostic test for benign paroxysmal positional vertigo, and has an 80 percent sensitivity for this specific condition. It should be stressed that the maneuver is NOT useful in diagnosing other vestibulopathies.",
"     </li>",
"     <li>",
"      The supine roll test for lateral semicircular canal-related vertigo may be performed in patients with a compatible history but a negative Dix-Hallpike maneuver [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The onset of vertigo and nystagmus with these maneuvers establishes vertigo as the patient's symptom, if the vertiginous sensation is the same as the patient previously experienced. The examiner notes features of the symptoms and signs to aid in the distinction between central and peripheral causes of vertigo (",
"    <a class=\"graphic graphic_table graphicRef73213 \" href=\"UTD.htm?18/15/18683\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other bedside tests of vestibulo-ocular function are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the patient with vertigo\", section on 'Other vestibular signs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27785433\">",
"    <span class=\"h3\">",
"     Postural instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of lesions of the vestibular system upon postural stability are variable, but it is common for patients with vertigo to have difficulty maintaining steady upright posture when walking, standing, and even sitting unsupported, particularly when the symptoms are acute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27785446\">",
"    <span class=\"h3\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of ear involvement are very suggestive of a peripheral cause of vertigo, although their absence does not exclude the diagnosis. The physician should ask if there has been any hearing loss, its duration and progression, whether unilateral or bilateral, and accompanying symptoms such as discharge or drainage from the ear, tinnitus, or a history of otitis.",
"   </p>",
"   <p>",
"    Subclinical hearing loss can be detected with reasonable sensitivity in the office by holding your fingers a few inches away from the patient's ear and rubbing them together softly or asking the patient to repeat a few numbers or words whispered into his or her ear. A 512-Hz tuning fork is also useful. Audiometry is more sensitive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27785457\">",
"    <span class=\"h3\">",
"     Brainstem signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of additional neurologic signs strongly suggests the presence of a central vestibular lesion. Symptoms such as staggering or ataxic gait, vomiting, headache, double vision, visual loss, slurred speech, numbness of the face or body, weakness, clumsiness, or incoordination should be reviewed with the patient.",
"   </p>",
"   <p>",
"    A careful neurologic examination should be performed for cranial nerve abnormalities, Horner syndrome, motor or sensory changes, dysmetria, or abnormal reflexes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .) However, the absence of other neurologic findings does not entirely exclude a central process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PRESYNCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presyncope is the prodromal symptom of fainting or a near faint. Presyncope occurs more commonly than syncope. It usually lasts for seconds to minutes and is often recognized by the patient as \"nearly blacking out\" or \"nearly fainting.\" When the symptoms are less intense, their description may be less clear. Patients may also report lightheadedness, a feeling of warmth, diaphoresis, nausea, and visual blurring occasionally proceeding to blindness. An observation of pallor by onlookers usually indicates presyncope. Presyncope usually occurs when the patient is standing or seated upright and not when supine (if the latter, one should suspect a cardiac arrhythmia rather than hypotension).",
"   </p>",
"   <p>",
"    A history of cardiac disease, including cardiac dysrhythmias (tachycardias or bradyarrhythmias), coronary heart disease, congestive heart failure, is relevant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/19\">",
"     19",
"    </a>",
"    ]. The patient should be asked specifically about palpitations, chest discomfort, or dyspnea (although this may suggest anxiety as an alternative cause as well).",
"   </p>",
"   <p>",
"    The etiology and evaluation of presyncope are the same as for syncope. Orthostatic hypotension, cardiac arrhythmias, and vasovagal attacks are some of the more common causes (",
"    <a class=\"graphic graphic_table graphicRef67409 graphicRef76776 \" href=\"UTD.htm?27/54/28525\">",
"     table 4A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DISEQUILIBRIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disequilibrium is a sense of imbalance that occurs primarily when walking. Chronic dizziness or disequilibrium can cause significant impairment of physical and social functioning, particularly in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disequilibrium may result from peripheral neuropathy, a musculoskeletal disorder interfering with gait, vestibular disorder, a cerebellar disorder,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cervical spondylosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Patients with Parkinson disease frequently suffer from disequilibrium and are subject to postural hypotension as well as imbalance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/22\">",
"     22",
"    </a>",
"    ]. Cervical spondylosis may be associated with dizziness that is apparently related to a disturbance in postural control [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/23\">",
"     23",
"    </a>",
"    ], although this is not a universally accepted cause of dizziness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/2\">",
"     2",
"    </a>",
"    ]. Visual impairment, whether from underlying eye disease or poor lighting, typically exacerbates the sense of imbalance. This is also true of cerebellar disorders. Cerebellar disorders can affect mainly gait, but often have associated dysarthria and eye signs, such as gaze-evoked nystagmus, poor smooth pursuit, and downbeat nystagmus. If the cerebellar hemisphere is also involved, there will be incoordination of limbs.",
"   </p>",
"   <p>",
"    The physician should inquire about symptoms of neurologic and gait disorders, especially those suggestive of Parkinsonism, cerebellar incoordination, or peripheral neuropathy. In the series cited above, few patients volunteered that their dizziness was associated with walking, standing, turning, or falling; most with disequilibrium required observation of gait and a neurologic examination to identify the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NONSPECIFIC DIZZINESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific dizziness is often difficult for the patient to describe. He or she may simply insist, \"I am dizzy.\" Patients may choose from suggested descriptions to say they are \"giddy\" or \"lightheaded\", however, they may also endorse a fainting or spinning sensation.",
"   </p>",
"   <p>",
"    Psychiatric disorders may be the primary cause of nonspecific dizziness in some cases. One-quarter of such individuals had major depression, one-quarter had generalized anxiety or panic disorder, and the remainder had somatization disorder, alcohol dependence,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    personality disorder in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/2\">",
"     2",
"    </a>",
"    ]. Other series report higher rates of panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/24\">",
"     24",
"    </a>",
"    ]. (See appropriate topic reviews for diagnostic discussions of these illnesses.) Ill-defined disorders such as fibromyalgia have also been associated with dizziness and vertigo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    .) Patients who have a chief cause of dizziness that is not psychiatric may also have a psychiatric disorder as a contributing factor. Psychotherapy may help manage this type of dizziness. A meta-analysis of three randomized trials that used cognitive behavioral therapy in combination with relaxation techniques or vestibular rehabilitation found that therapy was helpful in managing dizziness in the short term, although not associated anxiety and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonspecific dizziness is commonly related to hyperventilation. Dizziness that accompanies hyperventilation, anxiety, or depression often builds up gradually, waxes and wanes over a period of 20 minutes or longer, and gradually resolves. There may be no sensation of \"air hunger\" since these patients are hyperventilating only to a slight degree. This usually occurs in settings that are at least mildly stressful.",
"   </p>",
"   <p>",
"    Less intense versions of presyncope or vertigo may be experienced by the patient as nonspecific dizziness. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Vertigo'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Presyncope'",
"    </a>",
"    above.) Nonspecific dizziness (as well as vertigo) may follow head trauma or whiplash injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/27\">",
"     27",
"    </a>",
"    ]. Hypoglycemic episodes may also produce a nonspecific sensation of dizziness as the chief symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, patients should be asked about medications, especially antidepressants and anticholinergics; a variety of medications produce dizziness as a side effect or as a symptom of abrupt drug withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no physical signs that are diagnostic of nonspecific dizziness. Most patients are healthy, young individuals without detectable disease involving the neurologic, cardiovascular, or otolaryngologic systems. Purposeful hyperventilation is one means to confirm that diagnosis. The patient is coached to hyperventilate until he or she becomes dizzy, then to identify whether or not the dizziness mimics spontaneously occurring symptoms. If so, the patient will be convinced, as well as the physician, that hyperventilation is the etiology. However, the examiner must observe the eyes of the patient to see if there is nystagmus; some pathologic vestibular lesions are exacerbated or unmasked by hyperventilation. If nystagmus is seen, the diagnosis is a vestibular lesion, not hyperventilation.",
"   </p>",
"   <p>",
"    Reproducing symptoms by hyperventilation is often reassuring to the patient and in itself therapeutic. It is possible for individuals to learn to breathe less deeply and through the nose, thereby limiting hyperventilation. If patients understand that a number of minutes must elapse before the symptoms resolve, they can spontaneously abort their own attacks. Treatment of anxiety or depression with pharmacotherapy should be based upon the symptoms of these disorders, not necessarily upon the presence of nonspecific dizziness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIZZINESS IN OLDER PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dizziness in the older adult deserves specific mention because of its high prevalence, up to 38 percent in some series, and its attendant risk of falls, functional disability, institutionalization, and even death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/31\">",
"     31",
"    </a>",
"    ]. Assessment of dizziness in older patients is challenging because it is frequently attributable to multiple problems, including vertigo, cerebrovascular disease, neck disorders, physical deconditioning, and medications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/32\">",
"     32",
"    </a>",
"    ]. Visual impairment from cataracts and other conditions is common in older adults and likely exacerbates the disability that is associated with dizziness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/10\">",
"     10",
"    </a>",
"    ]. One study found that 44 percent of patients aged 65 to 95 years had more than one condition causing dizziness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/33\">",
"     33",
"    </a>",
"    ]. Some call this entity multiple-sensory defect dizziness.",
"   </p>",
"   <p>",
"    In a population-based study of 1087 community living individuals 72 years of age or older, 261 (24 percent) reported having an episode of dizziness during the two months prior to study onset and that the dizziness (whether persistent or intermittent) had been present for at least one month [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/31\">",
"     31",
"    </a>",
"    ]. The investigators found seven characteristics that were independently associated with dizziness on multivariate analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anxiety trait",
"     </li>",
"     <li>",
"      Depressive symptoms",
"     </li>",
"     <li>",
"      Impaired balance (path deviation and time to turn circle greater than four seconds)",
"     </li>",
"     <li>",
"      Past myocardial infarction",
"     </li>",
"     <li>",
"      Postural hypotension (mean decrease in blood pressure &ge;20 percent)",
"     </li>",
"     <li>",
"      Five or more medications",
"     </li>",
"     <li>",
"      Impaired hearing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only 10 percent of study participants with none of these seven characteristics reported dizziness. The prevalence of dizziness in those who had one, two, three, four, and five or more of these characteristics was 18, 27, 33, 50, and 68 percent, respectively. The authors concluded that while dizziness in some older individuals may primarily be due to one problem, a number of older patients likely have a multifactorial etiology.",
"   </p>",
"   <p>",
"    One study of 417 patients aged 65 to 95 years found that most, 69 percent, of patients had presyncope-type dizziness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/33\">",
"     33",
"    </a>",
"    ]. Underlying cardiovascular disease was the most common contributing factor in 57 percent, followed by peripheral vestibulopathy (14 percent), and psychiatric conditions (10 percent). Drug side effects were a minor contributor in 25 percent of patients.",
"   </p>",
"   <p>",
"    Treatment in these individuals should be directed at the most remediable problems [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23223/abstract/32\">",
"     32",
"    </a>",
"    ]. Physicians should also ask about falling or dizziness while driving, which would require intervention to prevent injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/59/41905?source=see_link\">",
"       \"Patient information: Vertigo (a type of dizziness) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/31/41460?source=see_link\">",
"       \"Patient information: Dizziness and vertigo (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complaint of dizziness is nonspecific and requires further clarification.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cause of dizziness (vertigo, presyncope, disequilibrium, or nonspecific dizziness) is best elucidated by the history and confirmed by physical examination. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with dizziness have vertigo. Most patients experience vertigo as an illusion of movement, not necessarily spinning, of themselves or the environment. A key historical aspect of vertigo is exacerbation by head movement (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Vertigo'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of nystagmus suggests that the dizziness is vertigo. Associated hearing loss or tinnitus suggests peripheral vertigo; associated brainstem signs suggest central vertigo. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Vertigo'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Presyncope is usually experienced as a sensation of impending faint. This diagnosis is suggested by the occurrence of dizziness only in the upright posture, in patients with cardiac disease, and when associated pallor is described by onlookers. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Presyncope'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dizziness that represents disequilibrium or a sense of imbalance may be the presenting symptom of a peripheral neuropathy, parkinsonism, cerebellar disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cervical myelopathy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Disequilibrium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonspecific dizziness is ill described and has a wide differential diagnosis that may include milder forms of vertigo, presyncope, and disequilibrium, as well as medication side effects, psychiatric disease, and metabolic derangements. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Nonspecific dizziness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Older patients often have multiple etiologic contributors to their dizziness. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Dizziness in older patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/1\">",
"      Neuhauser HK, Radtke A, von Brevern M, et al. Burden of dizziness and vertigo in the community. Arch Intern Med 2008; 168:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/2\">",
"      Kroenke K, Lucas CA, Rosenberg ML, et al. Causes of persistent dizziness. A prospective study of 100 patients in ambulatory care. Ann Intern Med 1992; 117:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/3\">",
"      Sloane PD, Dallara J, Roach C, et al. Management of dizziness in primary care. J Am Board Fam Pract 1994; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/4\">",
"      Herr RD, Zun L, Mathews JJ. A directed approach to the dizzy patient. Ann Emerg Med 1989; 18:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/5\">",
"      Alvord LS, Herr RD. ENG in the emergency room: subtest results in acutely dizzy patients. J Am Acad Audiol 1994; 5:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/6\">",
"      Madlon-Kay DJ. Evaluation and outcome of the dizzy patient. J Fam Pract 1985; 21:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/7\">",
"      Skiendzielewski JJ, Martyak G. The weak and dizzy patient. Ann Emerg Med 1980; 9:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/8\">",
"      Newman-Toker DE, Hsieh YH, Camargo CA Jr, et al. Spectrum of dizziness visits to US emergency departments: cross-sectional analysis from a nationally representative sample. Mayo Clin Proc 2008; 83:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/9\">",
"      Drachman DA, Hart CW. An approach to the dizzy patient. Neurology 1972; 22:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/10\">",
"      Nedzelski JM, Barber HO, McIlmoyl L. Diagnoses in a dizziness unit. J Otolaryngol 1986; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/11\">",
"      Sloane PD, Baloh RW. Persistent dizziness in geriatric patients. J Am Geriatr Soc 1989; 37:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/12\">",
"      Davis LE. Dizziness in elderly men. J Am Geriatr Soc 1994; 42:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/13\">",
"      Katsarkas A. Dizziness in aging: a retrospective study of 1194 cases. Otolaryngol Head Neck Surg 1994; 110:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/14\">",
"      Newman-Toker DE, Cannon LM, Stofferahn ME, et al. Imprecision in patient reports of dizziness symptom quality: a cross-sectional study conducted in an acute care setting. Mayo Clin Proc 2007; 82:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/15\">",
"      Newman-Toker DE, Dy FJ, Stanton VA, et al. How often is dizziness from primary cardiovascular disease true vertigo? A systematic review. J Gen Intern Med 2008; 23:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/16\">",
"      Stanton VA, Hsieh YH, Camargo CA Jr, et al. Overreliance on symptom quality in diagnosing dizziness: results of a multicenter survey of emergency physicians. Mayo Clin Proc 2007; 82:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/17\">",
"      Bhattacharyya N, Baugh RF, Orvidas L, et al. Clinical practice guideline: benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg 2008; 139:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/18\">",
"      Katsarkas A, Kirkham TH. Paroxysmal positional vertigo--a study of 255 cases. J Otolaryngol 1978; 7:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/19\">",
"      Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol 1997; 79:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/20\">",
"      Fielder H, Denholm SW, Lyons RA, Fielder CP. Measurement of health status in patients with vertigo. Clin Otolaryngol Allied Sci 1996; 21:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/21\">",
"      Grimby A, Rosenhall U. Health-related quality of life and dizziness in old age. Gerontology 1995; 41:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/22\">",
"      Hillen ME, Wagner ML, Sage JI. \"Subclinical\" orthostatic hypotension is associated with dizziness in elderly patients with Parkinson disease. Arch Phys Med Rehabil 1996; 77:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/23\">",
"      Karlberg M, Johansson R, Magnusson M, Fransson PA. Dizziness of suspected cervical origin distinguished by posturographic assessment of human postural dynamics. J Vestib Res 1996; 6:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/24\">",
"      Yardley L, Owen N, Nazareth I, Luxon L. Panic disorder with agoraphobia associated with dizziness: characteristic symptoms and psychosocial sequelae. J Nerv Ment Dis 2001; 189:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/25\">",
"      Rosenhall U, Johansson G, Orndahl G. Otoneurologic and audiologic findings in fibromyalgia. Scand J Rehabil Med 1996; 28:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/26\">",
"      Schmid G, Henningsen P, Dieterich M, et al. Psychotherapy in dizziness: a systematic review. J Neurol Neurosurg Psychiatry 2011; 82:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/27\">",
"      Fitzgerald DC. Head trauma: hearing loss and dizziness. J Trauma 1996; 40:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/28\">",
"      Jaap AJ, Jones GC, McCrimmon RJ, et al. Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin. Diabet Med 1998; 15:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/29\">",
"      McKiernan JM, Lowe FC. Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J 1997; 90:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/30\">",
"      Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/31\">",
"      Tinetti ME, Williams CS, Gill TM. Dizziness among older adults: a possible geriatric syndrome. Ann Intern Med 2000; 132:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/32\">",
"      Sloane PD. Evaluation and management of dizziness in the older patient. Clin Geriatr Med 1996; 12:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23223/abstract/33\">",
"      Maarsingh OR, Dros J, Schellevis FG, et al. Causes of persistent dizziness in elderly patients in primary care. Ann Fam Med 2010; 8:196.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5099 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23223=[""].join("\n");
var outline_f22_43_23223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VERTIGO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Distinguishing vertigo from other types of dizziness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27785385\">",
"      - Time course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27785393\">",
"      - Provoking factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27785401\">",
"      - Aggravating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Associated signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27785414\">",
"      - Nystagmus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27785433\">",
"      - Postural instability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27785446\">",
"      - Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27785457\">",
"      - Brainstem signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PRESYNCOPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DISEQUILIBRIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NONSPECIFIC DIZZINESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIZZINESS IN OLDER PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5099\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5099|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/21/16733\" title=\"table 1\">",
"      Causes of dizziness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/33/30235\" title=\"table 2\">",
"      Clinical features of central versus peripheral vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/15/18683\" title=\"table 3\">",
"      Dix Hallpike findings in central vs peripheral vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/50/24364\" title=\"table 4A\">",
"      Common causes of syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/11/18620\" title=\"table 4B\">",
"      Uncommon causes of syncope",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/31/41460?source=related_link\">",
"      Patient information: Dizziness and vertigo (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/59/41905?source=related_link\">",
"      Patient information: Vertigo (a type of dizziness) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_43_23224="Chapter 10B: Buffers";
var content_f22_43_23224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 10B: Buffers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23224/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23224/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23224/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23224/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23224/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23224/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/43/23224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the major ways in which large changes in H+ concentration are prevented is by buffering. The body buffers, which are primarily weak acids, are able to take up or release H+ so that changes in the free H+ concentration are minimized. For example, phosphate is an effective buffer, via the following reaction:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;HPO4(2-) &nbsp;+ &nbsp;H+ &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;H2PO4-",
"   </p>",
"   <p>",
"    If H+ ions are added to the extracellular fluid, they will drive this reaction to the right by combining with HPO4(2-) to form H2PO4-. Conversely, if H+ ions are lost from the extracellular fluid, the reaction will move to the left as H+ ions are released from H2PO4-. In contrast, strong acids, such as HCl, are poor buffers at the body pH, since they are almost completely ionized and cannot bind H+ ions.",
"   </p>",
"   <p>",
"    The efficiency of phosphate buffering can be appreciated from the following example. Let us assume that in 1 liter of solution there are 10 mmol each of HPO4(2-) and H2PO4- &nbsp;as the Na+ salts. From the Henderson equation:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[H2PO4-]",
"    <br/>",
"    &nbsp; &nbsp;[H+] &nbsp; = &nbsp; &nbsp; Ka &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [HPO4(2-)]",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;10",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; = &nbsp; 160 &nbsp; x &nbsp; &mdash;&mdash; &nbsp; &nbsp;= &nbsp; &nbsp;160",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    &nbsp; &nbsp; (pH=6.80)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;10",
"   </p>",
"   <p>",
"    Note that when the concentrations of acid (H2PO4-) and base (HPO4(2-)) are the same, the H+ concentration equals Ka &nbsp;and the pH equals pKa.",
"   </p>",
"   <p>",
"    If 2 mmol of HCl is added to this solution, the excess H+ ions can combine with HPO4(2-):",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;HCl &nbsp;+ &nbsp;Na2HPO4 &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;NaCl &nbsp;+ &nbsp;NaH2PO4",
"   </p>",
"   <p>",
"    If we assume that virtually all the added H+ is taken up by HPO4(2-), then the HPO4(2-) concentration will fall to 8",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and the H2PO4- concentration will rise to 12",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    The new H+ concentration will be,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;12",
"    <br/>",
"    &nbsp; &nbsp;[H+] &nbsp; = &nbsp; 160 &nbsp;x &nbsp; &mdash;&mdash; &nbsp; &nbsp;= &nbsp; 240",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    &nbsp; &nbsp; (pH &nbsp; = &nbsp; 6.62)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 8",
"   </p>",
"   <p>",
"    Thus, there has been an increase of 80",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    in the H+ concentration, even though 2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    or 2 million",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    of H+ has been added to the solution. As a result, more than 99.99 percent of the excess H+ ions has been taken up or buffered by HPO4(2-). If no buffers had been present, the H+ concentration would have been 2 million",
"    <span class=\"nowrap\">",
"     nanomol/L,",
"    </span>",
"    with a pH of 2.70.",
"   </p>",
"   <p>",
"    If more H+ ions are added or if H+ ions are removed by adding NaOH,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;NaOH &nbsp;+ &nbsp;NaH2PO4 &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;Na2HPO4 &nbsp; + &nbsp; H2O",
"   </p>",
"   <p>",
"    the change in pH (or H+ concentration) can be calculated in a similar manner. If the new pH is plotted against the amount of acid or base added, the result is the buffer curve in Figure 1 (",
"    <a class=\"graphic graphic_figure graphicRef74250 \" href=\"UTD.htm?21/11/21693\">",
"     figure 1",
"    </a>",
"    ). Although the shape of the curve is sigmoidal, there is a linear midregion (pH equals 5.80 to 7.80) in which relatively large amounts of acid or base can be added without much change in pH. Thus, a buffer is most efficient when the pH of the solution is within &plusmn; 1.0 pH unit of its pKa. If the pH is outside these limits, buffering will still occur, but a small amount of acid or base can produce a relatively large change in pH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BICARBONATE/CARBON DIOXIDE BUFFER SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbonic acid can dissociate into a hydrogen ion and a bicarbonate ion:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;H2CO3 &nbsp; &nbsp; &lt;&mdash;&gt; &nbsp; &nbsp; &nbsp;H+ &nbsp;+ &nbsp;HCO3-",
"   </p>",
"   <p>",
"    The pKa &nbsp;of this reaction is 3.57 (Ka &nbsp;equals 2.72 &nbsp;x &nbsp;10(-4)) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/1\">",
"     1",
"    </a>",
"    ]. Since this is far from the normal pH of 7.40, it seems as if HCO3- would be an ineffective buffer in the body. However, H2CO3 is formed from the hydration of carbon dioxide (CO2), and this buffer system can be more accurately described by the following series of reactions&dagger;:",
"   </p>",
"   <p>",
"    (Eq. 1) &nbsp; &nbsp;CO2 &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;CO2 &nbsp;+ &nbsp;H2O &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; H2CO3 &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; H+ &nbsp;+ &nbsp;HCO3-",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; gas &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; aqueous",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; phase &nbsp; &nbsp; &nbsp; phase",
"   </p>",
"   <p>",
"    &nbsp;&dagger; An additional reaction can occur, as HCO3- can dissociate into hydrogen and carbonate ions:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;HCO3- &nbsp; &nbsp; &lt;&mdash;&gt; &nbsp; &nbsp;H+ &nbsp;+ &nbsp;CO3(2-)",
"   </p>",
"   <p>",
"    However, the pKa of this reaction is 9.8, so that only trace amounts of carbonate are present in the physiologic pH range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dissolved carbon dioxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;All gases partially dissolve in water (that is, they enter the aqueous phase). The degree to which this occurs is proportional to the partial pressure of the gas in the solution. In humans, the partial pressure of CO2 (PCO2) in the arterial blood is in equilibrium with that in the alveolar air and normally is approximately 40 mmHg. At 37&ordm;C (normal body temperature), the amount of CO2 dissolved in the plasma is",
"   </p>",
"   <p>",
"    (Eq. 2) &nbsp; &nbsp;[CO2]dis &nbsp; &nbsp;= &nbsp; 0.03 PCO2",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;= &nbsp; &nbsp; 0.03 &nbsp;x &nbsp;40 &nbsp; = &nbsp; 1.2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"   </p>",
"   <p>",
"    where 0.03 is the solubility constant for CO2 in the plasma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hydration of Carbon Dioxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The equilibrium of the reaction",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;[CO2]dis &nbsp;+ &nbsp;H2O &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;H2CO3",
"   </p>",
"   <p>",
"    normally is far to the left so that there is approximately 340 molecules of CO2 in the solution for each molecule of H2CO3 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, an increase in the PCO2 &nbsp;increases the [CO2]dis &nbsp;and, therefore, the H2CO3 concentration. Thus, CO2, which is not an acid, increases the acidity of the solution through the formation of H2CO3.",
"   </p>",
"   <p>",
"    In certain tissues, such as red blood cells and the renal tubular epithelium, the rate of the hydration and dehydration reactions is enhanced by the enzyme carbonic anhydrase. The importance of this enzyme in renal H+ secretion and HCO3- reabsorption will be discussed in Chap. 11. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=see_link\">",
"     \"Chapter 11A: Renal hydrogen excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dissociation of carbonic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree to which H2CO3 dissociates into H+ &nbsp;+ &nbsp;HCO3- [Eq. (1)] can be appreciated from the law of mass action for this reaction:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [H+] [HCO3-]",
"    <br/>",
"    &nbsp; &nbsp;Ka &nbsp; &nbsp; = &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[H2CO3]",
"   </p>",
"   <p>",
"    Since the Ka &nbsp;is 2.72 &nbsp;x &nbsp;10-4 and the normal H+ concentration is 40 &nbsp;x &nbsp;10-9",
"    <span class=\"nowrap\">",
"     mol/L,",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 40 &nbsp;x &nbsp;10-9 &nbsp;x &nbsp;[HCO3-]",
"    <br/>",
"    &nbsp; &nbsp;2.72 &nbsp;x &nbsp;10-4 &nbsp; &nbsp;= &nbsp; &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[H2CO3]",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;[HCO3-]",
"    <br/>",
"    &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash; &nbsp; = &nbsp; 6.8 &nbsp;x &nbsp;103",
"    <br/>",
"    &nbsp; &nbsp;[H2CO3]",
"   </p>",
"   <p>",
"    Thus, there are approximately 6800 molecules of HCO3- for each molecule of H2CO3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Law of mass action for bicarbonate/carbon dioxide buffer system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the concentration of H2CO3 is so low in relation to the [CO2]dis (1:340) and to the HCO3- concentration (1:6800), the reactions",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;[CO2]dis &nbsp;+ &nbsp;H2O &nbsp; &nbsp; &lt;&mdash;&gt; &nbsp; H2CO3 &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;H+ &nbsp;+ &nbsp;HCO3-",
"   </p>",
"   <p>",
"    can be simplified to",
"   </p>",
"   <p>",
"    &nbsp;(Eq. 3) &nbsp; &nbsp;[CO2]dis &nbsp;+ &nbsp;H2O &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;H+ &nbsp;+ &nbsp;HCO3-",
"   </p>",
"   <p>",
"    The law of mass action for this reaction is",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[H+] [HCO3-]",
"    <br/>",
"    &nbsp; &nbsp;Ka &nbsp; &nbsp;= &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[CO2]dis [H2O]",
"   </p>",
"   <p>",
"    Since the concentration of water is constant, (Ka &nbsp; x &nbsp; [H2O]) can be replaced by K'a:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[H+] [HCO3-]",
"    <br/>",
"    (Eq. 4) &nbsp; &nbsp;K'a &nbsp; = &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [CO2]dis",
"   </p>",
"   <p>",
"    If we solve this equation for [H+]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;K'a &nbsp;x &nbsp;[CO2]dis",
"    <br/>",
"    &nbsp; &nbsp;[H+] &nbsp; = &nbsp; &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [HCO3-]",
"   </p>",
"   <p>",
"    In plasma at 37&ordm;C, K'a &nbsp;is equal to 800",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    (800 &nbsp;x &nbsp;10(-9)",
"    <span class=\"nowrap\">",
"     mol/L,",
"    </span>",
"    pK'a equals 6.10). Thus,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [CO2]dis",
"    <br/>",
"    (Eq. 5) &nbsp; &nbsp;[H+] &nbsp; = &nbsp; &nbsp; 800 &nbsp;x &nbsp;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [HCO3-]",
"   </p>",
"   <p>",
"    Substituting 0.03PCO2 &nbsp;for [CO2]dis,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;PCO2",
"    <br/>",
"    (Eq. 6) &nbsp; &nbsp;[H+] &nbsp; = &nbsp; &nbsp; 24 &nbsp;x &nbsp;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [HCO3-]",
"   </p>",
"   <p>",
"    Since the normal H+ concentration is 40",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    and the PCO2 &nbsp;is 40 mmHg, the normal HCO3- concentration can be calculated from Eq. (6):",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 40",
"    <br/>",
"    &nbsp; &nbsp;40 &nbsp; = &nbsp; 24 &nbsp;x &nbsp;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[HCO3-]",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;[HCO3-] &nbsp; = &nbsp; 24",
"    <span class=\"nowrap\">",
"     mmol/L&dagger;",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;&dagger; Since HCO3- is a univalent anion, this value also represents a concentration of 24",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    These relationships also can be expressed by the Henderson-Hasselbalch equation:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[HCO3-]",
"    <br/>",
"    (Eq. 7) &nbsp; &nbsp;pH &nbsp; = &nbsp; &nbsp; 6.10 &nbsp;+ &nbsp;log &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0.03 PCO2",
"   </p>",
"   <p>",
"    where 6.10 is the pK'a.",
"   </p>",
"   <p>",
"    The HCO3- concentration usually is measured in the laboratory in one of two ways [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/2\">",
"     2",
"    </a>",
"    ]. The first way is indirect, as the arterial pH and PCO2 &nbsp;are measured and the HCO3- concentration then calculated from the Henderson-Hasselbalch equation. The second method involves adding a strong acid to a venous blood sample and measuring the amount of CO2 generated by a colorimetric reaction. As the added H+ combines with plasma HCO3-, H2CO3 and then CO2 are formed as Eq. (1) is driven to the left. This method, however, measures the total CO2 content, which detects all of the forms in which CO2 is carried in the blood:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Total CO2 content &nbsp; = &nbsp; [HCO3-] &nbsp;+ &nbsp;[CO2]dis &nbsp;+ &nbsp;[H2CO3]",
"   </p>",
"   <p>",
"    Since the H2CO3 concentration is very low, it can be omitted. If 0.03PCO2 is substituted for [CO2]dis, then",
"   </p>",
"   <p>",
"    (Eq. 8) &nbsp; &nbsp;[HCO3-] &nbsp; = &nbsp; Total CO2 content &nbsp;- &nbsp;0.03 PCO2",
"   </p>",
"   <p>",
"    At a normal HCO3- concentration of 24",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and a normal PCO2 &nbsp;of 40 mmHg, the total CO2 content will be 24 &nbsp;+ &nbsp;(0.03 &nbsp;x &nbsp;40) or 25.2",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    Thus, when the total CO2 content is measured, Eq. (7) must be modified in the following way:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; total CO2 &nbsp;- &nbsp;0.03PCO2",
"    <br/>",
"    (Eq. 9) &nbsp; &nbsp;pH &nbsp; = &nbsp; &nbsp; log &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0.03PCO2",
"   </p>",
"   <p>",
"    For the sake of simplicity, only the HCO3- concentration will be used in this discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Buffering by bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the most efficient buffering occurs within 1.0 pH unit of the pKa. Although the pK'a &nbsp;for the",
"    <span class=\"nowrap\">",
"     HCO3-/CO2",
"    </span>",
"    system is 1.30 pH units less than the normal extracellular pH of 7.40, this system is able to buffer very effectively because the PCO2 can be regulated by changes in alveolar ventilation. An increase in ventilation augments CO2 excretion and lowers the PCO2 ; a reduction in ventilation decreases CO2 excretion, resulting in an increase in the PCO2. Thus, as H2CO3 is formed from the buffering of excess H+ ions by HCO3-, a subsequent elevation in the PCO2 &nbsp;(as Eq. (1) is driven to the left) can be prevented by an increase in alveolar ventilation, thereby enhancing the effectiveness of HCO3- buffering.",
"   </p>",
"   <p>",
"    The importance of this ability to regulate ventilation can be illustrated by the following example. Let us assume that 1 liter of plasma, in which HCO3- is the only buffer, has the following composition:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;[H+] &nbsp; = &nbsp; 40",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    &nbsp; &nbsp; (pH=7.40)",
"    <br/>",
"    &nbsp; &nbsp;[HCO3-] &nbsp; = &nbsp; 24",
"    <span class=\"nowrap\">",
"     mmol/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;PCO2 &nbsp; &nbsp;= &nbsp; 40 mmHg",
"    <br/>",
"    &nbsp; &nbsp;[CO2]dis &nbsp; &nbsp;= &nbsp; &nbsp; 1.2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    &nbsp; &nbsp; (0.03 &nbsp;x &nbsp;40 &nbsp; = &nbsp; 1.2)",
"   </p>",
"   <p>",
"    How many millimoles of HCl would have to be added to this solution to raise the H+ concentration to 80",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    (pH equals 7.10)? As each millimole of H+ combines with HCO3-, there will be an equimolar decrease in the HCO3- concentration and elevation in the [CO2]dis &nbsp;(rom Eq. 3) Thus, the new HCO3- concentration will be 24 &nbsp;- &nbsp;x &nbsp;and the new [CO2]dis &nbsp;will be 1.2 &nbsp;+ &nbsp;x. From Eq. 5,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[CO2]dis",
"    <br/>",
"    &nbsp; &nbsp;[H+] &nbsp; = &nbsp; &nbsp; 800 &nbsp;x &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[HCO3-]",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;1.2 &nbsp;+ &nbsp;x",
"    <br/>",
"    &nbsp; &nbsp;80 &nbsp; = &nbsp; 800 &nbsp;x &nbsp; &mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 24 &nbsp;- &nbsp;x",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;x &nbsp; = &nbsp; 1.1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"   </p>",
"   <p>",
"    This represents substantial buffering in that the H+ concentration has increased only from 40",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    to 80",
"    <span class=\"nowrap\">",
"     nanomol/L,",
"    </span>",
"    even though 1.1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (or 1.1 million",
"    <span class=\"nowrap\">",
"     nanomol/L)",
"    </span>",
"    has been added to the solution. However, this response would be physiologically inadequate, since the H+ concentration has risen to a potentially dangerous level after the addition of only 1.1 mmol of H+ per liter. The increase in the [CO2]dis &nbsp;to 2.3",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    in this setting is equivalent to an elevation in PCO2 &nbsp;to 77 mmHg (0.03 &nbsp; x &nbsp; 77 &nbsp; = &nbsp; 2.3).",
"   </p>",
"   <p>",
"    If, however, ventilation could be increased so that the PCO2 &nbsp;remained constant at 40 mmHg (and therefore the [CO2]dis &nbsp;at 1.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    then",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 1.2",
"    <br/>",
"    &nbsp; &nbsp;80 &nbsp; = &nbsp; 800 &nbsp;x &nbsp; &mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;24 &nbsp;- &nbsp;x",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;x &nbsp; = &nbsp; 12",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"   </p>",
"   <p>",
"    Thus, the ability to maintain the PCO2 at a constant level increases the efficiency of HCO3- buffering 11-fold. Furthermore, there will be an additional increase in the buffering capacity of HCO3- if ventilation can be sufficiently enhanced to reduce the PCO2 &nbsp;below 40 mmHg. If, for example, the PCO2 &nbsp;were lowered to 20 mmHg ([CO2]dis &nbsp; = &nbsp; 0.03 &nbsp;x &nbsp;20 &nbsp; = &nbsp; 0.6), then 18 mmol of H+ can be added to each liter of plasma before the H+ concentration increases to 80",
"    <span class=\"nowrap\">",
"     nanomol/L:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;0.6",
"    <br/>",
"    &nbsp; &nbsp;80 &nbsp; = &nbsp; 800 &nbsp;x &nbsp; &mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;24 &nbsp;- &nbsp;x",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;x &nbsp; = &nbsp; 18",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"   </p>",
"   <p>",
"    These changes in ventilation, which make the",
"    <span class=\"nowrap\">",
"     HCO3-/CO2",
"    </span>",
"    buffering system so effective, occur in humans, since the chemoreceptors controlling ventilation are sensitive to alterations in the extracellular H+ concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28852?source=see_link\">",
"     \"Chapter 11C: Effect of arterial pH on ventilation\"",
"    </a>",
"    .) If the H+ concentration is increased by the addition of HCl to the extracellular fluid, there will be an increase in ventilation, resulting in a reduction in the PCO2. This is an appropriate compensatory response, since the decrease in PCO2 &nbsp;will lower the H+ concentration toward normal. Conversely, a decrease in the H+ concentration (or increase in the pH) will reduce ventilation.",
"   </p>",
"   <p>",
"    The net effect is that the buffering capacity of the bicarbonate system differs from that of the nonbicarbonate buffers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/3\">",
"     3",
"    </a>",
"    ]. The latter is determined by the quantity of buffer and the extracellular pH as depicted in Figure 1 (",
"    <a class=\"graphic graphic_figure graphicRef74250 \" href=\"UTD.htm?21/11/21693\">",
"     figure 1",
"    </a>",
"    ). In comparison, the capacity of the bicarbonate system is primarily determined by the plasma HCO3- concentration; the ability to vary the PCO2 makes bicarbonate buffering capacity relatively independent of pH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ISOHYDRIC PRINCIPLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;From the law of mass action (Eq. 5), the",
"    <span class=\"nowrap\">",
"     acid/base",
"    </span>",
"    ratio of any weak acid is determined by its Ka &nbsp;and the H+ concentration of the solution. Since the H+ concentration affects each buffer, the following relationship is present:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0.03PCO2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [H2PO4-] &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [A-]",
"    <br/>",
"    (Eq. 10) &nbsp; &nbsp;[H+] &nbsp; = &nbsp; &nbsp; Ka1 &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; = &nbsp; Ka2 &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp;= &nbsp; Ka3 &nbsp;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[HCO3-] &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[HPO4(2-)] &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [HA]",
"   </p>",
"   <p>",
"    This is called the isohydric principle. If the H+ concentration is altered, the",
"    <span class=\"nowrap\">",
"     acid/base",
"    </span>",
"    ratio of all the buffers in the solution is affected. This means that studying the behavior of any one buffer is adequate to predict the behavior of the other buffers in the solution. Clinically, the acid-base status of a patient is expressed in terms of the principal extracellular buffer, the",
"    <span class=\"nowrap\">",
"     HCO3-/CO2",
"    </span>",
"    system:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PCO2",
"    <br/>",
"    &nbsp; &nbsp;[H+] &nbsp; = &nbsp; 24 &nbsp;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [HCO3-]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EXTRACELLULAR BUFFERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The body buffers are located in the extracellular and intracellular fluids and in bone. As described above, the ability of a particular buffer to protect the pH is proportional to its concentration and its pKa &nbsp;in relation to the ambient pH. In the extracellular fluid, HCO3- is the most important buffer, due both to its relatively high concentration and to the ability to vary the PCO2 &nbsp;via changes in alveolar ventilation. If, for example, H2SO4 is added to the extracellular fluid from the metabolism of the sulfur-containing amino acids methionine and cysteine&nbsp;&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/4\">",
"     4",
"    </a>",
"    ], the excess H+ will be buffered primarily by HCO3-:",
"   </p>",
"   <p>",
"    &nbsp;(Eq. 11) &nbsp; &nbsp;H2SO4 &nbsp;+ &nbsp;2NaHCO3 &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;Na2SO4 &nbsp;+ &nbsp;2H2CO3 &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;2CO2 &nbsp;+ &nbsp;2H2O",
"   </p>",
"   <p>",
"    The CO2 produced by this reaction is excreted by the lungs.",
"   </p>",
"   <p>",
"    Although HCO3- is an effective buffer for noncarbonic acids, it cannot buffer H2CO3, &nbsp;because the combination of H+ with HCO3- results in the regeneration of H2CO3:",
"   </p>",
"   <p>",
"    &nbsp;(Eq. 12) &nbsp; &nbsp;H2CO3 &nbsp;+ &nbsp;HCO3- &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;HCO3- &nbsp;+ &nbsp;H2CO3",
"   </p>",
"   <p>",
"    Consequently, H2CO3 is buffered primarily by the intracellular buffers (see below).",
"   </p>",
"   <p>",
"    There are other, quantitatively less important buffers in the extracellular fluid, including inorganic phosphates (plasma phosphate concentration of 1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    versus 24",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    of HCO3-) and the plasma proteins (Pr-) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    (Eq. 13) &nbsp; &nbsp;H+ &nbsp;+ &nbsp;Pr- &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;HPr",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INTRACELLULAR AND BONE BUFFERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary intracellular buffers are proteins, organic and inorganic phosphates, and, in the erythrocyte, hemoglobin (Hb-):",
"   </p>",
"   <p>",
"    (Eq. 14) &nbsp; &nbsp;H+ &nbsp;+ &nbsp;Hb- &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;HHb",
"   </p>",
"   <p>",
"    In addition, bone represents an important site of buffering of acid and base loads [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. An acid load, for example, is associated with uptake of some of the excess H+ ions by bone. This can occur in exchange for surface Na+ and K+, and by the dissolution of bone mineral, resulting in the release of buffer compounds, such as NaHCO3 and KHCO3 initially and then CaCO3 and CaHPO4, into the extracellular fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ]. This buffering reaction appears to be initiated in part by the fall in the plasma HCO3- concentration, since a similar reduction in extracellular pH induced by respiratory acidosis produces much less bone dissolution [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The loss of bone mineral with metabolic acidosis is not due simply to the physicochemical release of calcium during the buffering reaction, since a similar response is not seen in dead bone cells. This observation suggests cell activity must play a role and both decreased osteoblastic and increased osteoclastic function have been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/11\">",
"     11",
"    </a>",
"    ]. How this occurs is not known.",
"   </p>",
"   <p>",
"    Although it is difficult to measure the exact contribution of bone buffering, it has been estimated that as much as 40 percent of the buffering of an acute acid load takes place in bone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/12\">",
"     12",
"    </a>",
"    ]. The role of the bone buffers may be even greater in the presence of a chronic acid retention, such as that seen in patients with chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ]. It has been suggested that parathyroid hormone has a permissive effect on bone buffering [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/15\">",
"     15",
"    </a>",
"    ], but its physiologic importance remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone and intracellular buffers also participate in protecting the pH in the presence of base loads. For example, increased deposition of carbonate in bone has been demonstrated after the administration of NaHCO3 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, the associated reduction in the H+ concentration drives Eqs. 13 and 14 to the left, resulting in the release of H+ from proteins and hemoglobin, thereby tending to raise the H+ concentration toward normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical Implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;One consequence of bone buffering is that acid loading directly increases Ca2+ release from bone and urinary Ca2+ excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/9,16-18\">",
"     9,16-18",
"    </a>",
"    ], a relationship that may be an important contributing factor in some patients with calcium oxalate stone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H22#H22\">",
"     \"Risk factors for calcium stones in adults\", section on 'Protein'",
"    </a>",
"    .) A normal diet results in the generation of approximately 50 to 100 meq of H+ per day, most of which comes from the metabolism of sulfur-containing amino acids. Increasing the acid load by increasing protein intake can promote calcium stone formation via the following effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant rise in Ca2+ excretion.",
"     </li>",
"     <li>",
"      A reduction in the excretion of citrate by increasing its reabsorption in the proximal tubule. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36905?source=see_link&amp;anchor=H12#H12\">",
"       \"Chapter 3B: Primacy of sodium transport in proximal function\", section on 'Citrate'",
"      </a>",
"      .) Urinary citrate is normally an important inhibitor of stone formation, by forming a nondissociable but soluble complex with Ca2+, thereby decreasing the availability of free Ca2+ to precipitate with oxalate [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A reduction in urine pH. Although calcium oxalate precipitation is not pH-dependent, the more acid urine promotes the conversion of urinary urate to the much less soluble uric acid &nbsp;(urate- &nbsp; + &nbsp; H+ &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;uric acid) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/19,21\">",
"       19,21",
"      </a>",
"      ]. The possible subsequent precipitation of uric acid can then act as a nidus for calcium stone formation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another significant clinical effect of bone buffering is the gradual reduction in bone calcium stores in patients with end-stage renal disease, a disorder associated with progressive acid retention due to impaired urinary acid excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/22\">",
"     22",
"    </a>",
"    ]. Another site of buffering in these patients is skeletal muscle, which can lead to protein breakdown and muscle wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CHEMICAL BUFFERING OF ACIDS AND BASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <strong>",
"     Acidosis and alkalosis",
"    </strong>",
"    &mdash; The arterial H+ concentration is abnormal in a variety of clinical conditions. An increase in the H+ concentration (or decrease in the pH) is called acidemia; a decrease in the H+ concentration (or increase in the pH) is called alkalemia. Processes which tend to raise or lower the H+ concentration are called acidosis and alkalosis, respectively.",
"   </p>",
"   <p>",
"    In general, acidosis induces acidemia and alkalosis induces alkalemia. However, the difference between these phenomena becomes important in those patients who have mixed acid-base disturbances in which both acidotic and alkalotic processes may coexist. In this setting, the net pH may be acidemic, even though a disorder which induces an alkalosis is also present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relation between the H+ concentration, PCO2, and plasma bicarbonate concentration can be expressed as:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;PCO2",
"    <br/>",
"    (Eq. 1) &nbsp; &nbsp;[H+] &nbsp; = &nbsp; 24 &nbsp; x &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[HCO3-]",
"   </p>",
"   <p>",
"    Thus, a primary elevation in the PCO2 &nbsp;causes acidemia whereas a decrease in the PCO2 &nbsp;causes alkalemia. Since the PCO2 is regulated by the rate of alveolar ventilation, these disturbances are referred to as respiratory acidosis and respiratory alkalosis.",
"   </p>",
"   <p>",
"    The H+ concentration also varies inversely with the plasma HCO3- concentration. Processes which primarily lower or raise the plasma HCO3- concentration are called metabolic acidosis and metabolic alkalosis, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Buffer Responses to Acid and Base loads",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of the body buffers in protecting the pH can be appreciated from the data in Table 1 (",
"    <a class=\"graphic graphic_figure graphicRef68428 \" href=\"UTD.htm?1/13/1247\">",
"     figure 2",
"    </a>",
"    ). In these experiments, metabolic acidosis (with acidemia) was induced in dogs by the infusion of HCl. The dogs were nephrectomized to eliminate the effect of changes in renal H+ excretion. The total extracellular amounts of Na+, K+, HCO3-, and Cl- were calculated from the product of the extracellular fluid volume (estimated from the volume of distribution of sulfate, which is limited to the extracellular fluid) and the plasma electrolyte concentrations.",
"   </p>",
"   <p>",
"    An average of 180 mmol of HCl was administered to each dog (the mean weight being 18.9 kg). Let us assume that the total body water was 60 percent of the body weight, or 11.3 liters. If 180 mmol of H+ were distributed through 11.3 liters of distilled water, the H+ concentration would be 16",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (pH of 1.80), a level that is incompatible with life. In intact animals, however, the arterial pH only fell from 7.40 to 7.07 (H+ concentration of 86",
"    <span class=\"nowrap\">",
"     nanomol/L).",
"    </span>",
"    This was associated with a reduction in the plasma HCO3- concentration from 24 to 7",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (by the combination of extracellular HCO3- with the excess H+), and a compensatory increase in alveolar ventilation that lowered the PCO2 &nbsp;from 40 to 25 mmHg. Thus, the body buffers were extremely effective in minimizing the degree of acidemia.",
"   </p>",
"   <p>",
"    The relative contributions of the intracellular and extracellular buffers to this process can be estimated from the changes in the quantities of Na+, K+, HCO3, and Cl- in the extracellular fluid. The administered H+ ions either remain in the extracellular fluid or enter the cells (",
"    <a class=\"graphic graphic_figure graphicRef68866 \" href=\"UTD.htm?9/25/9628\">",
"     figure 3",
"    </a>",
"    ). The H+ ions that stay in the extracellular fluid are buffered by HCO3- (and, to a much lesser degree, the plasma proteins), resulting in a decrease in the amount of extracellular HCO3-. If H+ ions enter the cells, then, to maintain electroneutrality, either Cl- will follow H+ into the cells (primarily into the red blood cells, where H+ is buffered by Hb-) or Na+ and K+ ions will leave the cells (and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/10\">",
"     10",
"    </a>",
"    ] ) and enter the extracellular fluid. From Table 1 (",
"    <a class=\"graphic graphic_figure graphicRef68428 \" href=\"UTD.htm?1/13/1247\">",
"     figure 2",
"    </a>",
"    ), of the 180 mmol of H+ infused, 78 mmol has been buffered by HCO3- and 103 mmol has entered the cells: 65 mmol in exchange for Na+, 28 mmol in exchange for K+, and 10 mmol followed by Cl- (180 mmol of Cl- was infused but only 170 mmol remained in the extracellular fluid&dagger;). These results are depicted schematically in Figure 2 (",
"    <a class=\"graphic graphic_figure graphicRef53254 \" href=\"UTD.htm?40/13/41181\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;&dagger; An alternative explanation for the intracellular movement of Cl- is that Cl- enters the red cell in exchange for intracellular HCO3-. This HCO3- moves into the extracellular fluid and buffers the excess H+. The net effect is the same as HCl entry into the cell.",
"   </p>",
"   <p>",
"    Buffering by the extracellular and intracellular buffers follows a characteristic time course that is dependent upon the rapidity with which the administered H+ ions move into the different fluid compartments. Buffering by plasma HCO3- occurs almost immediately, whereas approximately 15 min is required for H+ to diffuse into the interstitial space to be buffered by interstitial HCO3-. H+ entry into the cells occurs more slowly, as buffering by cell buffers is not complete until 2 to 4 h have elapsed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potentially serious complication of the transcellular exchange of H+ for K+ that follows a H+ load is an elevation in the plasma K+ concentration, e.g., from the normal of 4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    to as high as 6 to 7",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in severe metabolic acidemia (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10136?source=see_link&amp;anchor=H9#H9\">",
"     \"Chapter 12A: Distribution of potassium between the cells and ECF\", section on 'Extracellular pH'",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/26\">",
"     26",
"    </a>",
"    ]. A similar increase may occur in the plasma Na+ concentration, because Na+ also leaves the cells. However, variations of several milliequivalents per liter are not physiologically important, since the normal plasma Na+ concentration is approximately 140",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"   </p>",
"   <p>",
"    The relative contribution of the HCO3- and nonbicarbonate buffers in the cells and bone to an acid load varies with the plasma HCO3- concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/3\">",
"     3",
"    </a>",
"    ]. In normal subjects, both buffer systems make equivalent contributions. This does not apply, however, to metabolic acidosis or severe chronic respiratory alkalosis, disorders associated with a low plasma HCO3- concentration (see below). In these settings, the role of the nonbicarbonate buffers becomes increasingly important since the cells and bone have a virtually limitless buffering capacity &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Respiratory Acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to respiratory acidosis (high PCO2) differs from that to metabolic acidosis in that there is virtually no extracellular buffering, since HCO3- is not an effective buffer for H2CO3.",
"   </p>",
"   <p>",
"    (Eq. 2) &nbsp; &nbsp;H2CO3 &nbsp;+ &nbsp;HCO3- &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;HCO3- &nbsp;+ &nbsp;H2CO3",
"   </p>",
"   <p>",
"    As the PCO2 increases, the elevation in H+ concentration is initially minimized by a buffer-induced rise in the plasma HCO3- concentration&dagger;. This HCO3- is derived from two major sources: (1) extracellular H2CO3 dissociates into HCO3- ions and H+ ions, with the latter moving into the cells (and bone) in exchange for intracellular Na+ and K+; and (2) HCO3- is released from erythrocytes in exchange for extracellular Cl- (",
"    <a class=\"graphic graphic_figure graphicRef65034 \" href=\"UTD.htm?36/3/36925\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp; &dagger;It is important to remember that the H+ concentration is determined by the ratio between, not the absolute levels of, PCO2 and HCO3-. Thus, the H+ concentration can be maintained at or near normal, when there are parallel changes in the PCO2 and plasma HCO3- concentration.",
"   </p>",
"   <p>",
"    The latter process occurs in the following manner. CO2 diffuses into the erythrocyte where it combines with H2O to form H2CO3. This reaction is catalyzed by the enzyme carbonic anhydrase. H2CO3 is then buffered by Hb-:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;H2CO3 &nbsp;+ &nbsp;Hb- &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;HHb &nbsp;+ &nbsp;HCO3-",
"   </p>",
"   <p>",
"    It is this HCO3- that moves into extracellular fluid. Of lesser importance is the uptake of H+ by the plasma proteins and by extracellular lactate:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Na lactate &nbsp;+ &nbsp;H2CO3 &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;lactic acid &nbsp;+ &nbsp;NaHCO3",
"   </p>",
"   <p>",
"    The lactic acid produced by this reaction is metabolized within the cells, either into CO2 and H2O or via gluconeogenesis into glucose.",
"   </p>",
"   <p>",
"    In humans, these buffers in the aggregate increase the plasma HCO3- concentration approximately 1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    for each 10 mmHg elevation in the PCO2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .) The degree to which this response protects the H+ concentration can be appreciated if we calculate the effects of increasing the PCO2 from 40 to 80 mmHg. If there is no buffering and the plasma HCO3- concentration remains constant, then the new H+ concentration will be",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;80",
"    <br/>",
"    &nbsp; &nbsp;[H+] &nbsp; = &nbsp; 24 &nbsp;x &nbsp;&mdash;&mdash;&mdash; &nbsp; &nbsp; = &nbsp; &nbsp; &nbsp;80",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    &nbsp; &nbsp;(pH &nbsp; = &nbsp; 7.10)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;24",
"   </p>",
"   <p>",
"    However, a 40 mmHg elevation in the PCO2 &nbsp;normally will induce roughly a 4",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    increase in the plasma HCO3- concentration. In this situation,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;80",
"    <br/>",
"    &nbsp; &nbsp;[H+] &nbsp; = &nbsp; 24 &nbsp;x &nbsp;&mdash;&mdash;&mdash; &nbsp; &nbsp;= &nbsp; &nbsp; 69",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    &nbsp; &nbsp; (pH &nbsp; = &nbsp; 7.17)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;28",
"   </p>",
"   <p>",
"    As illustrated by this example, the buffer-induced elevation in the plasma HCO3- concentration is not particularly effective in protecting the H+ concentration in respiratory acidosis. However, the most effective defense against respiratory acidosis is a further increase in the plasma HCO3- concentration produced by enhanced renal H+ excretion. This response, which takes 4 to 5 days to reach completion, results in a 3.5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    elevation in the plasma HCO3- concentration for every 10 mmHg increase in the PCO2. Thus, at a PCO2 of 80 mmHg, the combined buffering and renal responses will raise the plasma HCO3- concentration from 24 to about 38",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    resulting in much better protection of the arterial H+ concentration and pH:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;80",
"    <br/>",
"    &nbsp; &nbsp;[H+] &nbsp; = &nbsp; 24 &nbsp;x &nbsp;&mdash;&mdash;&mdash; &nbsp; &nbsp;= &nbsp; &nbsp;50",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    &nbsp; &nbsp;(pH &nbsp; = &nbsp; 7.30)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;38",
"   </p>",
"   <p>",
"    The intracellular and extracellular buffers also protect the pH in metabolic and respiratory alkalosis, as the buffer reactions move in the opposite direction from that observed in the acidemic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/27\">",
"     27",
"    </a>",
"    ] &dagger;. Thus, H+ ions are released, not taken up, by the buffers. For example,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;HPr &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;H+ &nbsp;+ &nbsp;Pr-",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;H2PO4- &nbsp; &nbsp; &mdash;&gt; &nbsp; &nbsp; &nbsp;H+ &nbsp;+ &nbsp;HPO4(2-)",
"   </p>",
"   <p>",
"    &nbsp;&dagger; Although similar buffers are involved, the percentage contributions of the individual intracellular and extracellular buffers are somewhat different in alkalemia than those shown in Figures 2 and 3 for acidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These H+ ions then react with HCO3-, resulting in an appropriate reduction in the plasma HCO3- concentration, which tends to lower the elevated pH toward normal. To the degree that these H+ ions are derived from cell buffers, their movement into the extracellular fluid occurs in exchange for extracellular Na+ and K+, which enter the cells. Thus, the plasma concentrations of Na+ and K+, which tend to rise with acidemia, may fall with alkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23224/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1922?source=see_link\">",
"     \"Chapter 10C: Intracellular pH\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/1\">",
"      Malnic G, Giebisch G. Symposium on acid-base homeostasis. Mechanism of renal hydrogenion secretion. Kidney Int 1972; 1:280.",
"     </a>",
"    </li>",
"    <li>",
"     Gennari, FJ, Cohen, JJ, Kassirer, JP. Measurement of acid-base status. In: Acid / Base, Cohen JJ, Kassirer JP (Ed), Little, Brown, Boston, 1982, pp.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/3\">",
"      Fernandez PC, Cohen RM, Feldman GM. The concept of bicarbonate distribution space: the crucial role of body buffers. Kidney Int 1989; 36:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/4\">",
"      Lennon EJ, Lemann J Jr, Litzow JR. The effects of diet and stool composition on the net external acid balance of normal subjects. J Clin Invest 1966; 45:1601.",
"     </a>",
"    </li>",
"    <li>",
"     Madias, NE, Cohen, JJ. Acid-base chemistry and buffering. In: Acid / Base, Cohen JJ, Kassirer JP (Ed), Little, Brown, Boston, 1982, pp.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/6\">",
"      Lemann J Jr, Lennon EJ. Role of diet, gastrointestinal tract and bone in acid-base homeostasis. Kidney Int 1972; 1:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/7\">",
"      Lemann J Jr, Litzow JR, Lennon EJ. The effects of chronic acid loads in normal man: further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis. J Clin Invest 1966; 45:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/8\">",
"      Bettice JA. Skeletal carbon dioxide stores during metabolic acidosis. Am J Physiol 1984; 247:F326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/9\">",
"      Green J, Kleeman CR. Role of bone in regulation of systemic acid-base balance. Kidney Int 1991; 39:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/10\">",
"      Chabala JM, Levi-Setti R, Bushinsky DA. Alteration in surface ion composition of cultured bone during metabolic, but not respiratory, acidosis. Am J Physiol 1991; 261:F76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/11\">",
"      Krieger NS, Sessler NE, Bushinsky DA. Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro. Am J Physiol 1992; 262:F442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/12\">",
"      Burnell JM. Changes in bone sodium and carbonate in metabolic acidosis and alkalosis in the dog. J Clin Invest 1971; 50:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/13\">",
"      Litzow JR, Lemann J Jr, Lennon EJ. The effect of treatment of acidosis on calcium balance in patients with chronic azotemic renal disease. J Clin Invest 1967; 46:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/14\">",
"      Lemann J, Litzow JR, Lennon EJ. Studies of the mechanism by which chronic metabolic acidosis augments urinary calcium excretion in man. J Clin Invest 1967; 46:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/15\">",
"      Arruda JA, Alla V, Rubinstein H, et al. Parathyroid hormone and extrarenal acid buffering. Am J Physiol 1980; 239:F533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/16\">",
"      Bleich HL, Moore MJ, Lemann J Jr, et al. Urinary calcium excretion in human beings. N Engl J Med 1979; 301:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/17\">",
"      Lau K, Wolf C, Nussbaum P, et al. Differing effects of acid versus neutral phosphate therapy of hypercalciuria. Kidney Int 1979; 16:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/18\">",
"      Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE. The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab 1990; 71:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/19\">",
"      Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988; 66:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/20\">",
"      Parks JH, Coe FL. A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 1986; 30:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/21\">",
"      Coe FL. Uric acid and calcium oxalate nephrolithiasis. Kidney Int 1983; 24:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/22\">",
"      Bushinsky DA. The contribution of acidosis to renal osteodystrophy. Kidney Int 1995; 47:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/23\">",
"      Bailey JL, Wang X, England BK, et al. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 1996; 97:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/24\">",
"      Graham KA, Reaich D, Channon SM, et al. Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int 1996; 49:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/25\">",
"      SCHWARTZ WB, ORNING KJ, PORTER R. The internal distribution of hydrogen ions with varying degrees of metabolic acidosis. J Clin Invest 1957; 36:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23224/abstract/26\">",
"      Adrogu&eacute; HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med 1981; 71:456.",
"     </a>",
"    </li>",
"    <li>",
"     Pitts, RF. Physiology of the Kidney and Body Fluids. Year Book, Chicago 1974; chap 11.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7261 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23224=[""].join("\n");
var outline_f22_43_23224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BICARBONATE/CARBON DIOXIDE BUFFER SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dissolved carbon dioxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hydration of Carbon Dioxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dissociation of carbonic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Law of mass action for bicarbonate/carbon dioxide buffer system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Buffering by bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ISOHYDRIC PRINCIPLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EXTRACELLULAR BUFFERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INTRACELLULAR AND BONE BUFFERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CHEMICAL BUFFERING OF ACIDS AND BASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Buffer Responses to Acid and Base loads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Respiratory Acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7261\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7261|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/11/21693\" title=\"figure 1\">",
"      Buffering by phosphate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/13/1247\" title=\"figure 2\">",
"      Buffering of acid load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/25/9628\" title=\"figure 3\">",
"      Acidosis and K distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/13/41181\" title=\"figure 4\">",
"      Buffers in metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/3/36925\" title=\"figure 5\">",
"      Buffers in respiratory acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1922?source=related_link\">",
"      Chapter 10C: Intracellular pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=related_link\">",
"      Chapter 11A: Renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28852?source=related_link\">",
"      Chapter 11C: Effect of arterial pH on ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10136?source=related_link\">",
"      Chapter 12A: Distribution of potassium between the cells and ECF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36905?source=related_link\">",
"      Chapter 3B: Primacy of sodium transport in proximal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_43_23225="Techniques for lower extremity amputation";
var content_f22_43_23225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Techniques for lower extremity amputation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23225/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23225/contributors\">",
"     Venkat Kalapatapu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23225/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23225/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23225/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23225/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/43/23225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H603460109\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower extremity amputation is performed to remove ischemic, infected or necrotic tissue, or locally unresectable tumor, and at times, may be life-saving. The majority of lower extremity amputations are performed for lower extremity ischemia (peripheral artery disease, embolism) and diabetes mellitus. Extremity trauma is the second leading cause for amputation, and malignancy accounts for the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The techniques for major amputation and foot amputations are reviewed here. The indications for lower extremity amputation, preoperative and postoperative care, complications and outcomes are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8810?source=see_link\">",
"     \"Lower extremity amputation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H729837576\">",
"    <span class=\"h1\">",
"     SURGICAL ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170898554\">",
"    <span class=\"h2\">",
"     Hip and thigh",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hip joint is a multiaxial ball-and-socket joint. The ligamentous structures of the joint are the fibrous capsule, the acetabular labrum, the ligament of the head of the femur, iliofemoral, ischiofemoral, pubofemoral and the transverse acetabular ligament.",
"   </p>",
"   <p>",
"    The muscles that surround the hip joint are divided into three groups: anterior, posterior, and inferior. The anterior group, lateral to medial, includes the rectus femoris, iliopsoas, and pectineus. Anterior to this group are the sartorius and tensor fascia lata. The posterior group consists of the piriformis, obturator internus, quadratus femoris, and obturator externus.",
"   </p>",
"   <p>",
"    The muscles of the thigh are divided into three groups (",
"    <a class=\"graphic graphic_figure graphicRef56894 \" href=\"UTD.htm?35/14/36071\">",
"     figure 1",
"    </a>",
"    ): The anterior group consists of the sartorius, tensor fascia lata, and quadriceps femoris (vastus medialis, intermedius, and lateralis, rectus femoris); the medial group includes the gracilis, pectineus, and adductor longus, brevis and magnus; the posterior group consists of the biceps femoris, semitendinosus and semimembranosus. The adductor muscles insert into the posterolateral femur along a narrow ridge called the linea aspera.",
"   </p>",
"   <p>",
"    The femur articulates with the tibia via the knee joint while the fibula articulates with the tibia via the superior tibiofibular joint. The stability of the knee joint depends upon the anterior and posterior cruciate ligaments and medial and lateral collateral ligaments. The patellar ligament is the central portion of the common tendon of the quadriceps femoris, which inserts on the tuberosity of the tibia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170898595\">",
"    <span class=\"h2\">",
"     Leg",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four compartments contain the muscles of the leg (",
"    <a class=\"graphic graphic_figure graphicRef68629 \" href=\"UTD.htm?41/27/42424\">",
"     figure 2",
"    </a>",
"    ). The anterior compartment contains the tibialis anterior, extensor hallucis longus and the extensor digitorum longus muscles, and the deep peroneal nerve. The lateral compartment contains the peroneus longus and brevis muscles and the superficial peroneal nerve. The posterior compartment is subdivided into superficial and deep compartments. The superficial posterior compartment consists of the gastrocnemius and soleus muscles. The deep posterior compartment contains the tibialis posterior, flexor digitorum longus and the flexor hallucis longus muscles. The tibial nerve runs distally in this compartment adjacent the posterior tibial artery.",
"   </p>",
"   <p>",
"    The sural artery arises from the popliteal artery proximal to the tibial trifurcation and supplies the gastrocnemius muscle and the posterior skin. The skin of the leg is also supplied by fasciocutaneous perforating arteries that arise from the posterior tibial, anterior tibial, sural, saphenous and peroneal arteries. To preserve adequate skin blood supply via these fasciocutaneous perforators, the skin and subcutaneous tissues should not be separated from the underlying fascia. The saphenous artery accompanies the saphenous vein and nerve (",
"    <a class=\"graphic graphic_figure graphicRef59888 \" href=\"UTD.htm?15/3/15409\">",
"     figure 3",
"    </a>",
"    ) below the knee, and supplies the skin of the anteromedial leg along with perforating branches of the posterior tibial artery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170898602\">",
"    <span class=\"h2\">",
"     Ankle and foot",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibia and the fibula are connected distally by a fibrous inferior tibiofibular joint that is sacrificed in conventional below-knee amputation (BKA). The tibia and the fibula articulate with the talus via the talocrural joint (",
"    <a class=\"graphic graphic_figure graphicRef58407 \" href=\"UTD.htm?12/56/13194\">",
"     figure 4",
"    </a>",
"    ). Ligamentous attachments include the deltoid, anterior and posterior talofibular, and the calcaneofibular ligaments. The talus articulates with the calcaneus at the subtalar joint. The medial and lateral talocalcaneal ligaments and the cervical ligament support this joint.",
"   </p>",
"   <p>",
"    The talocalcaneonavicular joint (",
"    <a class=\"graphic graphic_figure graphicRef58407 \" href=\"UTD.htm?12/56/13194\">",
"     figure 4",
"    </a>",
"    ) is a multiaxial joint supported by the talonavicular and plantar calcaneonavicular ligaments. A heavy fibrofatty heel pad firmly adheres to the calcaneus and the skin, and provides protection during heel strike. Supination (inversion) at this joint is produced by tibialis anterior and posterior. Pronation (eversion) is produced by the peroneus longus and brevis. When these strong ankle extensor attachments are divided during midfoot and hindfoot amputation, the Achilles tendon exerts unopposed plantar flexor forces on the residual foot. The Achilles tendon may require division or lengthening to prevent an equinus deformity. (See",
"    <a class=\"local\" href=\"#H603461888\">",
"     'Midfoot and hindfoot amputations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The metatarsal heads (",
"    <a class=\"graphic graphic_figure graphicRef58407 \" href=\"UTD.htm?12/56/13194\">",
"     figure 4",
"    </a>",
"    ) are stabilized by a series of segmental deep transverse metatarsal ligaments that connect the plantar ligaments of the adjacent metatarsophalangeal joints. Proximally, the metatarsals articulate with the three cuneiforms (medial, intermediate, and lateral) and the cuboid bone. These bones are connected by the dorsal and plantar tarsometatarsal and the interosseous cuneometatarsal ligaments. The tarsometatarsal, or Lisfranc&rsquo;s joint, connects the midfoot to the forefoot.",
"   </p>",
"   <p>",
"    There are two phalanges in the first toe and three in each of the remaining four toes (",
"    <a class=\"graphic graphic_figure graphicRef58407 \" href=\"UTD.htm?12/56/13194\">",
"     figure 4",
"    </a>",
"    ). The interphalangeal and metatarsophalangeal joints are hinge joints. Each has an articular capsule and medial and lateral collateral ligaments. The plantar surface of the articular capsule is strengthened to form a fibrous plate (plantar ligament), which limits toe extension. The flexor hallucis longus and flexor digitorum longus tendons insert on the distal phalanges. The flexor hallucis brevis inserts on the proximal phalanx of the first toe. There are typically two sesamoid bones contained within the flexor hallucis brevis tendon that articulate with the plantar surface of the first metatarsal head.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H729837590\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF AMPUTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the level of amputation, a number of general principles should be observed to minimize complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H738694683\">",
"    <span class=\"h2\">",
"     Staged amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staged (two-stage) amputation involves first a debriding amputation in the form of an open &ldquo;guillotine&rdquo; amputation (transfemoral, transtibial), through-the-joint amputation, or less commonly, cryoamputation, followed by definitive revision and wound closure after infection has been controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Debriding foot amputation at the toe, forefoot, or ankle level can also be used.",
"   </p>",
"   <p>",
"    A debriding amputation is a rapid and effective method for removing infected or necrotic tissue that is a source of sepsis. Non-staged amputations should be avoided in patients with severe lower extremity infections, particularly patients with diabetes with severe forefoot infections. A subset of patients with severe medical comorbidities may also benefit from a staged amputation. In two small trials, staged amputation was associated with better outcomes. In one of these trials, the incidence of postoperative stump infection was reduced (none versus 21 percent), rates of primary healing were higher (97 versus 78 percent) and fewer revisions (none versus 11 percent) were needed compared with non-staged amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/5\">",
"     5",
"    </a>",
"    ]. Disadvantages of this technique include the need for a second procedure, additional anesthetic, prolonged hospitalization, and increased cost. Another disadvantage is the pain associated with dressing changes to the open stump.",
"   </p>",
"   <p>",
"    Once the infected limb is removed, the patient is treated with antibiotics and open dressing changes for three to five days. If the white blood cell count is trending downward and the stump is clean, the second stage can be performed. At the second stage, the stump is debrided and closed. A drain is usually left in place. (See",
"    <a class=\"local\" href=\"#H170872506\">",
"     'Dressings and drains'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H614731798\">",
"    <span class=\"h3\">",
"     Cryoamputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoamputation refers to a bedside technique that uses dry ice to &ldquo;hard freeze&rdquo; the extremity, resulting in a physiologic amputation. Cryoamputation controls local infection by quarantining metabolic waste products within the frozen limb. For patients with indications for amputation but who have severe medical comorbidities that preclude safe anesthesia, cryoamputation can be used as a temporizing measure to avoid surgery until the patient can be stabilized medically [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, cryoamputation is rarely needed where modern surgical and anesthetic techniques are available. Proponents of the technique report improved mortality compared with emergency amputation in appropriately selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ]. The main complication associated with cryoamputation is migration of the frost line above the intended level of amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/11\">",
"     11",
"    </a>",
"    ]. The need for amputation stump revision may also be greater.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1672165516\">",
"    <span class=\"h2\">",
"     Draping",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mechanical barrier (impervious plastic sleeves, iodinated adhesive skin drape) should be used to isolate infected areas prior to undertaking amputation. For foot or toe amputation, adhesive drapes are impractical on the toes, but the finger of a surgical glove may serve as an effective condom to isolate a necrotic or septic area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1672165523\">",
"    <span class=\"h2\">",
"     Tourniquets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tourniquets have been shown to reduce intraoperative blood loss and decrease the need for postoperative blood transfusion in above-knee and below-knee amputations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/14\">",
"     14",
"    </a>",
"    ]. However, tourniquets are probably of little benefit in patients undergoing amputation for extremity ischemia.",
"   </p>",
"   <p>",
"    To use a tourniquet, the extremity is first exsanguinated using elastic compression (eg, Esmarch), followed by placement of a sterile tourniquet usually in the proximal thigh (above-knee and below-knee amputation) or calf (foot amputations) and insufflated to 1.5 to 2.0 times the systolic pressure. Exsanguination is omitted if there is associated soft tissue infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1672165562\">",
"    <span class=\"h2\">",
"     General techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific surgical techniques minimize tissue ischemia when performing lower extremity amputation in patients with lower extremity ischemia, and these practices are equally applicable to lower extremity amputation in patients with normal lower extremity perfusion, such as the younger patient with extremity injury or a patient with a Charcot foot deformity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Handle the soft tissues gently.",
"     </li>",
"     <li>",
"      Avoid beveling of the skin and tissues by maintaining the scalpel perpendicular to the skin surface.",
"     </li>",
"     <li>",
"      Do not separate the skin from the underlying fascia to prevent ischemia of the skin flaps.",
"     </li>",
"     <li>",
"      Use skin hooks or fine-toothed forceps to retract the skin, and not crushing instruments (eg, Debakey forceps). Some surgeons rely only on gentle finger retraction.",
"     </li>",
"     <li>",
"      Dissect named arteries and veins free from one another and ligate and divide each separately to prevent arteriovenous fistula formation. Oversew major arteries and ligate them more proximally. Simple ligation is adequate for occluded or partially occluded vessels (minimal flow). Simple ligation suffices for most veins.",
"     </li>",
"     <li>",
"      Ligate nerves just proximal to their point of transection to minimize bleeding from the perineurium and transect the nerve sharply proximal to the weight-bearing surface to avoid the development of neuroma, which can lead to chronic stump pain.",
"     </li>",
"     <li>",
"      Minimize the use of electrocautery by using suture ligatures for hemostasis.",
"     </li>",
"     <li>",
"      Avoid creating surgical scars (new or old) on the weight-bearing surface.",
"     </li>",
"     <li>",
"      Prevent scar retraction by interposing muscle and fascia between the skin and cut surface of bone.",
"     </li>",
"     <li>",
"      Approximate skin flaps without tension. Skin closure with either monofilament sutures or staples is acceptable.",
"     </li>",
"     <li>",
"      Avoid excessive trimming of small dog-ears or other minor cosmetic irregularities. Although a large amount of redundant soft tissue will interfere with proper prosthetic fit, minor irregularities will remodel.",
"     </li>",
"     <li>",
"      Irrigate the wound thoroughly once the dissection is complete to remove any debris or bony fragments.",
"     </li>",
"     <li>",
"      Stabilize antagonistic muscle groups using myoplasty (suture fixation of antagonistic muscle groups to bone) or myodesis (suturing the muscle to the periosteum) to prevent muscle atrophy and skeletal misalignment [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bevel bony prominences and file sharp edges smooth.",
"     </li>",
"     <li>",
"      Avoid excessive periosteal stripping to prevent ring sequestra or bony overgrowth.",
"     </li>",
"     <li>",
"      Close the amputation stump in layers with interrupted absorbable sutures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603464736\">",
"    <span class=\"h1\">",
"     MAJOR AMPUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major amputations of the lower extremity are those above the level of the ankle. These include hip disarticulation, above-knee amputation (transfemoral), knee disarticulation, and below-knee amputation (transtibial). Techniques to perform these procedures are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603461713\">",
"    <span class=\"h2\">",
"     Hip disarticulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;To perform a hip disarticulation, an anterior racquet incision or a long posterior flap incision can be used (",
"    <a class=\"graphic graphic_figure graphicRef71192 \" href=\"UTD.htm?29/63/30711\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior racquet incision starts an inch medial to the anterior superior iliac spine, extends to the pubic tubercle and continues posteriorly distal to the ischial tuberosity and gluteal crease. The incision continues anteriorly, medial to the greater trochanter and the anterior inferior iliac spine to rejoin the starting point.",
"     </li>",
"     <li>",
"      To create a posterior flap, the incision begins an inch inferior and parallel to the inguinal ligament anteriorly and extends to the posterior thigh to create a flap. The length of the posterior flap is one and a half times the diameter of the thigh at the level of the hip joint.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the skin incision has been made, the femoral artery and vein are identified and ligated. The musculature and associated vessels and nerves in the proximal thigh are divided, beginning anteriorly and progressing posteriorly (",
"    <a class=\"graphic graphic_figure graphicRef71192 \" href=\"UTD.htm?29/63/30711\">",
"     figure 5",
"    </a>",
"    ). The sartorius and iliopsoas muscles are divided at the anterior superior iliac spine and lesser trochanter, respectively. The pectineus, gracilis and adductor muscles are divided at their origins at the pubis and ischium. The obturator neurovascular bundle is then ligated and divided. The obturator externus muscle is divided from its insertion to the lesser trochanter. The hamstrings (semimembranosus, semitendinosus, and biceps femoris) are divided at the ischial tuberosity. Next, the tensor fascia lata, gluteus maximus and the rectus femoris are divided. Finally, the muscles attached to the greater trochanter are divided. The ligamentum teres is divided and the capsule of the hip joint is incised. The sciatic nerve is ligated and transected and will retract posterior into the piriformis muscle. The limb is passed off the operating table.",
"   </p>",
"   <p>",
"    Myoplasty is then performed by joining the flexors and extensors over the acetabulum. The quadratus femoris posteriorly is sutured to the iliopsoas anteriorly. Next, the gluteus medius laterally is sutured to the obturator externus medially. The gluteal fascia is approximated to the inguinal ligament and the skin closed loosely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603462367\">",
"    <span class=\"h2\">",
"     Above-knee amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For above-knee (transfemoral) amputation, the level of amputation can be chosen to divide the femur at the junction of its middle and distal third in most patients. A hemostatic tourniquet can be used if the femur is of sufficient length. (See",
"    <a class=\"local\" href=\"#H1672165523\">",
"     'Tourniquets'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A transversely oriented fish-mouth (",
"    <a class=\"graphic graphic_figure graphicRef51321 \" href=\"UTD.htm?43/38/44645\">",
"     figure 6",
"    </a>",
"    ) with equal anterior and posterior flaps is commonly used, but sagittal flaps are equally effective. Some surgeons prefer a simple, circular incision. Almost any incision that results in sufficient soft tissue coverage is appropriate.",
"   </p>",
"   <p>",
"    The fascia and muscles of the anterior thigh are divided and the superficial femoral artery and vein are identified medially, divided, and sutured closed. The remainder of the thigh musculature is divided laterally and posteriorly. The femur is transected two finger breadths proximal to the skin incision to provide adequate skin and soft tissue coverage over the bone. The sciatic nerve is ligated, divided sharply, and allowed to retract. The edges of the transected femur are smoothed with a rasp or file. It is important to flex the patient&rsquo;s hip prior to closing the wound. If hip flexion leads to tension on the wound, the femur should be shortened.",
"   </p>",
"   <p>",
"    Myopexy of the posteromedial musculature should be performed prior to skin closure. Myopexy prevents a dysfunctional and cosmetically unappealing stump due to the unopposed action of the hip flexors causing abduction and flexion of the proximal femur in the absence of the posteromedial adductor muscles. Myopexy is performed by sewing the muscles of the posterior and medial compartment to the periosteum anterolaterally on the femur. Some surgeons use direct myoplasty of the adductor muscles by passing nonabsorbable suture through holes drilled into the anterolateral femur. Following either myopexy or myoplasty, the deep fascia is approximated with absorbable suture. The skin can be closed using staples or interrupted monofilament sutures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H729837655\">",
"    <span class=\"h2\">",
"     Through-the-knee (knee disarticulation)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with a traditional transfemoral amputation, a through-the-knee amputation is an attractive alternative because it results in a longer lever arm and uses a simple end weight-bearing prosthesis compared with ischial weight-bearing that is needed for an above-knee prosthesis. Compared with transtibial amputation, the functional outcome may be superior in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/17\">",
"     17",
"    </a>",
"    ]. The main disadvantage of this amputation is that wound problems may require revision to a higher level. We reserve this technique for younger patients who have an above average rehabilitation potential who are not candidates for transtibial amputation. Whether there are any benefits in using a through-the-knee amputation in nonambulatory patients is unresolved.",
"   </p>",
"   <p>",
"    Equal anterior and posterior flaps (",
"    <a class=\"graphic graphic_figure graphicRef64135 \" href=\"UTD.htm?3/58/4005\">",
"     figure 7",
"    </a>",
"    ) are usually made, but equal sagittal",
"    <span class=\"nowrap\">",
"     (medial/lateral)",
"    </span>",
"    flaps can also be used. The apex of the anterior flap should be positioned between the distal patella and the tibial tuberosity. The skin is incised circumferentially and the medial and lateral collateral ligaments are divided. The patellar tendon is divided at its insertion into the tibia. The joint capsule is incised anteriorly and the cruciate ligaments are divided. The popliteal artery and vein are identified, divided, and sutured closed. The popliteus muscle and gastrocnemius muscles are then divided. The remaining attachments of the hamstring muscles are divided and the knee disarticulated. The transected end of the patellar tendon is sutured to the cruciate ligaments and the hamstring tendons in the intercondylar notch under slight tension using nonabsorbable suture. The wound is irrigated with sterile saline and closed in layers with interrupted absorbable sutures.",
"   </p>",
"   <p>",
"    The Gritti-Stokes amputation divides the distal femur (anterior to posterior angle of 10&deg;) just distal to the insertion of the adductor magnus prior to suturing the tendons together [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/18\">",
"     18",
"    </a>",
"    ]. The angulation allows the patella (after its articular surface has been resected) to fit snugly onto the end of the femur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/19\">",
"     19",
"    </a>",
"    ]. Another technique is to remove the posterior, medial, and lateral projections of the femoral condyles (Mazet modification) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603462183\">",
"    <span class=\"h2\">",
"     Below-knee amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amputation techniques for below-knee amputation are named for the origin of the flap used to cover the tibia. The posterior flap is the most commonly used technique for below-knee amputation and can be used for any indication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The advantage of this technique is the placement of the incision, and resultant scar, on a surface that is not weight-bearing. A disadvantage is the potential for ischemia in the posterior flap.",
"   </p>",
"   <p>",
"    Four other below-knee (transtibial) amputation techniques are described using sagittal, skew, medial, and fish-mouth flaps (",
"    <a class=\"graphic graphic_figure graphicRef53836 \" href=\"UTD.htm?16/12/16584\">",
"     figure 8",
"    </a>",
"    ), each of which may be more useful when one flap may be better vascularized than another. Amputations performed to resect tumors are dictated by the location of the tumor and the need for adequate margins.",
"   </p>",
"   <p>",
"    A systematic review identified three randomized trials comparing the posterior flap with other flap techniques for lower extremity amputation. No significant differences were observed in rates of primary stump healing, postoperative wound necrosis, reamputation or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923796509\">",
"    <span class=\"h3\">",
"     Posterior flap technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibia should be divided ideally 10 to 12 cm (three or four fingerbreadths) distal to the tibial tuberosity (",
"    <a class=\"graphic graphic_figure graphicRef72811 \" href=\"UTD.htm?9/14/9447\">",
"     figure 9",
"    </a>",
"    ). However, a functional stump may still be possible with as little as 5 cm of residual tibia.",
"   </p>",
"   <p>",
"    The anterior incision extends from medial to lateral, encompassing one-half to two-thirds of the circumference of the leg (",
"    <a class=\"graphic graphic_figure graphicRef53836 \" href=\"UTD.htm?16/12/16584\">",
"     figure 8",
"    </a>",
"    ). The length of the posterior flap is approximately one-third the circumference of the leg. A wider posterior flap may be better vascularized but will result in more prominent dog-ears with skin closure. Gently curving the transition of the posterior flap to the anterior incision will help reduce redundant skin and limit the formation of dog-ears. The skin and fascia are incised and divided beginning anteriorly and extending to the posterior flap. The muscles of the anterior and lateral compartment muscles are divided.",
"   </p>",
"   <p>",
"    The periosteum of the tibia is incised circumferentially two finger breadths proximal to the skin incision and the tibia is divided using a powered saw perpendicular to the long axis of the bone. The anterior surface of the tibia is beveled to eliminate sharp edges that may cause pressure on the overlying skin. The fibula is divided with a saw 1 to 2 cm proximal to the tibial transection site. Excessive resection of the fibula results in a conical stump that is difficult to fit properly with a prosthetic. The bony surfaces are filed smooth. The posterior flap is completed by dividing the residual posterior compartment musculature at a plane just deep to the tibia and fibula with a long amputation knife.",
"   </p>",
"   <p>",
"    Hemostasis is achieved by identifying the anterior tibial, posterior tibial, and peroneal vessels. The arteries are suture ligated; the veins may be simply ligated. The associated tibial and peroneal nerves are ligated and sharply divided and allowed to retract. The sural nerve is identified in the subcutaneous tissue in the midline of the posterior flap and divided 5 or 6 cm proximal to the skin edge. Smaller vessels bleeding from the surface of the musculature are suture-ligated.",
"   </p>",
"   <p>",
"    The deep fascia of the posterior flap is sutured to the fascia anteriorly with interrupted absorbable sutures taking care to completely cover the tibia without tension. Some surgeons prefer to advance the posterior flap 3 to 4 cm proximal to the tibial osteotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/25\">",
"     25",
"    </a>",
"    ]. If the posterior flap is too bulky to allow tension-free closure, the soleus muscle can be excised at the proximal level of the tibial osteotomy and removed, taking care to preserve the fascia and gastrocnemius muscle. The skin is closed with staples or interrupted monofilament suture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923796516\">",
"    <span class=\"h3\">",
"     Other flap techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the creation of a long posterior flap is not possible, skew or sagittal flaps can be used. The disadvantage of these techniques is the creation of a scar on the weight-bearing surface. Fish-mouth and medial-based flap techniques are discussed below for completion, but these techniques are rarely used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skew &ndash; With a skew flap technique, equal anteromedial and posterolateral fasciocutaneous flaps are created (",
"      <a class=\"graphic graphic_figure graphicRef53836 \" href=\"UTD.htm?16/12/16584\">",
"       figure 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef52849 \" href=\"UTD.htm?27/46/28386\">",
"       figure 10",
"      </a>",
"      ). The posterior muscle flap is similar to the conventional long posterior flap and based on the gastrocnemius muscle but is shorter [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/26\">",
"       26",
"      </a>",
"      ]. The skew technique is useful if there is inadequate skin to create a conventional long-posterior flap.",
"     </li>",
"     <li>",
"      Sagittal &ndash; In the sagittal flap technique, equal length medial and lateral myocutaneous flaps are created (",
"      <a class=\"graphic graphic_figure graphicRef53836 \" href=\"UTD.htm?16/12/16584\">",
"       figure 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/27\">",
"       27",
"      </a>",
"      ]. A myoplasty is performed to cover the tibia by suturing the anterior and lateral compartment muscles to the medial component of the gastrocnemius and soleus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medial &ndash; A medial flap technique constructs a long medial flap and short lateral flap. Incisional planning is based on thermographic imaging (",
"      <a class=\"graphic graphic_figure graphicRef53836 \" href=\"UTD.htm?16/12/16584\">",
"       figure 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef65706 \" href=\"UTD.htm?11/11/11445\">",
"       figure 11",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fish mouth &ndash; Prior to the development of the long posterior flap, the equal anterior and posterior flap technique was the most common transtibial amputation technique (",
"      <a class=\"graphic graphic_figure graphicRef53836 \" href=\"UTD.htm?16/12/16584\">",
"       figure 8",
"      </a>",
"      ). The main disadvantage is the vulnerability of the anterior flap to ischemia. The fish-mouth incision has no advantages over other techniques and is rarely indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603464772\">",
"    <span class=\"h1\">",
"     FOOT AMPUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are more likely to ambulate with a foot amputation compared with a below-knee amputation; however, more distal amputations are more likely to require reamputation or revision to a higher level compared with more proximal amputation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8810?source=see_link&amp;anchor=H1576717368#H1576717368\">",
"     \"Lower extremity amputation\", section on 'Need for re-amputation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases in which there is a low likelihood of healing of a minor amputation, it is important to explain to the patient the risk and consequences of failure. Although the patient may wish to preserve the extremity for as long as possible, prolonging the patient&rsquo;s course with multiple trips to the operating room to manage a nonhealing amputation stump or progressively more proximal amputations cannot be justified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603462351\">",
"    <span class=\"h2\">",
"     Ankle disarticulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open ankle disarticulation is a quick and simple amputation that can be used to manage a septic foot. Because no bones are transected, it can be performed with local anesthesia (and sedation, if tolerated hemodynamically) at the bedside if the patient is too ill to transport to the operating room. The procedure involves making a circumferential incision at the level of the ankle joint after the placement of a proximal tourniquet. The incision is carried through the tendons of the foot and into the joint capsule followed by transection of the ligaments. The subcutaneous anterior tibial and posterior tibial vessels are identified, ligated, and divided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603461888\">",
"    <span class=\"h2\">",
"     Midfoot and hindfoot amputations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five midfoot and hindfoot amputations are available and are occasionally useful in selected populations of patients. These include Lisfranc, Chopart, Syme, Boyd and Pirogoff amputation (",
"    <a class=\"graphic graphic_figure graphicRef78430 graphicRef54456 \" href=\"UTD.htm?0/19/313\">",
"     figure 12A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These amputations were developed when options for lower extremity prostheses were limited and preservation of any portion of the foot was an advantage. The Boyd and Pirogoff hindfoot amputations are used primarily in children to preserve length and bony growth centers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/30,32-34\">",
"     30,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of midfoot and hindfoot amputations in patients with diabetes remains controversial. Many surgeons recommend formal transtibial (below-knee amputation) if transmetatarsal amputation (TMA) cannot be performed or has failed. Others suggest that increased limb salvage rates can be improved using proximal foot amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. Preservation of limb length may have a survival advantage for patients with diabetes, with one study reporting that patients with diabetes undergoing proximal foot amputations had better function and survival compared with below-knee amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/34\">",
"     34",
"    </a>",
"    ]. These findings were not observed in dialysis-dependent patients with diabetes.",
"   </p>",
"   <p>",
"    The chief advantage of the Syme amputation is the preservation of native limb length that may allow brief periods of weight bearing without the need for a prosthesis, such as during transfer from a bed to wheelchair or to the bathroom. The disadvantages include a slight leg length discrepancy, which may lead to biomechanical side-effects in more proximal or contralateral joints. When a prosthesis is used, it is typically quite bulky at the ankle and less cosmetically appealing than a conventional below-knee prosthesis, which can be designed with a near-normal ankle profile. Because the Syme amputation is an end weight-bearing stump, the heel fat pad may become unstable and can migrate medially exposing the distal tibia to excessive force. Thus, the Syme amputation has its greatest utility in young, otherwise healthy patients (eg, extensive forefoot injury) who are highly motivated to avoid transtibial amputation. Diabetic neuropathy is a relative contraindication to Syme amputation because of the patient&rsquo;s inability to protect the stump from injuries.",
"   </p>",
"   <p>",
"    The basic principles of the more common midfoot and hindfoot amputations are described below [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syme amputation &ndash; The anterior incision of the Syme amputation extends across the ankle just distal to the tip of each malleolus (",
"      <a class=\"graphic graphic_figure graphicRef63160 \" href=\"UTD.htm?10/63/11253\">",
"       figure 13",
"      </a>",
"      ). The posterior incision extends from the malleoli vertically and transversely across the heel. The extensor tendons are divided at the level of the skin incision. The dorsalis pedis artery and vein are divided and ligated. The ankle joint capsule is incised while plantar-flexing the foot. The medial and lateral ankle ligaments are divided. The tendons of the posterior tibialis and flexor hallucis longus are transected, taking care to avoid injury to the posterior tibial artery. The heel fat pad is carefully dissected by staying close to the calcaneus to avoid creating a buttonhole. The ankle joint is disarticulated and the foot is passed from the table.",
"      <br/>",
"      <br/>",
"      In a single-stage amputation, the malleoli are divided with a saw at the level of the articular surface of the tibia and the width is reduced by vertical bone excision. Holes are drilled in the medial, anterior, and lateral parts of the distal tibia and fibula to secure the heel pad directly under the tibia. In a two-stage Syme amputation, the wound is closed by suturing the heel flap to the dorsal fascia. Six weeks later, the malleoli are removed through separate vertical incisions.",
"     </li>",
"     <li>",
"      Lisfranc tarsometatarsal disarticulation &ndash; The incision is placed over the metatarsal heads and produces a long plantar flap. The tendons and synovial sheaths are divided at the level of the skin incision. The 2",
"      <sup>",
"       nd",
"      </sup>",
"      metatarsal is divided 1 to 2 cm distal to the medial cuneiform (",
"      <a class=\"graphic graphic_figure graphicRef78430 graphicRef54456 \" href=\"UTD.htm?0/19/313\">",
"       figure 12A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/18\">",
"       18",
"      </a>",
"      ]. The 1",
"      <sup>",
"       st",
"      </sup>",
"      , 3",
"      <sup>",
"       rd",
"      </sup>",
"      , 4",
"      <sup>",
"       th",
"      </sup>",
"      and 5",
"      <sup>",
"       th",
"      </sup>",
"      tarso-metatarsal joints are disarticulated. To reduce the risk of developing equinovarus deformity, a modification of the Lisfranc amputation (Sanders) preserves the insertion of the peroneus brevis muscle at the base of the 5",
"      <sup>",
"       th",
"      </sup>",
"      metatarsal [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/33\">",
"       33",
"      </a>",
"      ]. The Achilles tendon is released by transection or Z-plasty [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. The plantar fascia of the posterior flap is approximated to the dorsal periosteum with absorbable sutures and the skin is closed.",
"     </li>",
"     <li>",
"      Chopart midfoot amputation &ndash; The incision is placed over the talocalcaneonavicular joint and a long plantar flap is created similar to the Lisfranc amputation. The amputation is performed through the talocalcaneonavicular joint and calcaneocuboid joints (",
"      <a class=\"graphic graphic_figure graphicRef78430 graphicRef54456 \" href=\"UTD.htm?0/19/313\">",
"       figure 12A-B",
"      </a>",
"      ). The extensor hallucis longus and the tibialis anterior tendons can be reattached to the talar neck. The extensor digitorum longus can be reattached to the calcaneus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/18\">",
"       18",
"      </a>",
"      ]. To prevent equinovarus deformity due to unopposed plantar flexion, Achilles tendon release should be performed. The plantar fascia of the flap is approximated to the dorsal periosteum and the skin is closed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603461749\">",
"    <span class=\"h2\">",
"     Transmetatarsal amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmetatarsal amputation (TMA) is appropriate for wounds that involve the entire forefoot. TMA offers the benefits of full limb length, normal shoes and near-normal ambulation. Foot mechanics, healing and rehabilitation rates may be improved with TMA compared with first ray amputation and TMA may be preferred to manage foot wounds in selected patients. TMA is contraindicated if excessive bony deformity is present in the midfoot or hindfoot that would compromise foot stability. (See",
"    <a class=\"local\" href=\"#H923797199\">",
"     'Ray'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The incision is made from a point just medial to the first metatarsal head transversely across the dorsum of the foot to the lateral aspect of the fifth metatarsal head [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/32\">",
"     32",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef75994 \" href=\"UTD.htm?10/15/10483\">",
"     figure 14",
"    </a>",
"    ). The incision extends around to the plantar surface to the base of the toes to create a plantar flap. The extensor tendons and sheaths are divided at, or slightly proximal to, the dorsal skin incision to expose the metatarsal shafts. The periosteum is divided just proximal to the metatarsal heads and the metatarsals are transected using a power microsaw.",
"   </p>",
"   <p>",
"    We prefer to divide the metatarsals in a gentle curve from medial to lateral starting at the great toe with each successive shaft (digits 2 through 5) transected 3 to 5 mm shorter than the previous one. Some surgeons advocate transecting the metatarsal shaft with a 30 to 45 degree plantar-oriented bevel to facilitate lift-off during ambulation.",
"   </p>",
"   <p>",
"    Following transection of the metatarsal bones, the distal metatarsal fragments can be grasped with a bone clamp or bone hook and retracted to divide the associated plantar myofascial attachments. The flexor tendons and sheaths are poorly vascularized and these should be excised individually along with associated fibrocartilaginous structures on the plantar flap, taking care to not incise too deeply into the flap.",
"   </p>",
"   <p>",
"    The wound is irrigated and closed in two layers with interrupted absorbable sutures in the fascia. The skin is closed loosely with interrupted nonabsorbable monofilament sutures or staples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603461644\">",
"    <span class=\"h2\">",
"     Toe amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple toe amputation is appropriate for wounds limited to the mid- to distal toe and not involving the skin overlying the metatarsal head. More proximal wounds typically require ray amputation.",
"   </p>",
"   <p>",
"    Local anesthesia (ankle or digital nerve block) is usually adequate for most toe amputations. Care should be taken to avoid direct puncture of the pedal arteries or excessive infiltration of anesthetic in the dysvascular foot because of the risk of exacerbating ischemia. Some surgeons avoid the use of ankle blocks and digital blocks in the setting of local foot sepsis because of concern for spreading infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H26#H26\">",
"     \"Peripheral nerve block: Techniques\", section on 'Ankle block'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H27#H27\">",
"     \"Peripheral nerve block: Techniques\", section on 'Digital nerve block (toe)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923797185\">",
"    <span class=\"h3\">",
"     Simple",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial or complete amputation of any toe can be performed. However, since a hallux valgus deformity commonly develops following isolated partial or complete second toe amputation, a second ray amputation may be preferable to simple toe amputation because it reduces the angle between the first and third metatarsals. (See",
"    <a class=\"local\" href=\"#H923797199\">",
"     'Ray'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Almost any incision that results in tension-free coverage of the transected bone can be used. For partial toe amputation, a transverse or vertical fish-mouth skin incision should suffice. The simplest technique for complete toe amputation is with a racquet incision (",
"    <a class=\"graphic graphic_figure graphicRef56269 \" href=\"UTD.htm?12/57/13205\">",
"     figure 15",
"    </a>",
"    ). For amputation of the first and fifth toes, we prefer to orient the handle of the racquet on the medial or lateral surface of the respective metatarsal head. For the second, third, and fourth toes, the handle of the racquet is oriented longitudinally along the dorsal surface of the digit.",
"   </p>",
"   <p>",
"    The flexor and extensor tendons are divided at the level of the skin incision and allowed to retract. The bone is divided at the appropriate level. If disarticulation is needed, a #15 knife blade can be inserted into the joint and the joint capsule incised sharply to avoid injury to surrounding soft tissue. Since the articular cartilage is poorly vascularized, we prefer to excise it with a rongeur. We also gently shape the exposed bone to eliminate any bony projections that might lead to wound or skin problems. After irrigation and hemostasis, the skin is closed without tension with a single layer of nonabsorbable monofilament sutures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923797199\">",
"    <span class=\"h3\">",
"     Ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;ray amputation&rdquo; is used to describe amputation of the toe along with all or part of the corresponding metatarsal bone. Ray amputation is useful for managing mal perforans ulcers in the neuropathic diabetic foot, particularly when associated with osteomyelitis of the metatarsal head. Ray amputation is also appropriate for the treatment of digit thromboembolism that involves the toe and its base. In these circumstances, resection of the toe alone may leave insufficient skin to cover the exposed metatarsal head.",
"   </p>",
"   <p>",
"    Although an isolated single ray amputation can be durable, multiple ray amputations narrow the foot excessively and create an unstable foot that increases the load on the remaining metatarsal heads, which can result in new areas of increased pressure, callus formation, and ulceration. Transmetatarsal amputation is preferred to multiple ray amputations. (See",
"    <a class=\"local\" href=\"#H603461749\">",
"     'Transmetatarsal amputation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Near-normal foot mechanics can be achieved after amputation of the individual lateral four rays, but amputation of the great toe and first metatarsal head markedly alters foot mechanics and normal ambulation. Recurrent ulceration following first ray amputation occurs in up to 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/40\">",
"     40",
"    </a>",
"    ]. As a result, some surgeons recommend formal transmetatarsal amputation rather than isolated first ray amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/41\">",
"     41",
"    </a>",
"    ]. However, given that 40 percent of patients do not require revision or reamputation, others feel that first ray amputation is justified [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Given the lack of consensus, the choice between first ray amputation and transmetatarsal amputation should be individualized. (See",
"    <a class=\"local\" href=\"#H603461749\">",
"     'Transmetatarsal amputation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a typical ray amputation, we modify the racquet incision by extending the handle of the racquet along the dorsal surface to provide exposure of the shaft of the metatarsal bone (",
"    <a class=\"graphic graphic_figure graphicRef67983 \" href=\"UTD.htm?40/7/41077\">",
"     figure 16",
"    </a>",
"    ). The extensor tendons are divided and allowed to retract and the shaft of the metatarsal head is transected with a power microsaw. The distal segment of metatarsal is retracted with a bone hook and the remaining plantar soft tissue attachments are divided. Care is taken to stay close to the bone to avoid injury to the adjacent digital arteries and nerves. Sesamoid bones are excised and the flexor tendons are transected under tension so they retract. After irrigation and hemostasis, the skin is closed without tension with a single layer of nonabsorbable monofilament sutures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170872506\">",
"    <span class=\"h1\">",
"     DRESSINGS AND DRAINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of soft, semirigid and rigid removable dressings have been developed for use after amputation, but there is no consensus regarding the optimal method of stump treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23225/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The ideal stump dressing protects the wound from contamination and trauma, allows easy access for wound examination, prevents contractures, and minimizes edema without restricting stump perfusion.",
"   </p>",
"   <p>",
"    All caregivers should be aware that accidental injury following amputation is a frequent cause of stump failure and need for stump revision. Injury to the stump is prevented by the use of appropriate protective soft or rigid dressings depending upon the nature of the amputation. In most cases, weight bearing should be completely avoided until the wounds are well-healed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8810?source=see_link&amp;anchor=H614729018#H614729018\">",
"     \"Lower extremity amputation\", section on 'Weight bearing and ambulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, our initial postoperative dressing consists of a gauze dressing or wrap on the stump over which a loose elastic dressing is placed. A rigid dressing (splint, immobilizer) may also be placed. The dressing is maintained for a 24-hour period, after which it is removed. Suggested dressings for the various amputation sites are given below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Toe &ndash; Simple, bulky, soft dressing and postoperative shoe.",
"     </li>",
"     <li>",
"      Partial foot &ndash; For transmetatarsal amputation, a posterior plaster splint is applied to maintain the foot at 90&deg;. For proximal foot amputations, a short leg plaster cast is used over the sterile dressings. The cast must be molded to ensure that the talus is slightly dorsiflexed in relation to the tibia and the calcaneal tuberosity is parallel to the long axis of the tibia. The cast is changed weekly to check the healing of the wound.",
"     </li>",
"     <li>",
"      Below-knee &ndash; A soft dressing is applied over the stump and a rigid dressing used to prevent postoperative knee contracture. We prefer a simple knee immobilizer with Velcro straps because it is widely available and can be easily removed to examine the wound. A foam cylinder can be cut to shape and inserted into the end of the knee immobilizer to provide additional protection to the stump.",
"     </li>",
"     <li>",
"      Above-knee &ndash; A simple dressing is appropriate for above-knee and through-knee amputations. Care must be taken to avoid constrictive, circumferential dressings that impair blood flow. A simple and effective dressing consists of nonadherent gauze on the suture line covered with a protective adhesive sheet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H729837683\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications following lower extremity amputation are common. Local wound complications include stump hematoma, infection, flexion contracture, and chronic stump pain, whereas systemic complications include, but are not limited to, acute cardiac events, venous thromboembolism, pneumonia, new onset renal failure, and sepsis. The complications of lower extremity amputation are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8810?source=see_link&amp;anchor=H614729032#H614729032\">",
"     \"Lower extremity amputation\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603464531\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower extremity amputation is indicated to remove ischemic, infected or necrotic tissue, or locally unresectable tumor, and at times, may be life-saving. Peripheral artery disease and diabetes are the leading causes of lower extremity amputation in the United States. Extremity trauma is the next most common cause of amputation. (See",
"      <a class=\"local\" href=\"#H603460109\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major amputations are those amputations performed above the ankle and include hip disarticulation, above-knee (transfemoral) amputation, through-knee amputation, and below-knee (transtibial) amputation. A variety of foot amputations are available that may salvage the patient&rsquo;s ability to ambulate using orthotic shoe modifications. These include transmetatarsal amputation, toe amputation and various midfoot and hindfoot amputations (Syme, Lisfranc, Chopart). The amputation techniques for each are discussed above. (See",
"      <a class=\"local\" href=\"#H603464736\">",
"       'Major amputations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H603464772\">",
"       'Foot amputations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe lower extremity infection, particularly in diabetic patients, we suggest a staged amputation over non-staged amputation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Staged amputation involves first a debriding amputation in the form of an open &ldquo;guillotine&rdquo; amputation (transfemoral, transtibial), through-the-joint amputation, or less commonly cryoamputation, with definitive revision and wound closure after infection has been controlled. Debriding foot amputation at the toe, forefoot, or ankle level can also be used. (See",
"      <a class=\"local\" href=\"#H738694683\">",
"       'Staged amputation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain general techniques are universal to all amputations, regardless of the level. These include gentle tissue handling, minimizing tissue ischemia, ensuring adequate hemostasis, using techniques that prevent postoperative complications (eg, oversewing named vessels, minimizing electrocautery), liberal wound irrigation before closure, and closure without tension. The use of a proximal tourniquet, whenever possible, minimizes blood loss and the need for postoperative transfusion. (See",
"      <a class=\"local\" href=\"#H1672165562\">",
"       'General techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For transtibial amputation, we suggest the posterior flap technique over other flap techniques (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The advantage of this technique is the placement of the incision, and the resultant scar, on a surface that is not weight-bearing. A disadvantage is the potential for posterior flap ischemia. Four other below-knee (transtibial) amputation techniques (named for the origin of the flap used to cover the tibia) are sagittal, skew, medial, and fish-mouth flap (",
"      <a class=\"graphic graphic_figure graphicRef53836 \" href=\"UTD.htm?16/12/16584\">",
"       figure 8",
"      </a>",
"      ), each of which may be more useful where one flap may be better vascularized than another. Amputations performed to resect tumors are dictated by the location of the tumor and the need for adequate margins.(See",
"      <a class=\"local\" href=\"#H603462183\">",
"       'Below-knee amputation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/1\">",
"      Dillingham TR, Pezzin LE, MacKenzie EJ. Limb amputation and limb deficiency: epidemiology and recent trends in the United States. South Med J 2002; 95:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/2\">",
"      Heikkinen M, Saarinen J, Suominen VP, et al. Lower limb amputations: differences between the genders and long-term survival. Prosthet Orthot Int 2007; 31:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/3\">",
"      Humzah MD, Gilbert PM. Fasciocutaneous blood supply in below-knee amputation. J Bone Joint Surg Br 1997; 79:441.",
"     </a>",
"    </li>",
"    <li>",
"     Eidt JF, Kalapatapu VR. Lower extremity amputation: Techniques and Results. In: Rutherford's Vascular Surgery, 7th ed, 2010. Vol 2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/5\">",
"      McIntyre KE Jr, Bailey SA, Malone JM, Goldstone J. Guillotine amputation in the treatment of nonsalvageable lower-extremity infections. Arch Surg 1984; 119:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/6\">",
"      Fisher DF Jr, Clagett GP, Fry RE, et al. One-stage versus two-stage amputation for wet gangrene of the lower extremity: a randomized study. J Vasc Surg 1988; 8:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/7\">",
"      Desai Y, Robbs JV, Keenan JP. Staged below-knee amputations for septic peripheral lesions due to ischaemia. Br J Surg 1986; 73:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/8\">",
"      Payne JE, Breust M, Bradbury R. Reduction in amputation stump infection by antiseptic pre-operative preparation. Aust N Z J Surg 1989; 59:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/9\">",
"      Scher KS, Steele FJ. The septic foot in patients with diabetes. Surgery 1988; 104:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/10\">",
"      Hunsaker RH, Schwartz JA, Keagy BA, et al. Dry ice cryoamputation: a twelve-year experience. J Vasc Surg 1985; 2:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/11\">",
"      Winburn GB, Wood MC, Hawkins ML, et al. Current role of cryoamputation. Am J Surg 1991; 162:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/12\">",
"      Brinker MR, Timberlake GA, Goff JM, et al. Below-knee physiologic cryoanesthesia in the critically ill patient. J Vasc Surg 1988; 7:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/13\">",
"      Bunt TJ. Physiologic amputation. Preliminary cryoamputation of the gangrenous extremity. AORN J 1991; 54:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/14\">",
"      Choksy SA, Lee Chong P, Smith C, et al. A randomised controlled trial of the use of a tourniquet to reduce blood loss during transtibial amputation for peripheral arterial disease. Eur J Vasc Endovasc Surg 2006; 31:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/15\">",
"      Jaegers SM, Arendzen JH, de Jongh HJ. Changes in hip muscles after above-knee amputation. Clin Orthop Relat Res 1995; :276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/16\">",
"      Sugarbaker PH, Chretien PB. A surgical technique for hip disarticulation. Surgery 1981; 90:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/17\">",
"      Cull DL, Taylor SM, Hamontree SE, et al. A reappraisal of a modified through-knee amputation in patients with peripheral vascular disease. Am J Surg 2001; 182:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/18\">",
"      Blanc CH, Borens O. Amputations of the lower limb--an overview on technical aspects. Acta Chir Belg 2004; 104:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/19\">",
"      Faber DC, Fielding LP. Gritti-Stokes (through-knee) amputation: should it be reintroduced? South Med J 2001; 94:997.",
"     </a>",
"    </li>",
"    <li>",
"     Mazet, R.J. and C.A. Hennessy, Knee Disarticulation: a new technique and a new knee-joint mechanism. J Bone Joint Surg Am 1966; 48:126.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/21\">",
"      Burgess EM, Romano RL, Zettl JH, Schrock RD Jr. Amputations of the leg for peripheral vascular insufficiency. J Bone Joint Surg Am 1971; 53:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/22\">",
"      Allcock PA, Jain AS. Revisiting transtibial amputation with the long posterior flap. Br J Surg 2001; 88:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/23\">",
"      Smith DG, Fergason JR. Transtibial amputations. Clin Orthop Relat Res 1999; :108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/24\">",
"      Tisi PV, Callam MJ. Type of incision for below knee amputation. Cochrane Database Syst Rev 2004; :CD003749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/25\">",
"      Assal M, Blanck R, Smith DG. Extended posterior flap for transtibial amputation. Orthopedics 2005; 28:542.",
"     </a>",
"    </li>",
"    <li>",
"     Robinson KP. Amputations in vascular patients. In: Surgical Management of Vascular Disease, Bell PRF (Ed), W.B. Saunders, London 1992. p.609.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/27\">",
"      Persson BM. Sagittal incision for below-knee amputation in ischaemic gangrene. J Bone Joint Surg Br 1974; 56:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/28\">",
"      Termansen NB. Below-knee amputation for ischaemic gangrene. Prospective, randomized comparison of a transverse and a sagittal operative technique. Acta Orthop Scand 1977; 48:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/29\">",
"      Jain AS, Stewart CP, Turner MS. Transtibial amputation using a medially based flap. J R Coll Surg Edinb 1995; 40:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/30\">",
"      Pinzur M, Kaminsky M, Sage R, et al. Amputations at the middle level of the foot. A retrospective and prospective review. J Bone Joint Surg Am 1986; 68:1061.",
"     </a>",
"    </li>",
"    <li>",
"     Barnes R, Cox B. Amputations: An illustrated manual, 1st ed, Hanley &amp; Belfus, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/32\">",
"      Early JS. Transmetatarsal and midfoot amputations. Clin Orthop Relat Res 1999; :85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/33\">",
"      Sanders LJ. Transmetatarsal and midfoot amputations. Clin Podiatr Med Surg 1997; 14:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/34\">",
"      Stone PA, Back MR, Armstrong PA, et al. Midfoot amputations expand limb salvage rates for diabetic foot infections. Ann Vasc Surg 2005; 19:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/35\">",
"      Chang BB, Bock DE, Jacobs RL, et al. Increased limb salvage by the use of unconventional foot amputations. J Vasc Surg 1994; 19:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/36\">",
"      HULNICK A, HIGHSMITH C, BOUTIN FJ. Amputations for failure in reconstructive surgery. J Bone Joint Surg Am 1949; 31A:639.",
"     </a>",
"    </li>",
"    <li>",
"     Richardson D. Amputations of the foot. In: Campbell's Operative Orthopedics, Canale S, Beaty J (Eds), Elsevier, Philadelphia  p.595.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/38\">",
"      Armstrong DG, Stacpoole-Shea S, Nguyen H, Harkless LB. Lengthening of the Achilles tendon in diabetic patients who are at high risk for ulceration of the foot. J Bone Joint Surg Am 1999; 81:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/39\">",
"      HATT RN, LAMPHIER TA. Triple hemisection: a simplified procedure for lengthening the Achilles tendon. N Engl J Med 1947; 236:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/40\">",
"      Murdoch DP, Armstrong DG, Dacus JB, et al. The natural history of great toe amputations. J Foot Ankle Surg 1997; 36:204.",
"     </a>",
"    </li>",
"    <li>",
"     Bowker J. Amputations and disarticulations. In: Foot and Ankle Disorders, M. MS (Ed), WB Saunders, Philadelphia 2000. p.466.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/42\">",
"      Dalla Paola L, Faglia E, Caminiti M, et al. Ulcer recurrence following first ray amputation in diabetic patients: a cohort prospective study. Diabetes Care 2003; 26:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/43\">",
"      Funk C, Young G. Subtotal pedal amputations. Biomechanical and intraoperative considerations. J Am Podiatr Med Assoc 2001; 91:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/44\">",
"      Tang PC, Ravji K, Key JJ, et al. Let them walk! Current prosthesis options for leg and foot amputees. J Am Coll Surg 2008; 206:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/45\">",
"      Nawijn SE, van der Linde H, Emmelot CH, Hofstad CJ. Stump management after trans-tibial amputation: a systematic review. Prosthet Orthot Int 2005; 29:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23225/abstract/46\">",
"      Kane TJ 3rd, Pollak EW. The rigid versus soft postoperative dressing controversy: a controlled study in vascular below-knee amputees. Am Surg 1980; 46:244.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15186 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23225=[""].join("\n");
var outline_f22_43_23225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H603464531\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603460109\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H729837576\">",
"      SURGICAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170898554\">",
"      Hip and thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170898595\">",
"      Leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170898602\">",
"      Ankle and foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H729837590\">",
"      GENERAL PRINCIPLES OF AMPUTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H738694683\">",
"      Staged amputation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H614731798\">",
"      - Cryoamputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1672165516\">",
"      Draping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1672165523\">",
"      Tourniquets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1672165562\">",
"      General techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603464736\">",
"      MAJOR AMPUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H603461713\">",
"      Hip disarticulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H603462367\">",
"      Above-knee amputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H729837655\">",
"      Through-the-knee (knee disarticulation)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H603462183\">",
"      Below-knee amputation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H923796509\">",
"      - Posterior flap technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H923796516\">",
"      - Other flap techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603464772\">",
"      FOOT AMPUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H603462351\">",
"      Ankle disarticulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H603461888\">",
"      Midfoot and hindfoot amputations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H603461749\">",
"      Transmetatarsal amputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H603461644\">",
"      Toe amputation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H923797185\">",
"      - Simple",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H923797199\">",
"      - Ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H170872506\">",
"      DRESSINGS AND DRAINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H729837683\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603464531\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15186\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15186|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/14/36071\" title=\"figure 1\">",
"      Muscle compartments of the thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/27/42424\" title=\"figure 2\">",
"      Muscle compartments of the leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/3/15409\" title=\"figure 3\">",
"      Saphenous nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/56/13194\" title=\"figure 4\">",
"      Anatomy of the foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/63/30711\" title=\"figure 5\">",
"      Technique of hip disarticulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/38/44645\" title=\"figure 6\">",
"      Technique of above-knee amputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/58/4005\" title=\"figure 7\">",
"      Technique of through-knee amputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/12/16584\" title=\"figure 8\">",
"      Fascio-cutaneous blood supply of amputations flaps of the leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/14/9447\" title=\"figure 9\">",
"      Technique of below-knee amputation with long posterior flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/46/28386\" title=\"figure 10\">",
"      Technique of below-knee amputation with skew flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/11/11445\" title=\"figure 11\">",
"      Technique of below-knee amputation with medial-based flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/19/33074\" title=\"figure 12A\">",
"      Foot amputations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/34/23077\" title=\"figure 12B\">",
"      Transmetatarsal Lisfranc and Chopart amputations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/63/11253\" title=\"figure 13\">",
"      Technique of Syme amputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/15/10483\" title=\"figure 14\">",
"      Technique of transmetatarsal amputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/57/13205\" title=\"figure 15\">",
"      Great toe amputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/7/41077\" title=\"figure 16\">",
"      Technique of ray amputation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8810?source=related_link\">",
"      Lower extremity amputation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_43_23226="Bartter and Gitelman syndromes";
var content_f22_43_23226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bartter and Gitelman syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23226/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23226/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23226/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23226/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/43/23226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/43/23226/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/43/23226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3869704\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartter syndrome and Gitelman syndrome (also called tubular hypomagnesemia-hypokalemia with hypocalciuria) are",
"    <strong>",
"     autosomal recessive",
"    </strong>",
"    disorders with a characteristic set of metabolic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. These include hypokalemia, metabolic alkalosis, hyperreninemia, hyperplasia of the juxtaglomerular apparatus (the source of renin in the kidney), hyperaldosteronism, and, in some patients, hypomagnesemia.",
"   </p>",
"   <p>",
"    The hyperaldosteronism associated with Bartter and Gitelman syndrome is a secondary form of hyperaldosteronism that results from a volume contraction induced increase in renin. These patients are not hypertensive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3869711\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gitelman syndrome is a much more common disease than Bartter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In a report from the Framingham Heart Study, the prevalence of Gitelman syndrome was 1 in 40,000 compared with 1 in 1,000,000 for Bartter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/6\">",
"     6",
"    </a>",
"    ]. The estimated prevalence of heterozygotes with one of the genetic mutations that cause these disorders is at least 1 percent. (See",
"    <a class=\"local\" href=\"#H3869761\">",
"     'Clinical manifestations in heterozygotes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3869718\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary defect in both Bartter syndrome and Gitelman syndrome is an impairment in one of the transporters involved in sodium chloride reabsorption in the loop of Henle and distal tubule, respectively (",
"    <a class=\"graphic graphic_table graphicRef68035 \" href=\"UTD.htm?42/61/43996\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5551669\">",
"    <span class=\"h2\">",
"     Overview of common and distinctive features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tubular defects in sodium chloride transport are almost identical to that seen with chronic ingestion of a loop diuretic (mimicking Bartter syndrome) or a thiazide diuretic (mimicking Gitelman syndrome). The salt wasting that occurs results in the following features common to patients with both disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired sodium chloride reabsorption leads to mild volume depletion and activation of the renin-angiotensin-aldosterone system.",
"     </li>",
"     <li>",
"      The combination of secondary hyperaldosteronism and increased distal flow and sodium delivery enhances potassium and hydrogen secretion at the secretory sites in the connecting tubules and collecting tubules, leading to hypokalemia and metabolic alkalosis. (See",
"      <a class=\"local\" href=\"#H168860066\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with Bartter and Gitelman syndromes, as well as heterozygotes of both disorders, have a lower blood pressure than seen in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/6\">",
"       6",
"      </a>",
"      ]. In addition to volume depletion, another possible contributor to a lower blood pressure in Bartter syndrome is increased renal release of vasodilator prostaglandins (prostaglandin E2). (See",
"      <a class=\"local\" href=\"#H3869754\">",
"       'Role of prostaglandins'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Diluting capacity is reduced in patients with both disorders because maximal dilution of the urine requires intact function of both the thick ascending limb of the loop of Henle and the distal tubule. In normal individuals, sodium chloride is reabsorbed without water in both sites and, if ADH is suppressed, maximal urine dilution occurs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there are distinctive features that correspond to the tubular location of disrupted sodium chloride reabsorption (ie, loop of Henle in Bartter syndrome and distal tubule in Gitelman syndrome) (",
"    <a class=\"graphic graphic_table graphicRef68035 \" href=\"UTD.htm?42/61/43996\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with Bartter syndrome tend to have a blunted response to a loop diuretic, while patients with Gitelman syndrome tend to have a blunted response to a thiazide diuretic. (See",
"      <a class=\"local\" href=\"#H168860094\">",
"       'Response to thiazide and loop diuretics'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Concentrating ability is impaired in Bartter syndrome but is relatively preserved in Gitelman syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/2,10,11\">",
"       2,10,11",
"      </a>",
"      ]. Maximal urine concentration requires intact function of the thick ascending limb of the loop of Henle and maximal ADH activity, but is not substantially impaired by the reduced distal tubule function in Gitelman syndrome.",
"     </li>",
"     <li>",
"      Urinary calcium excretion is normal or high in patients with Bartter syndrome, as it is with a loop diuretic, since calcium reabsorption in the thick ascending limb requires normal NaCl reabsorption. In contrast, urinary calcium excretion is typically reduced in patients with Gitelman syndrome as it is with a thiazide diuretic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"       \"Diuretics and calcium balance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3869725\">",
"    <span class=\"h2\">",
"     Bartter syndrome",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H396471884\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartter syndrome is an autosomal recessive disorder that often presents",
"    <strong>",
"     in childhood",
"    </strong>",
"    and may be associated with the following clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Growth and mental retardation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/2,12\">",
"       2,12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypokalemia",
"     </li>",
"     <li>",
"      Metabolic alkalosis",
"     </li>",
"     <li>",
"      Polyuria and polydipsia due to decreased urinary concentrating ability [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/2,12\">",
"       2,12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Normal to increased urinary calcium excretion",
"     </li>",
"     <li>",
"      Normal or mildly decreased serum magnesium concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypophosphatemia in occasional patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/13-15\">",
"       13-15",
"      </a>",
"      ], with secondary hyperparathyroidism being a possible mechanism [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations are much less pronounced in heterozygotes. (See",
"    <a class=\"local\" href=\"#H3869761\">",
"     'Clinical manifestations in heterozygotes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5551767\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features in patients with Bartter syndrome are compatible with a primary defect in sodium chloride reabsorption in the medullary thick ascending limb of the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. Mild volume depletion leads to secondary hyperaldosteronism; this, along with increased distal delivery of sodium, results in increased urinary potassium losses and hydrogen ion secretion.",
"   </p>",
"   <p>",
"    Sodium chloride reabsorption without water in the loop of Henle plays a central role in creating the medullary concentration gradient that is required for excretion of maximally concentrated urine in the presence of antidiuretic hormone (ADH). The impaired concentrating ability and polyuria in Bartter syndrome is due to the impaired sodium transport in the loop of Henle, and perhaps also to the development of chronic hypokalemia, which can cause nephrogenic diabetes insipidus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary dilution is also impaired since sodium chloride reabsorption in the loop of Henle reduces the osmolality of the tubular fluid and, in the absence of ADH, contributes to the excretion of a dilute urine.",
"   </p>",
"   <p>",
"    In addition, both calcium and magnesium are passively reabsorbed in the thick ascending limb down the electrochemical gradient created by sodium chloride transport. The net effect is that urinary calcium excretion is normal or increased in Bartter syndrome and the serum magnesium concentration may be low (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H396471898\">",
"    <span class=\"h3\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic defect in Bartter syndrome results in reduced activity of one of several electrolyte transporters in the thick ascending limb. To understand how altered function of these various transporters can result in the clinical features of Bartter syndrome, the physiology of transport in the thick ascending limb of Henle's loop will be briefly reviewed here. A more detailed description is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=see_link\">",
"     \"Chapter 4A: Cell model for loop of Henle transport\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following sequence summarizes normal ion transport in the medullary thick ascending limb:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The energy for sodium chloride reabsorption throughout the nephron is generated by Na-K ATPase, which reduces the intracellular sodium concentration.",
"     </li>",
"     <li>",
"      The resulting sodium gradient from lumen to intracellular fluid drives the simultaneous reabsorption of one sodium, one potassium, and two chloride ions via the Na-K-2Cl (NKCC2) loop diuretic-sensitive cotransporter that is present in the luminal membrane.",
"     </li>",
"     <li>",
"      Reabsorbed potassium reenters the lumen via potassium channels (ROMK). This generates a lumen positive electrical charge, which drives passive paracellular calcium and magnesium reabsorption, and also provides potassium for continued Na-K-2Cl cotransport [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several different basolateral chloride channels play a role in chloride reabsorption. The most important chloride channel in the basolateral membrane of the medullary thick ascending limb is Cl-channel kidney B (ClC-Kb). Another chloride channel, ClC-Ka, may have redundant functionality. A small protein beta-subunit, named barttin, must interact with each of these chloride channels for them to function appropriately. These chloride channels also play an important role in ion transport in the ear, accounting for the association between some genetic renal transport defects and deafness. Deafness occurs in rare cases of Bartter syndrome, as discussed below. (See",
"    <a class=\"local\" href=\"#H88846686\">",
"     'Types I through IV'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H396471905\">",
"    <span class=\"h3\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartter syndrome can result from a defect in any of the genes that direct the synthesis or membrane insertion of the transporters mentioned in the preceding section [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/3,4,18-20\">",
"     3,4,18-20",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defective function of the Na-K-2Cl (NKCC2, SLC12A1) cotransporter in the luminal membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/3\">",
"       3",
"      </a>",
"      ], the luminal potassium channel (ROMK, KCNJ1) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/4,18\">",
"       4,18",
"      </a>",
"      ], or the basolateral chloride channel (ClC-Kb, CLCNKB) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/19,20\">",
"       19,20",
"      </a>",
"      ] are the causes of Bartter syndrome types I, II, and III, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Defects that affect both ClC-Ka and ClC-Kb cause Bartter syndrome associated with sensorineural deafness (types IV and IVb).",
"     </li>",
"     <li>",
"      Abnormalities that enhance the function of the calcium sensing receptor (CaSR) in the basolateral membrane of the thick ascending limb can impair sodium chloride transport and generate a mild Bartter phenotype called type V. The major clinical manifestation of this class of Bartter syndrome is hypocalcemia. (See",
"      <a class=\"local\" href=\"#H88846693\">",
"       'Type V'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88846686\">",
"    <span class=\"h4\">",
"     Types I through IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity and clinical presentation of Bartter syndrome varies with each type:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Types I and II are usually severe disorders that cause polyhydramnios during pregnancy and prematurity. Patients who survive infancy develop hypokalemia, metabolic alkalosis, polyuria, and hypercalciuria.",
"     </li>",
"     <li>",
"      The classic form of Bartter syndrome, type III, is less severe and presents later in life with hypokalemia, metabolic alkalosis, and hypercalciuria. The reduced severity of type III Bartter syndrome may be due to redundancy of chloride channels in the cells of the thick ascending limb. Although loss of ClC-Kb activity leads to disease, coexistent ClC-Ka activity appears to ameliorate the process. For reasons that are not well understood, some patients with ClC-Kb mutations have one or more features of Gitelman syndrome including hypomagnesemia, hypocalciuria not hypercalciuria, and unresponsiveness to thiazide rather than loop diuretics [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H168860094\">",
"       'Response to thiazide and loop diuretics'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Late manifestations that have been described in type III Bartter syndrome include proteinuria and impaired kidney function, which were detected in one series at a median follow-up of 14 years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Types IV and IVb have combined defects that involve both the ClC-Ka and ClC-Kb channels and cause severe disease, generally with antenatal presentation and hearing loss. Patients with type IV or IVb have neurosensory deafness since the two chloride channels are critical for ion transport in the stria vascularis of the inner ear [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/25-29\">",
"       25-29",
"      </a>",
"      ]. Because of redundancy of functions, hearing loss requires defects in both ClC-Ka and ClC-Kb.",
"      <br/>",
"      <br/>",
"      Two genetic mechanisms can produce combined defects in ClC-Ka and ClC-Kb:",
"      <br/>",
"      <br/>",
"      As discussed above, the barttin subunit is a critical component of both channels. Thus, a single defect that affects the barttin subunit reduces the function of both channels (type IV) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/25-29\">",
"       25-29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Double mutations, which reduce the function of both ClC-Ka and ClC-Kb, produce a phenotype similar to type IV generally called type IVb [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/30\">",
"       30",
"      </a>",
"      ]. Some propose that this variant be called type V disease; however, most groups use the designation of type V Bartter disease for patients with the gain-of-function mutation in the calcium sensing receptor as described in the next section.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88846693\">",
"    <span class=\"h4\">",
"     Type V",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type V, usually called autosomal dominant hypocalcemia or autosomal dominant hypoparathyroidism, is due to a gain-of-function mutation in the calcium-sensing receptor (CaSR) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In the parathyroid gland, this results in a downward \"resetting\" of the normal range for serum calcium. As a result, a lower than normal serum calcium concentration can inhibit parathyroid hormone release, resulting in hypocalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link&amp;anchor=H15#H15\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\", section on 'Autosomal dominant hypocalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CaSR is also expressed in the basolateral membrane of the thick ascending limb where it is involved in the regulation of renal calcium transport and sodium chloride reabsorption. Activation of the CaSR blunts potassium efflux through the ROMK channel and also may reduce activity of the Na-K-2Cl cotransporter (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/4,31,33\">",
"     4,31,33",
"    </a>",
"    ]. Some patients have gain-of-function mutations in the CaSR that are severe enough to produce mild to moderate renal sodium chloride wasting, which leads to volume contraction and increased aldosterone and renin levels. Renal potassium wasting, hypokalemia, and metabolic alkalosis ensue, creating a phenotype similar to Bartter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/21,32\">",
"     21,32",
"    </a>",
"    ]. This form of Bartter syndrome is distinguished from the others by the presence of hypocalcemia and hypomagnesemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88846700\">",
"    <span class=\"h4\">",
"     Variability in disease severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned in the preceding section, Bartter syndrome types I, II, IV, and IVb usually present in early life and with more severe disease, while types III and V are characterized by milder symptoms and later age of onset. However, this correlation between the underlying genetic abnormality and clinical phenotype is not universal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/20,24,34,35\">",
"     20,24,34,35",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two brothers who were compound heterozygotes for mutations in the gene encoding the Na-K-2Cl cotransporter (type I Bartter syndrome) presented in adolescence with mild disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients with mutations affecting the basolateral chloride (ClC-Kb) channel (type III Bartter syndrome) develop a phenotype more consistent with Gitelman disease or a hybrid clinical picture rather than a classic Bartter phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3869739\">",
"    <span class=\"h4\">",
"     Bartter-like phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phenotype resembling Bartter syndrome can occur in other clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EAST syndrome &mdash; A rare inherited disorder that presents in infancy, named EAST syndrome, is characterized by Epilepsy, severe Ataxia, moderate Sensorineural deafness, and Tubulopathy leading to renal salt-wasting, hypokalemia, metabolic alkalosis, and a normal blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/36\">",
"       36",
"      </a>",
"      ]. The disorder results from homozygous mutations in the KCNJ10 gene, which encodes for a potassium channel that is expressed in the kidney and brain. This observation provides additional evidence that renal tubulopathies are markedly heterogeneous.",
"     </li>",
"     <li>",
"      Aminoglycosides &mdash; A Bartter-like syndrome has been described in patients treated with aminoglycosides such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. This disorder is characterized by hypokalemia, metabolic alkalosis, hypomagnesemia with urinary magnesium wasting, and hypercalciuria, which resolve two to six weeks after drug termination. Drugs in this class are polycations, which act as calcimimetics and can activate the calcium-sensing receptor (CaSR) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/40\">",
"       40",
"      </a>",
"      ]. Thus, this disorder represents an acquired form of type V Bartter syndrome. (See",
"      <a class=\"local\" href=\"#H88846693\">",
"       'Type V'",
"      </a>",
"      above.) Alternatively, direct drug induced tubular damage may be the etiologic mechanism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3869747\">",
"    <span class=\"h2\">",
"     Gitelman syndrome",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H396471920\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gitelman syndrome is an autosomal recessive disorder that presents with hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalciuria, and normal blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/9,12,41,42\">",
"     9,12,41,42",
"    </a>",
"    ]. In contrast to the typically early clinical presentation in Bartter syndrome, Gitelman syndrome is usually not diagnosed until late childhood or adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/12\">",
"     12",
"    </a>",
"    ], although presentation in infancy has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/43\">",
"     43",
"    </a>",
"    ]. The clinical manifestations are less pronounced in heterozygotes. (See",
"    <a class=\"local\" href=\"#H3869761\">",
"     'Clinical manifestations in heterozygotes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most patients with Gitelman syndrome develop symptoms and serious clinical manifestations can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/9,41,42,44,45\">",
"     9,41,42,44,45",
"    </a>",
"    ]. Manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cramps of the arms and legs, which may be severe, are observed in almost all patients. They are due at least in part to hypokalemia and hypomagnesemia; the latter is due both to renal magnesium wasting and reduced intestinal magnesium absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/9\">",
"       9",
"      </a>",
"      ]. Approximately 10 percent of affected patients have tetany at diagnosis.",
"     </li>",
"     <li>",
"      Fatigue, which may be severe. This is more common in those with greater degrees of renal salt wasting, leading to reduced blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polyuria and nocturia are found in approximately 50 and 80 percent of patients, respectively. The polyuria is probably due to salt and water loss. The underlying genetic defect should not affect concentrating ability because function in the medullary thick ascending limb is relatively intact. However, chronic hypokalemia is a cause of nephrogenic diabetes insipidus (",
"      <a class=\"graphic graphic_table graphicRef68035 \" href=\"UTD.htm?42/61/43996\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Hypokalemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chondrocalcinosis (calcium pyrophosphate deposits and arthritis) may occur and may be related to chronic severe hypomagnesemia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rarely, patients present at a young age and have growth retardation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H396471939\">",
"    <span class=\"h3\">",
"     Genetics and pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with classic Gitelman syndrome, which is an autosomal recessive disease, have mutations in the gene coding for the thiazide-sensitive Na-Cl cotransporter in the distal tubule (NCCT, SLC12A3) (",
"    <a class=\"graphic graphic_figure graphicRef64975 \" href=\"UTD.htm?36/27/37309\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/5,46,47\">",
"     5,46,47",
"    </a>",
"    ]. The most common mutation causes impaired cellular routing of the cotransporter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/5,46\">",
"     5,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduced NCCT activity will mimic the effects of persistent thiazide diuretic action, which include volume contraction, reduced blood pressure, increased renin activity and aldosterone levels, renal potassium wasting and hypokalemia, renal magnesium wasting and hypomagnesemia, and a fall in urinary calcium excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=see_link\">",
"     \"Regulation of magnesium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link&amp;anchor=H3#H3\">",
"     \"Diuretics and calcium balance\", section on 'Distal tubule and thiazide diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of NCCT mutations may be variable, with phenotypes that include those similar to Bartter syndrome. This was illustrated in a study of five patients from two unrelated families with the same mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/48\">",
"     48",
"    </a>",
"    ]. Two men, who were the probands in each family, had marked symptomatic hypokalemia (1.6 and 1.8",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    normal serum magnesium concentrations, normal calcium excretion rates, and impaired maximal renal concentrating ability (Bartter phenotype), while three women had less severe and asymptomatic hypokalemia (2.8, 2.6, and 3.0",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    hypomagnesemia, hypocalciuria, and intact maximal renal concentrating ability (Gitelman phenotype).",
"   </p>",
"   <p>",
"    Although classic Gitelman syndrome is caused by mutations that reduce transport by NCCT, other transporter defects can also generate a Gitelman phenotype. As an example, the ClC-Kb chloride channel is present in both the thick ascending limb and the distal tubule. Mutations in this channel usually cause type III Bartter syndrome. (See",
"    <a class=\"local\" href=\"#H88846686\">",
"     'Types I through IV'",
"    </a>",
"    above.) However, mutations which that ClC-Kb chloride channel activity can also produce a syndrome with clinical features of Gitelman syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/21,49,50\">",
"     21,49,50",
"    </a>",
"    ]. The following observations have been noted in different families with ClC-Kb mutations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phenotype that is a hybrid between Bartter and Gitelman syndrome or that evolves over time from Bartter syndrome to Gitelman syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An identical mutation in the gene directing ClC-Kb synthesis can lead to either classic Gitelman syndrome or classic Bartter syndrome within the same family [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is possible that the observed clinical variability is due at least in part to differences in function or expression of other basolateral chloride transporters (such as the KCl cotransporter, ClC-Ka, the cystic fibrosis transmembrane conductance regulator, or the voltage-gated chloride channel), or to variable modulation of these transporters by modulatory kinase cascades. However, the specific explanation remains unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/21,49\">",
"     21,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3869754\">",
"    <span class=\"h2\">",
"     Role of prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal prostaglandin E2 (PGE2) production is often markedly elevated in the types of Bartter syndrome characterized by severe symptoms and presentation in utero or in the neonate (type I, II, IV and IVB) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The increased renal production of prostaglandin E2 results from impaired entry of sodium chloride into the macula densa cells at the end of the thick ascending limb of the loop of Henle, which increases the expression of cyclooxygenase 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/51\">",
"     51",
"    </a>",
"    ]. PGE2 levels can also be increased by loop diuretics, which produce an effect similar to the defect in Bartter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PGE2 directly stimulates renin release from juxtaglomerular cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/51,54,55\">",
"     51,54,55",
"    </a>",
"    ] and contributes to the electrolyte abnormalities that are seen in Bartter syndrome. This is important clinically since inhibitors of prostaglandin synthesis (nonsteroidal antiinflammatory drugs) can reverse many of the clinical and laboratory abnormalities of Bartter syndrome with the exception of the impairment in sodium reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H168860108\">",
"     'Primary therapeutic approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In comparison, prostaglandin excretion appears to be normal and prostaglandin synthesis inhibitors are of little benefit in Gitelman syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/56\">",
"     56",
"    </a>",
"    ]. This difference parallels the differences in the urine prostaglandin response to diuretic administration. Loop diuretics (similar to Bartter syndrome) increase urinary prostaglandin excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/57\">",
"     57",
"    </a>",
"    ], at least in part via increased prostaglandin synthesis in the thick ascending limb [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In contrast, thiazide diuretics (similar to Gitelman syndrome) produce little or no increase in prostaglandin excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3869761\">",
"    <span class=\"h2\">",
"     Clinical manifestations in heterozygotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both Bartter and Gitelman syndromes are autosomal recessive diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. This has led to speculation about the phenotypes of heterozygotes who carry these mutations, which are estimated to be present in at least 1 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/6\">",
"     6",
"    </a>",
"    ]. Data are limited about the clinical manifestations in heterozygotes but the following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an animal model of Bartter syndrome, no abnormalities in blood pressure or fluid balance were observed among mice with heterozygous disruption of the loop diuretic-sensitive Na-K-2Cl (NKCC2) cotransporter [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/60\">",
"       60",
"      </a>",
"      ]. The normal phenotype was probably due to at least in part to posttranscriptional compensation for the defect, which resulted in near normal levels of the NKCC2 cotransporter and a similar cellular distribution as observed in wild-type mice. These findings suggest that genetic carriers of the loop diuretic-sensitive cotransporter are unlikely to exhibit significant clinical abnormalities, although subtle abnormalities remain possible.",
"     </li>",
"     <li>",
"      A study of 65 patients with genetically defined hypokalemic salt-losing nephropathies included seven patients who had hypocalciuria and were heterozygous for mutations in the thiazide-sensitive Na-Cl cotransporter (NCCT) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/61\">",
"       61",
"      </a>",
"      ]. This suggests that the manifestations of Gitelman syndrome were either due to heterozygosity for NCCT mutations or an unidentified second mutation.",
"     </li>",
"     <li>",
"      Heterozygotes and homozygotes for Gitelman syndrome have a higher rate of sodium excretion than wild-type individuals that is probably due to self-selected higher salt intake [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/42\">",
"       42",
"      </a>",
"      ]. Although Gitelman and Bartter syndrome are salt-wasting disorders, initial volume loss leads to hormonal adaptations (increased activity of the renin-angiotensin-aldosterone system and reduced release of natriuretic peptides) that restore the balance between salt intake and excretion and prevent further losses. A similar sequence occurs with thiazide diuretics used to treat hypertension. Salt wasting is transient, and a steady state (with restoration of balance between sodium intake and excretion) is achieved at a lower extracellular fluid volume (",
"      <a class=\"graphic graphic_figure graphicRef74940 \" href=\"UTD.htm?15/33/15901\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=see_link&amp;anchor=H2#H2\">",
"       \"Time course of loop and thiazide diuretic-induced electrolyte complications\", section on 'Sodium and water losses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heterozygotes are less likely to develop hypertension. In the Framingham Heart Study, the average blood pressure of heterozygous participants with Gitelman or Bartter mutations during follow-up was",
"      <span class=\"nowrap\">",
"       6.3/3.4",
"      </span>",
"      mmHg lower than individuals without mutations. In addition, the risk of developing hypertension by age 60 was significantly lower in heterozygotes (relative risk 0.41, 95 percent CI 0.29-0.77) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3869768\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Bartter or Gitelman syndrome is largely one of exclusion, made in patients who present with unexplained hypokalemia and metabolic alkalosis with a normal or low blood pressure, and in whom other, more common, etiologies are ruled out. The diagnosis is usually made with a careful history, physical examination, measurement of the urine chloride concentration, and a urine diuretic screen. Other tests, such as genetic testing and measurement of the change in fractional excretion of chloride in response to loop and thiazide diuretics, are not widely performed. (See",
"    <a class=\"local\" href=\"#H168859978\">",
"     'Genetic testing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H168860094\">",
"     'Response to thiazide and loop diuretics'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    In patients thought to have either Bartter or Gitelman syndrome, measurement of urinary calcium excretion can help differentiate between these disorders. As mentioned above, urinary calcium excretion is high-normal or elevated in patients with Bartter syndrome and below normal in patients with Gitelman syndrome. Urinary calcium excretion can be determined with a 24-hour urine collection or estimated from the calcium-to-creatinine ratio in a spot urine specimen.",
"   </p>",
"   <p>",
"    The range of normal values for these measurements is wide and can vary with age and body weight. In addition, the urine calcium-to-creatinine ratio in a given individual can vary with the urine osmolality and, due to an unclear mechanism, with both the urine and serum concentrations of magnesium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/62\">",
"     62",
"    </a>",
"    ]. In normal adults, the upper limit for 24-hour urinary calcium excretion is approximately 275 mg (6.9 mmol) in women and 300 mg (7.5 mmol) in men. The upper range for the urine calcium-to-creatinine ratio in normal adults is approximately 200",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    of creatinine (565",
"    <span class=\"nowrap\">",
"     mmol/mol).",
"    </span>",
"   </p>",
"   <p>",
"    There is no clearly defined definition of hypocalciuria as would be present in Gitelman syndrome. One study in children found that the urine calcium-to-creatinine ratio was less than 44",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     mmol/mol)",
"    </span>",
"    in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/63\">",
"     63",
"    </a>",
"    ]. Similar data are not available in adults, but urinary calcium excretion of less than 75 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is considered low and therefore consistent with Gitelman syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168860066\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of unexplained hypokalemia and metabolic alkalosis associated with a normal or low blood pressure must be excluded before making the diagnosis of Bartter or Gitelman syndrome. The most common disorders that have a similar presentation and must be excluded are surreptitious vomiting and surreptitious diuretic use. It is not uncommon for patients to have both surreptitious vomiting and diuretic abuse. Clinical clues often suggest one these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=see_link&amp;anchor=H16729862#H16729862\">",
"     \"Clinical manifestations and evaluation of metabolic alkalosis\", section on 'Diagnostic approach in unexplained metabolic alkalosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary aldosteronism, which is another cause of hypokalemia and metabolic alkalosis, is usually",
"    <strong>",
"     not",
"    </strong>",
"    in the differential diagnosis since affected patients tend to be hypertensive and have a low plasma renin activity in contrast to elevated values in Bartter and Gitelman syndromes and with vomiting or diuretic use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features of primary aldosteronism\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352702326\">",
"    <span class=\"h3\">",
"     Surreptitious vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the physical examination and measurement of the urine chloride concentration usually distinguish surreptitious self-induced vomiting from Bartter and Gitelman syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Patients who chronically induce vomiting often develop characteristic physical findings such as scarring on the dorsum of the hand (from insertion into the mouth), dental erosions from exposure to acidic gastric secretions, and parotitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/65\">",
"     65",
"    </a>",
"    ]. However, the absence of such findings does not exclude surreptitious vomiting.",
"   </p>",
"   <p>",
"    The most helpful laboratory test is measurement of the urine chloride concentration, which is usually less than 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in patients with vomiting due to both hypovolemia and hypochloremia (",
"    <a class=\"graphic graphic_table graphicRef53478 \" href=\"UTD.htm?31/42/32427\">",
"     table 2",
"    </a>",
"    ). In contrast, the urine chloride concentration is typically much higher (usually greater than 40",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    in patients with Bartter or Gitelman syndrome in whom chloride excretion is equal to dietary chloride intake (mostly from salt) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The urine chloride is measured because the urine sodium concentration may not be an accurate indicator of volume status in patients with vomiting-induced metabolic alkalosis. Sodium wasting is a common finding in the first few days and occasionally later in patients with vomiting because the hypovolemic drive to retain sodium can be counteracted by the excretion of sodium and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"     potassium bicarbonate",
"    </a>",
"    when the serum bicarbonate level has risen rapidly and exceeds the renal threshold (",
"    <a class=\"graphic graphic_table graphicRef63175 \" href=\"UTD.htm?17/8/17547\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Significant bicarbonaturia is typically characterized by a urine pH above 7.0, while bicarbonate excretion is low at a urine pH below 6.5. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=see_link\">",
"     \"Clinical manifestations and evaluation of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352702429\">",
"    <span class=\"h3\">",
"     Surreptitious diuretic use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surreptitious diuretic use (also called diuretic abuse) should be considered in all patients with unexplained hypokalemia and metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/68-70\">",
"     68-70",
"    </a>",
"    ], even in infants who may be given diuretics by their parents or caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/71\">",
"     71",
"    </a>",
"    ]. In the past, a search of an inpatient's room was often a helpful diagnostic maneuver, but this is now rarely performed due to legal concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The urine chloride concentration is variable in diuretic abusers, being elevated while the diuretic is acting and then appropriately low when the diuretic effect wears off. A marked day-to-day variability in urine chloride suggests the possibility of intermittent diuretic use while, as mentioned in the preceding section, urinary chloride excretion is equal to intake and usually greater than 40",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in Bartter and Gitelman syndromes and typically less than 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with surreptitious vomiting.",
"   </p>",
"   <p>",
"    In the absence of a positive history, diuretic abuse can only be confirmed by a urine assay for diuretics. However, the sensitivity and specificity of this test is not known. Measurement of plasma renin and aldosterone levels is not helpful because they are increased in all of these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24588597\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other disorders that cause volume depletion but do not affect renal tubular function can partially mimic the Bartter or Gitelman phenotype. Two examples are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cystic fibrosis who lose salt-rich sweat during hot summer months. Although such patients will usually have established cystic fibrosis, patients with more moderate disease can present with unexplained hypokalemia and metabolic alkalosis as their initial clinical manifestation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/74-76\">",
"       74-76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infants given chloride deficient liquid formula can develop hypokalemia and metabolic alkalosis. As an example, an epidemic developed in the late 1970s and 1980s when a chloride-deficient soy based formula was introduced [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/77-80\">",
"       77-80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nephrotoxic agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      chemotherapy and tubulointerstitial nephritis in the setting of Sj&ouml;gren syndrome can induce electrolyte abnormalities resembling Gitelman syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/81,82\">",
"       81,82",
"      </a>",
"      ], presumably by damaging cells in the distal tubule that express the thiazide-sensitive Na-Cl cotransporter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions have sometimes been called \"pseudo-Bartter syndrome\" or \"pseudo-Gitelman syndrome,\" terms that have also been applied to self-induced vomiting and surreptitious diuretic use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168859978\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic analysis for many of the suspected gene mutations is possible and increasingly available. However, the large size of the involved genes, the multitude of recognized mutations, the absence of \"hot spots\" along the gene, intrafamilial heterogeneity, and high cost limit the practicality of this approach. The National Center for Biotechnology Information (NCBI), a division of the National Institute of Health, maintains a list of all laboratories offering genetic testing. This helpful site can be accessed at:",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/genetests/lab?db=genetests\">",
"     file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=genetests",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168860094\">",
"    <span class=\"h2\">",
"     Response to thiazide and loop diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Gitelman syndrome, who have a defect in the thiazide-sensitive Na-Cl cotransporter in the distal tubule, have a blunted response to thiazide diuretics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/23,83-88\">",
"     23,83-88",
"    </a>",
"    ]. Conversely, patients with Bartter syndrome, who have a defect in the thick ascending of the loop of Henle, should have a blunted response to loop diuretics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/23\">",
"     23",
"    </a>",
"    ] and should have an increased response to thiazide diuretics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/83\">",
"     83",
"    </a>",
"    ] due to compensatory hypertrophy of those distal tubule cells which reabsorb most of the excess sodium delivered out of the loop of Henle.",
"   </p>",
"   <p>",
"    One study formally tested the response to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (50 mg in adults or, in children or adolescents, 1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    among 41 patients with genetically confirmed Gitelman syndrome, seven patients with genetically confirmed Bartter syndrome, and four patients with either surreptitious vomiting or diuretic use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/83\">",
"     83",
"    </a>",
"    ]. A blunted thiazide response (defined as less than a 2.3 percent increase in the fractional excretion of chloride) was found in 38 of the 41 patients with Gitelman syndrome and in none of the patients with Bartter syndrome, surreptitious vomiting or diuretic use. The formula for the fractional excretion of chloride is similar to that for the fractional excretion of sodium, which is mostly used in the evaluation of acute kidney injury (acute renal failure). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of evaluating the chloride response to diuretic therapy is uncertain. It may help differentiate Gitelman from Bartter syndrome but will probably not separate the genetic disorders from surreptitious diuretic use. Other concerns are that test performance has not been clearly defined only a small number of patients have been studied, and that the safety of the test has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53267299\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of polyhydramnios is often apparent from ultrasonography or the alpha fetoprotein assay. However, a genetic renal or colon salt transport defect should be considered when such studies are unrevealing. The family history may also raise the suspicion for a renal or colonic disorder. In such cases, analysis of the amniotic fluid chloride concentration can be very helpful. The normal amniotic fluid chloride concentration is 109",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at a gestational age of 25 weeks and 107",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at 37 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. A higher amniotic fluid chloride concentration is consistent with one of the neonatal forms of Bartter syndrome or congenital chloride diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. In one study, for example, the amniotic fluid chloride concentration ranged from 114 to 123",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in four cases of neonatal Bartter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/89\">",
"     89",
"    </a>",
"    ]. Values above 112",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    have also been considered elevated in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4808?source=see_link&amp;anchor=H4#H4\">",
"     \"Polyhydramnios\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=see_link&amp;anchor=H3479576#H3479576\">",
"     \"Overview of the causes of chronic diarrhea in children\", section on 'Congenital chloride diarrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the polyhydramnios is severe, the pregnant mother may be treated until gestational week 31 with nonsteroidal antiinflammatory drugs (NSAIDs) to inhibit prostaglandin production and slow the rate of amniotic fluid production [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/91\">",
"     91",
"    </a>",
"    ]. However, NSAIDs given to pregnant women at 32 weeks gestation or later may cause premature closure of the ductus arteriosus. Thus, treatment of women with severe polyhydramnios during the third trimester requires intermittent drainage of the amniotic fluid or, if NSAIDs are used, repeated ultrasound assessment for the development of tricuspid regurgitation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3869775\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tubular defects in Bartter or Gitelman syndrome cannot be corrected. As a result, treatment, which must be life-long, is aimed at minimizing the effects of the secondary increases in prostaglandin, renin, and aldosterone production and at correcting the volume deficit and electrolyte abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168860108\">",
"    <span class=\"h2\">",
"     Primary therapeutic approaches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53268858\">",
"    <span class=\"h3\">",
"     NSAIDs and potassium-sparing diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred therapeutic regimens are somewhat different in patients with Bartter and Gitelman syndrome. As described above, the defect in loop of Henle function in Bartter syndrome increases renal prostaglandin E2 production, similar to the effect of loop diuretics. In particular, patients with Bartter syndromes type I, II, or IV have markedly elevated renal prostaglandin E2 levels. In such patients, nonsteroidal antiinflammatory drugs (NSAIDs) are an essential component of therapy and can ameliorate many of the abnormalities. However, careful monitoring is required since NSAIDs can have significant adverse effects including renal and gastrointestinal toxicity. (See",
"    <a class=\"local\" href=\"#H3869754\">",
"     'Role of prostaglandins'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The preferred initial therapy in patients with Bartter syndrome is most often the combination of an NSAID and a potassium-sparing diuretic such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    , frequently in higher than usual doses of up to 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and 40",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    respectively. This regimen can raise the serum potassium, reverse the metabolic alkalosis, and partially correct the hypomagnesemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/13,92,93\">",
"     13,92,93",
"    </a>",
"    ]. Among patients with hypokalemia due to potassium wasting of any cause, potassium-sparing diuretics are typically more effective and better tolerated than potassium supplementation. (See",
"    <a class=\"local\" href=\"#H53269181\">",
"     'Potassium and magnesium supplementation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of primary aldosteronism\", section on 'Medical therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/41/43668?source=see_link\">",
"     \"Diuretics and magnesium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A long-term study described the outcomes in 12 children with Bartter syndrome who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    and potassium supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/13\">",
"     13",
"    </a>",
"    ]. At presentation, all children had polyuria and polydipsia, metabolic and electrolyte disturbances (such as hypokalemia, hypophosphatemia and nephrocalcinosis), and failure to thrive. After 50 months of therapy, hypophosphatemia was corrected, hypokalemia persisted in some patients, and growth velocity recovered. Two patients had decreased renal function and gastrointestinal complications were common (mostly gastric ulcers and gastritis).",
"   </p>",
"   <p>",
"    In contrast to Bartter syndrome, urinary PGE2 excretion appears to be normal in Gitelman syndrome and NSAIDs are of little benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/56\">",
"     56",
"    </a>",
"    ]. Thus, initial therapy consists of a potassium-sparing diuretic alone. In a study of six adults with Gitelman syndrome who were treated for 1 to 18 months,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (200 to 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    (10 to 30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in partially correcting the hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that, in states of marked hyperaldosteronism, directly antagonizing the action of aldosterone with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    is more effective than blocking the collecting tubule sodium channels with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    . The same difference in efficacy has been noted in patients with cirrhosis and ascites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Diuretic regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53269123\">",
"    <span class=\"h3\">",
"     Angiotensin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors reduce the production of angiotensin II and aldosterone and may be a useful adjunctive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. In a report of seven patients with Bartter syndrome, for example, the serum potassium rose from 2.4 to 3.9",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    after three months of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    ; there was also partial correction of hypomagnesemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/95\">",
"     95",
"    </a>",
"    ]. Angiotensin receptor blockers (ARBs) should have similar efficacy but have not been well studied in these patients.",
"   </p>",
"   <p>",
"    The acute reduction in circulating angiotensin II levels can lead to symptomatic hypotension in patients with Bartter or Gitelman syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/97\">",
"     97",
"    </a>",
"    ]. This problem is often transient and can be minimized by the initial use of low doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53269181\">",
"    <span class=\"h3\">",
"     Potassium and magnesium supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients require oral potassium and magnesium supplementation, since therapy with NSAIDs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    potassium-sparing diuretics is often incompletely effective. However, the restoration of normal serum potassium and magnesium concentrations is often difficult to achieve for one or more of the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blocking potassium secretion in the cortical collecting tubule with a potassium-sparing diuretic with or without an ACE inhibitor in patients with Bartter syndrome will not reverse the primary defect, which is impaired potassium reabsorption in the loop of Henle. As an example, a mutation that impairs the Na-K-2Cl cotransporter can cause persistent potassium wasting. (See",
"      <a class=\"local\" href=\"#H5551767\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypomagnesemia can contribute to urinary potassium loss. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link&amp;anchor=H3#H3\">",
"       \"Signs and symptoms of magnesium depletion\", section on 'Hypokalemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When hypokalemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypomagnesemia are due to urinary wasting, potassium or magnesium supplementation has limited efficacy. As the serum potassium or magnesium falls in the untreated patient, the antikaliuretic effect of hypokalemia and the antimagnesiuretic effect of hypomagnesemia gradually lower potassium and magnesium excretion until a new steady state is attained in which intake and urinary excretion are back in balance and the serum potassium and magnesium concentrations are stable at a lower than normal level.",
"      <br/>",
"      <br/>",
"      The rise in serum concentrations following the administration of potassium and magnesium supplements will reduce the stimulus to potassium and magnesium retention. As a result, most of the administered potassium or magnesium will be excreted in the urine. High doses, which are often difficult to tolerate (eg, diarrhea with magnesium), are required to achieve a substantial elevation in serum potassium or magnesium. Similar considerations apply to hypokalemia and hypomagnesemia due to other causes of urinary wasting of these cations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H23441650#H23441650\">",
"       \"Clinical manifestations and treatment of hypokalemia\", section on 'Ongoing losses and the steady state'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=see_link\">",
"       \"Evaluation and treatment of hypomagnesemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168860445\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplantation should correct the transport abnormalities in Gitelman and Bartter syndromes and recurrent disease in the transplant should not occur and has not been described. This aggressive intervention has primarily been performed in isolated case reports of patients who developed end-stage renal disease due to coexisting renal disease or to complications related to volume depletion, electrolyte abnormalities, drug-related side effects,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nephrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. In addition, successful preemptive bilateral nephrectomy and renal transplantation has been performed in a patient with severe neonatal Bartter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141701676\">",
"    <span class=\"h2\">",
"     Experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental therapies other than renal transplantation that are being investigated are based upon the discovery that some mutations in Gitelman and Bartter syndrome give rise to functionally normal transporters that are sequestered in various intracellular compartments and are therefore not correctly inserted into the cell membrane. If successfully inserted into the cell membrane, these transporters can be fully functional and at least partially correct the underlying defect.",
"   </p>",
"   <p>",
"    In vitro studies have been performed in cell lines with trafficking mutations in the mutant thiazide-sensitive Na-Cl cotransporter in Gitelman syndrome and in the mutant ROMK channel in antenatal Bartter syndrome (type II Bartter syndrome). (See",
"    <a class=\"local\" href=\"#H396471905\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of molecular chaperones, such as 4-phenylbutyrate, can improve the delivery to and insertion of these otherwise functional proteins in the cell membrane and partially rescue sodium chloride reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?22/43/23226/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168863669\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bartter syndrome and Gitelman syndrome are autosomal recessive disorders characterized by hypokalemia, metabolic alkalosis, secondary hyperreninemia and hyperaldosteronism, and, in some patients, hypomagnesemia. These patients are not hypertensive (See",
"      <a class=\"local\" href=\"#H3869704\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both conditions are rare. The prevalence of Gitelman and Bartter syndromes, respectively, are estimated to be 1 in 40,000 and 1 in a million. (See",
"      <a class=\"local\" href=\"#H3869711\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tubular defect in Bartter syndrome mimics that of chronic loop diuretic ingestion. The following manifestations are common (",
"      <a class=\"graphic graphic_table graphicRef68035 \" href=\"UTD.htm?42/61/43996\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H3869725\">",
"       'Bartter syndrome'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypokalemia with metabolic alkalosis",
"     </li>",
"     <li>",
"      Polyuria, polydipsia, and a decreased concentrating ability",
"     </li>",
"     <li>",
"      Urinary calcium is increased, and the serum magnesium is either normal or mildly reduced",
"     </li>",
"     <li>",
"      Growth retardation in severe cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bartter syndrome can result from a defect in any one of several genes that are integral to sodium chloride reabsorption in the thick ascending limb of Henle's loop (",
"      <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"       figure 1",
"      </a>",
"      ). The severity of disease and the timing of presentation vary according to which gene is involved, with some cases presenting in utero or during infancy. Patients with severe Bartter syndrome may have elevated systemic prostaglandin E2 levels. This prostaglandin is produced in the macula densa and may contribute to the pathogenesis of the disorder. (See",
"      <a class=\"local\" href=\"#H396471898\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3869754\">",
"       'Role of prostaglandins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gitelman syndrome, which is generally more benign than Bartter syndrome and usually presents in late childhood or adulthood, is due to a tubular defect in sodium chloride reabsorption in the distal tubule (mimicking chronic thiazide diuretic ingestion). The clinical manifestations include (",
"      <a class=\"graphic graphic_table graphicRef68035 \" href=\"UTD.htm?42/61/43996\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H3869747\">",
"       'Gitelman syndrome'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypokalemia, which is often severe, and metabolic alkalosis",
"     </li>",
"     <li>",
"      Polyuria and nocturia, but with normal concentrating ability",
"     </li>",
"     <li>",
"      Urinary calcium is reduced, and severe hypomagnesemia is common",
"     </li>",
"     <li>",
"      Cramps of the arms and legs, and, occasionally, severe fatigue",
"     </li>",
"     <li>",
"      Chondrocalcinosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with Gitelman syndrome usually have mutations in the gene coding for the thiazide-sensitive Na-Cl cotransporter in the distal tubule (NCCT) (",
"      <a class=\"graphic graphic_figure graphicRef64975 \" href=\"UTD.htm?36/27/37309\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Although Bartter and Gitelman syndromes are autosomal recessive disorders, heterozygotes occasionally develop electrolyte abnormalities and may have lower blood pressure than others in the population. (See",
"      <a class=\"local\" href=\"#H3869761\">",
"       'Clinical manifestations in heterozygotes'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The diagnosis of Bartter or Gitelman syndrome is largely one of exclusion, made in someone who presents with unexplained hypokalemia and metabolic alkalosis with a normal or low blood pressure, and in whom other, more common, etiologies (ie, surreptitious vomiting and diuretic use) are ruled out. The diagnosis is usually made with a careful history, physical examination, measurement of the urine chloride concentration, and a urine diuretic screen (see",
"      <a class=\"local\" href=\"#H168860066\">",
"       'Differential diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The daily urine chloride excretion in patients with Bartter or Gitelman syndromes is generally similar to their daily chloride intake despite relative volume depletion. This means that the urine chloride concentration is typically greater than 25",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"     </li>",
"     <li>",
"      In contrast, patients with hypokalemia and metabolic",
"      <strong>",
"      </strong>",
"      alkalosis caused by vomiting have a urine chloride concentration that is usually less than 25",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (reflecting volume depletion and chloride deficiency).",
"     </li>",
"     <li>",
"      Patients who secretively take diuretics",
"      <strong>",
"      </strong>",
"      have a variable urine chloride concentration; it is high when the diuretic effect is present and low when it dissipates. A urine diuretic screen should be sent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although genetic testing is increasingly available for many of the suspected gene mutations, there are multiple recognized and, probably, several unrecognized mutations, and the cost is high. Thus, the practicality of genetic testing is limited. (See",
"      <a class=\"local\" href=\"#H168859978\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of patients with Bartter and Gitelman syndromes usually combines life-long administration of a potassium-sparing diuretic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      ), and supplementation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"       potassium chloride",
"      </a>",
"      and magnesium. In addition, patients with Bartter syndrome are often treated with non-steroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H168860108\">",
"       'Primary therapeutic approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/1\">",
"      Kurtz I. Molecular pathogenesis of Bartter's and Gitelman's syndromes. Kidney Int 1998; 54:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/2\">",
"      Stein JH. The pathogenetic spectrum of Bartter's syndrome. Kidney Int 1985; 28:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/3\">",
"      Simon DB, Karet FE, Hamdan JM, et al. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 1996; 13:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/4\">",
"      Simon DB, Karet FE, Rodriguez-Soriano J, et al. Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 1996; 14:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/5\">",
"      Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996; 12:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/6\">",
"      Ji W, Foo JN, O'Roak BJ, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008; 40:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/7\">",
"      Gladziwa U, Schwarz R, Gitter AH, et al. Chronic hypokalaemia of adults: Gitelman's syndrome is frequent but classical Bartter's syndrome is rare. Nephrol Dial Transplant 1995; 10:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/8\">",
"      Konrad M, Weber S. Recent advances in molecular genetics of hereditary magnesium-losing disorders. J Am Soc Nephrol 2003; 14:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/9\">",
"      Monnens L, Bindels R, Gr&uuml;nfeld JP. Gitelman syndrome comes of age. Nephrol Dial Transplant 1998; 13:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/10\">",
"      Gill JR Jr, Bartter FC. Evidence for a prostaglandin-independent defect in chloride reabsorption in the loop of Henle as a proximal cause of Bartter's syncrome. Am J Med 1978; 65:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/11\">",
"      Uribarri J, Alveranga D, Oh MS, et al. Bartter's syndrome due to a defect in salt reabsorption in the distal convoluted tubule. Nephron 1985; 40:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/12\">",
"      Bettinelli A, Bianchetti MG, Girardin E, et al. Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes. J Pediatr 1992; 120:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/13\">",
"      Vaisbich MH, Fujimura MD, Koch VH. Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 2004; 19:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/14\">",
"      Dillon MJ, Shah V, Mitchell MD. Bartter's syndrome: 10 cases in childhood. Results of long-term indomethacin therapy. Q J Med 1979; 48:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/15\">",
"      Sann L, David L, Bernheim J, Fran&ccedil;ois R. Hypophosphatemia and hyperparathyroidism in a case of Bartter's syndrome. Helv Paediatr Acta 1978; 33:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/16\">",
"      Gamba G. Molecular biology of distal nephron sodium transport mechanisms. Kidney Int 1999; 56:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/17\">",
"      Waldegger S, Jentsch TJ. From tonus to tonicity: physiology of CLC chloride channels. J Am Soc Nephrol 2000; 11:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/18\">",
"      Lorenz JN, Baird NR, Judd LM, et al. Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter's syndrome. J Biol Chem 2002; 277:37871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/19\">",
"      Simon DB, Bindra RS, Mansfield TA, et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet 1997; 17:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/20\">",
"      Konrad M, Vollmer M, Lemmink HH, et al. Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol 2000; 11:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/21\">",
"      Zelikovic I. Hypokalaemic salt-losing tubulopathies: an evolving story. Nephrol Dial Transplant 2003; 18:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/22\">",
"      Seyberth HW. An improved terminology and classification of Bartter-like syndromes. Nat Clin Pract Nephrol 2008; 4:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/23\">",
"      Nozu K, Iijima K, Kanda K, et al. The pharmacological characteristics of molecular-based inherited salt-losing tubulopathies. J Clin Endocrinol Metab 2010; 95:E511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/24\">",
"      Bettinelli A, Borsa N, Bellantuono R, et al. Patients with biallelic mutations in the chloride channel gene CLCNKB: long-term management and outcome. Am J Kidney Dis 2007; 49:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/25\">",
"      Birkenh&auml;ger R, Otto E, Sch&uuml;rmann MJ, et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 2001; 29:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/26\">",
"      Est&eacute;vez R, Boettger T, Stein V, et al. Barttin is a Cl- channel beta-subunit crucial for renal Cl- reabsorption and inner ear K+ secretion. Nature 2001; 414:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/27\">",
"      Izzedine H, Tankere F, Launay-Vacher V, Deray G. Ear and kidney syndromes: molecular versus clinical approach. Kidney Int 2004; 65:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/28\">",
"      Kobayashi K, Uchida S, Okamura HO, et al. Human CLC-KB gene promoter drives the EGFP expression in the specific distal nephron segments and inner ear. J Am Soc Nephrol 2002; 13:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/29\">",
"      Janssen AG, Scholl U, Domeyer C, et al. Disease-causing dysfunctions of barttin in Bartter syndrome type IV. J Am Soc Nephrol 2009; 20:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/30\">",
"      Schlingmann KP, Konrad M, Jeck N, et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med 2004; 350:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/31\">",
"      Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 1996; 50:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/32\">",
"      Watanabe S, Fukumoto S, Chang H, et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 2002; 360:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/33\">",
"      Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol 1996; 271:C103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/34\">",
"      Jentsch TJ. Chloride transport in the kidney: lessons from human disease and knockout mice. J Am Soc Nephrol 2005; 16:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/35\">",
"      Pressler CA, Heinzinger J, Jeck N, et al. Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol 2006; 17:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/36\">",
"      Bockenhauer D, Feather S, Stanescu HC, et al. Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med 2009; 360:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/37\">",
"      Chou CL, Chen YH, Chau T, Lin SH. Acquired bartter-like syndrome associated with gentamicin administration. Am J Med Sci 2005; 329:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/38\">",
"      Chen YS, Fang HC, Chou KJ, et al. Gentamicin-induced Bartter-like syndrome. Am J Kidney Dis 2009; 54:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/39\">",
"      Chrispal A, Boorugu H, Prabhakar AT, Moses V. Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia. J Postgrad Med 2009; 55:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/40\">",
"      Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol 2009; 5:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/41\">",
"      Cruz DN, Shaer AJ, Bia MJ, et al. Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 2001; 59:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/42\">",
"      Cruz DN, Simon DB, Nelson-Williams C, et al. Mutations in the Na-Cl cotransporter reduce blood pressure in humans. Hypertension 2001; 37:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/43\">",
"      Tammaro F, Bettinelli A, Cattarelli D, et al. Early appearance of hypokalemia in Gitelman syndrome. Pediatr Nephrol 2010; 25:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/44\">",
"      Ea HK, Blanchard A, Dougados M, Roux C. Chondrocalcinosis secondary to hypomagnesemia in Gitelman's syndrome. J Rheumatol 2005; 32:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/45\">",
"      Riveira-Munoz E, Chang Q, Godefroid N, et al. Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. J Am Soc Nephrol 2007; 18:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/46\">",
"      De Jong JC, Van Der Vliet WA, Van Den Heuvel LP, et al. Functional expression of mutations in the human NaCl cotransporter: evidence for impaired routing mechanisms in Gitelman's syndrome. J Am Soc Nephrol 2002; 13:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/47\">",
"      Vargas-Poussou R, Dahan K, Kahila D, et al. Spectrum of mutations in Gitelman syndrome. J Am Soc Nephrol 2011; 22:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/48\">",
"      Lin SH, Cheng NL, Hsu YJ, Halperin ML. Intrafamilial phenotype variability in patients with Gitelman syndrome having the same mutations in their thiazide-sensitive sodium/chloride cotransporter. Am J Kidney Dis 2004; 43:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/49\">",
"      Zelikovic I, Szargel R, Hawash A, et al. A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int 2003; 63:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/50\">",
"      Jeck N, Konrad M, Peters M, et al. Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. Pediatr Res 2000; 48:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/51\">",
"      K&ouml;mhoff M, Reinalter SC, Gr&ouml;ne HJ, Seyberth HW. Induction of microsomal prostaglandin E2 synthase in the macula densa in children with hypokalemic salt-losing tubulopathies. Pediatr Res 2004; 55:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/52\">",
"      Fujita T, Ando K, Sato Y, et al. Independent roles of prostaglandins and the renin-angiotensin system in abnormal vascular reactivity in Bartter's syndrome. Am J Med 1982; 73:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/53\">",
"      Ciabattoni G, Pugliese F, Cinotti GA, et al. Characterization of furosemide-induced activation of the renal prostaglandin system. Eur J Pharmacol 1979; 60:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/54\">",
"      Friis UG, Stubbe J, Uhrenholt TR, et al. Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells. Am J Physiol Renal Physiol 2005; 289:F989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/55\">",
"      Jensen BL, Schmid C, Kurtz A. Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Physiol 1996; 271:F659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/56\">",
"      L&uuml;thy C, Bettinelli A, Iselin S, et al. Normal prostaglandinuria E2 in Gitelman's syndrome, the hypocalciuric variant of Bartter's syndrome. Am J Kidney Dis 1995; 25:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/57\">",
"      Patak RV, Fadem SZ, Rosenblatt SG, et al. Diuretic-induced changes in renal blood flow and prostaglandin E excretion in the dog. Am J Physiol 1979; 236:F494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/58\">",
"      Miyanoshita A, Terada M, Endou H. Furosemide directly stimulates prostaglandin E2 production in the thick ascending limb of Henle's loop. J Pharmacol Exp Ther 1989; 251:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/59\">",
"      Liguori A, Casini A, Di Loreto M, et al. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Eur J Clin Pharmacol 1999; 55:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/60\">",
"      Takahashi N, Brooks HL, Wade JB, et al. Posttranscriptional compensation for heterozygous disruption of the kidney-specific NaK2Cl cotransporter gene. J Am Soc Nephrol 2002; 13:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/61\">",
"      Peters M, Jeck N, Reinalter S, et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 2002; 112:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/62\">",
"      Ring T, Knoers N, Oh MS, Halperin ML. Reevaluation of the criteria for the clinical diagnosis of Gitelman syndrome. Pediatr Nephrol 2002; 17:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/63\">",
"      Bianchetti MG, Edefonti A, Bettinelli A. The biochemical diagnosis of Gitelman disease and the definition of \"hypocalciuria\". Pediatr Nephrol 2003; 18:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/64\">",
"      Veldhuis JD, Bardin CW, Demers LM. Metabolic mimicry of Bartter's syndrome by covert vomiting: utility of urinary chloride determinations. Am J Med 1979; 66:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/65\">",
"      Mitchell JE, Seim HC, Colon E, Pomeroy C. Medical complications and medical management of bulimia. Ann Intern Med 1987; 107:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/66\">",
"      Sherman RA, Eisinger RP. The use (and misuse) of urinary sodium and chloride measurements. JAMA 1982; 247:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/67\">",
"      Kassirer JP, Schwartz WB. The response of normal man to selective depletion of hydrochloric acid. Factors in the genesis of persistent gastric alkalosis. Am J Med 1966; 40:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/68\">",
"      Jamison RL, Ross JC, Kempson RL, et al. Surreptitious diuretic ingestion and pseudo-Bartter's syndrome. Am J Med 1982; 73:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/69\">",
"      Colussi G, Rombol&agrave; G, Airaghi C, et al. Pseudo-Bartter's syndrome from surreptitious diuretic intake: differential diagnosis with true Bartter's syndrome. Nephrol Dial Transplant 1992; 7:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/70\">",
"      Sasaki H, Kawasaki T, Yamamoto T, et al. [Pseudo-Bartter's syndrome induced by surreptitious ingestion of furosemide to lose weight: a case report and possible pathophysiology]. Nihon Naibunpi Gakkai Zasshi 1986; 62:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/71\">",
"      D'Avanzo M, Santinelli R, Tolone C, et al. Concealed administration of frusemide simulating Bartter syndrome in a 4.5-year-old boy. Pediatr Nephrol 1995; 9:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/72\">",
"      Lukie BE, Wright CJ. The room search. J Clin Gastroenterol 1984; 6:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/73\">",
"      Plumeri PA. The room search. J Clin Gastroenterol 1984; 6:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/74\">",
"      Kose M, Pekcan S, Ozcelik U, et al. An epidemic of pseudo-Bartter syndrome in cystic fibrosis patients. Eur J Pediatr 2008; 167:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/75\">",
"      Kennedy JD, Dinwiddie R, Daman-Willems C, et al. Pseudo-Bartter's syndrome in cystic fibrosis. Arch Dis Child 1990; 65:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/76\">",
"      Escobar Castro H, Medina E, Kirchschl&auml;ger E, et al. Metabolic alkalosis with hypo-electrolytaemia or pseudo-Bartter syndrome as a presentation of cystic fibrosis in infancy. Discription of three cases. Eur J Pediatr 1995; 154:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/77\">",
"      Roy S 3rd, Arant BS Jr. Hypokalemic metabolic alkalosis in normotensive infants with elevated plasma renin activity and hyperaldosteronism: role of dietary chloride deficiency. Pediatrics 1981; 67:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/78\">",
"      Linshaw MA, Harrison HL, Gruskin AB, et al. Hypochloremic alkalosis in infants associated with soy protein formula. J Pediatr 1980; 96:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/79\">",
"      Malloy MH, Graubard B, Moss H, et al. Hypochloremic metabolic alkalosis from ingestion of a chloride-deficient infant formula: outcome 9 and 10 years later. Pediatrics 1991; 87:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/80\">",
"      Reznik VM, Griswold WR, Mendoza SA, McNeal RM. Neo-Mull-Soy metabolic alkalosis: a model of Bartter's syndrome? Pediatrics 1980; 66:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/81\">",
"      Panichpisal K, Angulo-Pernett F, Selhi S, Nugent KM. Gitelman-like syndrome after cisplatin therapy: a case report and literature review. BMC Nephrol 2006; 7:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/82\">",
"      Kim YK, Song HC, Kim WY, et al. Acquired Gitelman syndrome in a patient with primary Sj&ouml;gren syndrome. Am J Kidney Dis 2008; 52:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/83\">",
"      Colussi G, Bettinelli A, Tedeschi S, et al. A thiazide test for the diagnosis of renal tubular hypokalemic disorders. Clin J Am Soc Nephrol 2007; 2:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/84\">",
"      Puschett JB, Greenberg A, Mitro R, et al. Variant of Bartter's syndrome with a distal tubular rather than loop of Henle defect. Nephron 1988; 50:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/85\">",
"      Sutton RA, Mavichak V, Halabe A, Wilkins GE. Bartter's syndrome: evidence suggesting a distal tubular defect in a hypocalciuric variant of the syndrome. Miner Electrolyte Metab 1992; 18:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/86\">",
"      Colussi G, Rombol&agrave; G, Brunati C, De Ferrari ME. Abnormal reabsorption of Na+/CI- by the thiazide-inhibitable transporter of the distal convoluted tubule in Gitelman's syndrome. Am J Nephrol 1997; 17:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/87\">",
"      Bettinelli A, Vezzoli G, Colussi G, et al. Genotype-phenotype correlations in normotensive patients with primary renal tubular hypokalemic metabolic alkalosis. J Nephrol 1998; 11:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/88\">",
"      Kageyama K, Terui K, Shoji M, et al. Diagnosis of a case of Gitelman's syndrome based on renal clearance studies and gene analysis of a novel mutation of the thiazide-sensitive Na-Cl cotransporter. J Endocrinol Invest 2005; 28:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/89\">",
"      Proesmans W, Massa G, Vandenberghe K, Van Assche A. Prenatal diagnosis of Bartter syndrome. Lancet 1987; 1:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/90\">",
"      Proesmans W. Threading through the mizmaze of Bartter syndrome. Pediatr Nephrol 2006; 21:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/91\">",
"      Tourne G, Collet F, Varlet MN, et al. [Prenatal Bartter's syndrome. Report of two cases]. J Gynecol Obstet Biol Reprod (Paris) 2003; 32:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/92\">",
"      Vinci JM, Gill JR Jr, Bowden RE, et al. The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition. J Clin Invest 1978; 61:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/93\">",
"      Griffing GT, Komanicky P, Aurecchia SA, et al. Amiloride in Bartter's syndrome. Clin Pharmacol Ther 1982; 31:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/94\">",
"      Colussi G, Rombol&agrave; G, De Ferrari ME, et al. Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. Am J Nephrol 1994; 14:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/95\">",
"      Hen&eacute; RJ, Koomans HA, Dorhout Mees EJ, et al. Correction of hypokalemia in Bartter's syndrome by enalapril. Am J Kidney Dis 1987; 9:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/96\">",
"      Morales JM, Ruilope LM, Praga M, et al. Long-term enalapril therapy in Bartter's syndrome. Nephron 1988; 48:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/97\">",
"      Mizuno K, Yamazaki M, Fukuchi S. Hypotensive response to angiotensin I-converting enzyme inhibitor in Bartter's syndrome. N Engl J Med 1979; 300:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/98\">",
"      Cal&ograve; LA, Marchini F, Davis PA, et al. Kidney transplant in Gitelman's syndrome. Report of the first case. J Nephrol 2003; 16:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/99\">",
"      Kim JY, Kim GA, Song JH, et al. A case of living-related kidney transplantation in Bartter's syndrome. Yonsei Med J 2000; 41:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/100\">",
"      Takahashi M, Yanagida N, Okano M, et al. A first report: living related kidney transplantation on a patient with Bartter's syndrome. Transplant Proc 1996; 28:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/101\">",
"      Chaudhuri A, Salvatierra O Jr, Alexander SR, Sarwal MM. Option of pre-emptive nephrectomy and renal transplantation for Bartter's syndrome. Pediatr Transplant 2006; 10:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/102\">",
"      de Jong JC, Willems PH, Goossens M, et al. Effects of chemical chaperones on partially retarded NaCl cotransporter mutants associated with Gitelman's syndrome in a mouse cortical collecting duct cell line. Nephrol Dial Transplant 2004; 19:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/43/23226/abstract/103\">",
"      Peters M, Ermert S, Jeck N, et al. Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 2003; 64:923.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2344 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23226=[""].join("\n");
var outline_f22_43_23226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H168863669\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3869704\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3869711\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3869718\">",
"      PATHOGENESIS AND CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5551669\">",
"      Overview of common and distinctive features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3869725\">",
"      Bartter syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H396471884\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5551767\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H396471898\">",
"      - Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H396471905\">",
"      - Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88846686\">",
"      Types I through IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88846693\">",
"      Type V",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H88846700\">",
"      Variability in disease severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3869739\">",
"      Bartter-like phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3869747\">",
"      Gitelman syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H396471920\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H396471939\">",
"      - Genetics and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3869754\">",
"      Role of prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3869761\">",
"      Clinical manifestations in heterozygotes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3869768\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168860066\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H352702326\">",
"      - Surreptitious vomiting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H352702429\">",
"      - Surreptitious diuretic use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24588597\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168859978\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168860094\">",
"      Response to thiazide and loop diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53267299\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3869775\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168860108\">",
"      Primary therapeutic approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53268858\">",
"      - NSAIDs and potassium-sparing diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53269123\">",
"      - Angiotensin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53269181\">",
"      - Potassium and magnesium supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168860445\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141701676\">",
"      Experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H168863669\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2344\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2344|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/62/31725\" title=\"figure 1\">",
"      Loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/27/37309\" title=\"figure 2\">",
"      Distal tubule transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/33/15901\" title=\"figure 3\">",
"      Time course of diuretic action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2344|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/61/43996\" title=\"table 1\">",
"      The inherited salt-losing renal tubulopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/42/32427\" title=\"table 2\">",
"      Urine Cl in metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/8/17547\" title=\"table 3\">",
"      Urine electrolytes vomiting",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=related_link\">",
"      Chapter 4A: Cell model for loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=related_link\">",
"      Clinical manifestations and evaluation of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/41/43668?source=related_link\">",
"      Diuretics and magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11254?source=related_link\">",
"      Evaluation and treatment of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=related_link\">",
"      Overview of the causes of chronic diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4808?source=related_link\">",
"      Polyhydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=related_link\">",
"      Regulation of magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=related_link\">",
"      Treatment of primary aldosteronism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_43_23227="Body CT in stage III melanoma";
var content_f22_43_23227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Body computerized tomography for staging asymptomatic patients with stage III melanoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Institution",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        True positive, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        False positive, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        New primaries, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MDACC",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        22.4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MSKCC",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        University of Michigan",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MDACC: The University of Texas M.D. Anderson Cancer Center; MSKCC: Memorial Sloan-Kettering Cancer Center.",
"     <br>",
"      Results of computerized tomography of the chest, abdomen and pelvis in asymptomatic patients with documented local-regional metastases who have a normal chest x-ray and serum LDH concentration.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Antonio Buzaid, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23227=[""].join("\n");
var outline_f22_43_23227=null;
var title_f22_43_23228="Anaphylaxis diagnosis";
var content_f22_43_23228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for anaphylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anaphylaxis is highly likely when any ONE of the following&nbsp;three criteria is fulfilled:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         AND AT LEAST ONE OF THE FOLLOWING:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF in older children and adults, hypoxemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Reduced BP* or associated symptoms of end-organ dysfunction (eg, hypotonia, collapse, syncope, incontinence)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        2. TWO OR MORE OF THE FOLLOWING that occur rapidly",
"        <em>",
"         after exposure to a LIKELY allergen for that patient",
"        </em>",
"        (minutes to several hours):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips-tongue-uvula)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF in older children and adults, hypoxemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. Reduced BP* or associated symptoms (eg, hypotonia, collapse, syncope, incontinence)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D. Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        3. Reduced BP*",
"        <em>",
"         after exposure to a KNOWN allergen for that patient",
"        </em>",
"        (minutes to several hours):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Infants and children: low systolic BP (age specific)* or greater than 30 percent decrease in systolic BP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Adults: systolic BP of less than 90 mmHg or greater than 30 percent decrease from that person's baseline",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PEF: peak expiratory flow; BP: blood pressure.",
"     <br>",
"      * Low systolic blood pressure for children is defined as:",
"      <br>",
"       - less than 70 mmHg from&nbsp;one month to&nbsp;one year,",
"       <br>",
"        - less than (70 mmHg + [2 x age]) from 1 to 10 years, and",
"        <br>",
"         - less than 90 mmHg from 11 to 17 years",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391. Copyright &copy; 2006 The American Academy of Allergy, Asthma, and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23228=[""].join("\n");
var outline_f22_43_23228=null;
var title_f22_43_23229="Monitoring type1 GD A";
var content_f22_43_23229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mimimum recommended initial assessment and monitoring recommendations for patients with nonneuronopathic Gaucher disease - part 1*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Initial assessment",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Not receiving ERT",
"       </td>",
"       <td class=\"subtitle2\">",
"        Receiving ERT, has not achieved goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Physical examination",
"       </td>",
"       <td>",
"        Every 6 months",
"       </td>",
"       <td>",
"        Every 6 to 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Blood tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"       <td>",
"        Every 3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Platelets",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"       <td>",
"        Every 3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chitotriodase, TRAP, ACE, HDL",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"       <td>",
"        Every 3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beta-glucosidase and mutation analysis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antibody sample",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Not necessary",
"       </td>",
"       <td>",
"        Optional sample after six months of therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum immunoelectrophoresis",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Every 12-24 months in patients &gt;50 years",
"       </td>",
"       <td>",
"        Every 12-24 months in patients &gt;50 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Radiographs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Visceral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Spleen volume (MRI or US)",
"       </td>",
"       <td>",
"        Every 12-24 months",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Liver volume (MRI or US)",
"       </td>",
"       <td>",
"        Every 12-24 months",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Skeletal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Spine (sagittal T1-weighted)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 24 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Femora (coronal T1- and T2- weighted)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 24 months (T1- and T2-weighted)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12 month (T1 and T2-weighted)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Plain radiographs",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Children: pelvis, long bones, spine",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12-24 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Adult: lateral spine; AP of entire Femora",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12-24 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        DEXA spine and hips",
"       </td>",
"       <td>",
"        Every 12-24 months",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    (This table is continued).",
"    <div class=\"footnotes\">",
"     ERT: enzyme replacement therapy; TRAP: tartrate resistant acid phosphatase; ACE: angiotensin converting enzyme; HDL: high density lipoprotein; MRI: magnetic resonance imaging; US: ultrasonography; DEXA: dual energy X-ray absorptiometry.",
"     <br>",
"      * The entire assessment should be performed at baseline and every 12 to 24 months in patients who are receiving ERT and have achieved therapeutic goals (DEXA should be performed every 24 months in these patients); the entire assessment also should be performed at the time of dosage change or the development of a significant complication.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       To be stored and tested only if clinically indicated.",
"       <br>",
"        &Delta; Only in children.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Sites not included here should be evaluated if symptoms develop.",
"         <br>",
"          &sect; Plain radiographs of the spine only when patient is symptomatic (eg, back pain), disease is severe, there is poor growth or kyphosis.",
"          <br>",
"           &yen; Optional in absence of new symptoms or evidence of disease progression.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23229=[""].join("\n");
var outline_f22_43_23229=null;
var title_f22_43_23230="Immunoglobulin genes";
var content_f22_43_23230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Immunoglobulin genes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 195px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The &micro; and &delta; C genes are those nearest to the assembled VDJ sequence. Transcription of a complete immunoglobulin heavy-chain gene starts at the V sequence and proceeds through the &micro; and &delta; sequences before terminating. The mature B cell expresses both IgM and IgD, which are the only isotypes produced by B lymphocytes prior to contact with antigen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23230=[""].join("\n");
var outline_f22_43_23230=null;
var title_f22_43_23231="Late development edema";
var content_f22_43_23231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Late development of interstitial pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 504px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The quantity of fluid pouring from the capillaries overwhelms the capacity of the interstitium and the lymphatics, resulting in interstitial edema. Arrows represent lymphatic movement; small circles represent protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_43_23231=[""].join("\n");
var outline_f22_43_23231=null;
  